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A considerable amount of effort has been directed to develop porous materials as drug 
delivery systems (DDSs) – one of the most promising emerging applications in healthcare, as 
most anticancer therapeutics have toxic dose dependence due to a lack of tumour selectivity 
– as their hierarchical porosity can be used to store and release challenging drugs. 
Among them, Metal-Organic Frameworks (MOFs) – emerging hybrid, highly porous crystalline 
structures – offer several advantages compared to other available DDS, as they combine 
desirable features from both organic (biocompatibility, e.g. porous polymers) and inorganic 
(high loadings, e.g. mesoporous silica) porous materials. MOFs are highly amenable to 
functionalisation, meaning fine control over their physical properties can be achieved, and 
thus they have experienced tremendous development during the past decade in many 
applications. Despite surface engineering being advantageous for diverse fields – in 
biomedicine, it can both improve stability and dispersion, and provide the possibility of targeted 
carriers, decreasing the immune system recognition – surface functionalization of MOFs is 
underdeveloped. The multiple synthetic steps – synthesis, drug loading and surface 
modification – and the lack of orthogonality between them hinder their industrial manufacturing 
as DDSs. 
This thesis focuses on the development of surface functionalisation protocols of Zirconium 
MOFs, particularly UiO-66, a Zr-terephthalate MOF, the study of their cell internalisation fate 
and routes and the correlation with their therapeutic activity.  
During Chapter 1, an introduction to the use of DDSs in anticancer therapy, followed by 
examples of the most relevant MOFs from a coordination chemistry point of view, is given, in 
which zirconium MOFs and their synthesis are highlighted. Particular focus is given to the 
coordination modulation process, in which monodentate modulators are introduced to the 
MOFs synthesis to compete with the multidentate linkers during nucleation, enhancing 
properties such as porosity through the induction of defects. Then, the most relevant examples 
of surface functionalization of Zr MOFs for drug delivery are discussed with respect to the 
effects on properties such as colloidal dispersion in aqueous solvents, physiological stability, 
and drug release kinetics.  
In Chapter 2 different functionalised modulators (i.e p-functionalised benzoic acids, folic acid 
or biotin) are introduced to UiO-66 synthesis to obtain surface-functionalised UiO-66 with the 
appropriate size for drug delivery by one-pot synthesis. Full characterisation of the materials 
shows them to be remarkably porous due to the defects formed when modulators attach to 
available zirconium positions in the pores and on the surfaces of the MOFs. Furthermore, the 
use of a carboxylate-containing anticancer metabolic target (dichloroacetic acid, DCA) as a 
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modulator of UiO-66 synthesis is explored, and co-modulated samples, in which both DCA 
and functionalised modulators are introduced to UiO-66 synthesis, are synthesised and fully 
characterised, resulting in drug-containing (ca. 20% w/w) surface-functionalised MOFs by one 
pot syntheses. Importantly, DCA modulation induces a high number of defects, and 
consequently highly charged nanoparticles which are colloidally stable in aqueous solvents. 
Particle size control in the DCA modulated synthesis of the UiO family of isoreticular MOFs – 
including UiO-66 and its bromo, amino and nitro derivatives, and extended structures Zr-
Naphthalenedicarboxylate (NDC) and Zr-Biphenyldicarboxylate (BPDC) – is achieved, 
obtaining ca. 100 nm particles of UiO-66 derivatives and microcrystals of Zr-NDC and Zr-
BPDC when ZrCl4 is the metal precursor, and mesoporous < 20 nm UiO-66 derivatives and 
ca. 200 nm Zr-NDC and Zr-BPDC when ZrOCl2 is used as the metal precursor. The high 
porosity of the DCA modulated samples, due to DCA attachment to the inner and outer surface 
at defect sites, allows the loading of a second drug, the well-known anticancer drug 5-
fluorouracil (5-FU), into the pores of the isoreticular MOFs to create dual DDSs.  
Different postsynthetic modes of surface coating, based in both coordination and covalent 
chemistry, are studied during Chapter 3. The functionalities of the p-functionalised benzoic 
acid modulators, introduced to UiO-66 structure during Chapter 2, are used to covalently 
attach short-chain alkanes and long-chain polymers to UiO-66 surface through copper-
catalysed azide-alkyne cycloaddition. Exhaustive characterisation confirms that the 
attachment occurs through covalent chemistry and not through surface adhesion or 
electrostatic forces. Folic acid and biotin, which are introduced to UiO-66 surface as synthetic 
modulators during Chapter 2, are also introduced to UiO-66 surface postsynthetically. 
Colloidal dispersion and stability towards phosphates are investigated and compared to bare 
MOFs, in order to gain insights into the effect of both surface chemistry and mode of 
attachment on physical properties.  
A comprehensive overview of in vitro studies of cellular internalisation of zirconium MOFs is 
given in Chapter 4, focussing on the relevance of the endocytosis internalisation routes, which 
are strictly correlated with therapeutic efficacy. The postsynthetic surface functionalisation 
protocols investigated in Chapter 3 are applied to analogous calcein-loaded UiO-66 samples. 
Calcein is a fluorescent molecule not able to efficiently cross the cell membrane by itself, and 
hence serves as an in ideal probe of MOFs cellular internalisation. Its release from bare and 
poly(ethylene glycol) coated UiO-66 into phosphate buffered saline at pH 7.4 and 5.5, in order 
to simulate extracellular and intracellular conditions, is found to be pH responsive (more 
pronounced at 5.5) for all MOFs, but an ideal decrease in calcein release at pH 7.4 occurs 
only for PEGylated MOFs. Internalisation of calcein-loaded MOFs by HeLa cervical cancer 
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cells is studied by fluorescence assisted cell sorting, highlighting the effects of surface 
chemistry on endocytosis efficiencies and internalisation mechanisms.  
A discussion of in vitro studies into anticancer drug delivery from Zr MOFs is provided in 
Chapter 5, alongside a summary of the therapeutic effects of DCA and approaches to enhance 
its anticancer efficacy. Experimental assessment of the in vitro anticancer performance 
towards MCF-7 breast cancer cells of the DCA-containing MOFs of the UiO family of different 
sizes (ca. 100 nm and <20 nm), synthesised by coordination modulation during Chapter 2, is 
given. The effect of dual-drug containing MOFs (DCA and 5-FU) is also examined, to 
investigate the possible synergic effect of the drug combination. Then, the cytoxicity of bare 
and surface functionalised, DCA-loaded and empty UiO-66 MOFs is studied at first upon 
incubation with HeLa cells, for which the cellular routes of internalisation were elucidated in 
Chapter 4. The most promising MOFs are then tested for selective anticancer activity against 
a series of cancerous and healthy cells lines, and their macrophage uptake and ROS 
production is also analysed, to determine the effect of surface functionalization. The selective 
anticancer cytotoxicity of folate-coated MOFs is attributed to a combination of cancer cell 
targeting and optimal cell internalisation routes. 
To summarise, the one-pot synthesis of drug-loaded, surface functionalised UiO-66 has been 
successfully performed, resulting in porous, crystalline MOFs with the appropriate size for 
drug delivery. The use of a carboxylate-containing anticancer metabolic target as a modulator 
has been explored for the UiO family of isoreticular MOFs, resulting in well-dispersed 
nanoMOFs with enhanced anticancer activity, into which a second drug can be loaded, 
enabling the creation of dual DDSs. A series of postsynthetic surface modifications are 
performed, enabling the study of the MOF’s properties (colloidal dispersion, physiological 
stability and biocompatibility) with respect to their surface chemistry and coating mode, but 
more importantly providing valuable insights into correlations between surface chemistry, 
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1.1. The Use of Drug Delivery Systems (DDSs) 
Cancer is the price the human race has to pay as a consequence of our remarkable evolution. 
It is estimated that between one third and one half of the developed countries population will 
be diagnosed with cancer at some point of their life. In this context, developing effective and 
innovative cancer treatment and diagnosis has become a major priority within the scientific 
community and revolutionary thinking and design of drugs and their delivery systems may 
lead to more effective treatments and to its final cure.  
Cancer cells are so fast growing because their metabolism differs from healthy cells. In some 
cancer cells, once glucose has been transformed to two molecules of pyruvate, instead of 
being transformed to acetylCoA (AcCoA) in the cytosol, entering the mitochondria to undergo 
oxidative phosphorylation and ATP formation during the Krebs cycle, pyruvate is aleternatively 
transfored to lactate in the cytosol, even in the presence of oxygen. This process is known as 
the Warburg effect. 1-4 Mitochondria are the primary regulators of apoptosis, or cellular suicide, 
allowing cancer cells to avoid this process, as well as being able to grow in the absence of 
oxygen.1-4 Radiation and chemotherapy are well established treatments for cancer, but these 
often result in healthy cell damage, as most therapeutics have toxic dose dependence due to 
a lack of tumour selectivity, consequence of the potency required to overcome the high 
resistance and invasion of cancer tissue.5-9 Additionally, some tumours have developed 
resistance to anticancer drugs such as doxorubicin, 5-fluorouracil (5-FU) or cis-platin.10-13 
With the aim of circumventing these and other problems associated with available 
therapeutics, nanotechnology offers the possibility of introducing Trojan horses loaded with 
anti-cancer drugs which are selectively delivered to damaged cells.14-18 This may be achieved 
through local acummulation of drugs in the damaged tissue by targeted delivery and controlled 
release, offering the best way to minimise side effects and toxicity, while maximizing impact 
of treatment (Figure 1.1 a).19-22 




Figure 1.1. a) Ideal body distribution of targeted drug delivery compared to conventional drug delivery. 
b) Composition of a drug delivery system (DDS). 
A drug delivery system (DDS) should be designed to avoid any indiscriminate biological 
interactions, selectively reaching the desired tissue to release the drug at an optimal rate and 
degrade into non-toxic components while having little to no side effects. 
DDSs are generally composed of a core and a corona. The former is designed to control the 
release of the drugs stored within its pores or covalently attached to its structure, and should 
be made of pharmacologically degradable material, and the latter, which is responsible for bio 
distribution and targeting, can be tuned by surface modifications (Figure 1.1 b).15 In order to 
test the suitability of the drug delivery process, the drug release should be able to be 
monitored. Imaging components can be incorporated into the corona by postsynthetic 
modifications,23, 24 or in the core as multidentate ligands,25, 26 metal connecting points (such as 
Gd3+, Fe3+, and Mn2+)27, 28 or stored in the pores.29, 30 
Cancer cells are known to have enhanced permeability and retention (EPR), thus uptake and 
accumulation of DDSs are enhanced in cancer over healthy tissue.31, 32 Cancer cells also 
contain overexpressed enzymes and receptors on their cell membrane surface, so DDSs can 
be functionalised with targeting moieties allowing their uptake to be directed to damaged 
tissue. Hence, DDS have aroused an enormous interest for tailored treatment over the past 
decade and its approach has been validated in the clinic with the FDA approval.20 
However, drawbacks such as uncontrollable drug release,25, 33, 34 usually as a consequence of 
carrier degradation, or accumulation in the body,35, 36 often due to macrophage recognition 37, 
38 and to low carrier degradation fate,39, 40 hinder the clinical application of DDSs. Toxicity and 
biocompatibility are also important factors to take into count when designing a novel DDS,41-
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43 together with drug loading capacity and efficient cell internalisation.44-46 Most available DDSs 
are purely organic or inorganic, with their own strengths and weaknesses. Purely organic 
materials such as liposomes, dendrimers or polymers have poor drug payloads compared to 
purely inorganic materials,47-49 such as Fe3O4, Au or silica nanoparticles, but the latter tend to 
be less biocompatible and easily excreted before reaching their target.14, 50, 51 
Metal-Organic Frameworks (MOFs) are a new generation of hybrid materials which are 
promising DDSs candidates. MOFs have properties from organic and inorganic materials, and 
consequently they have some potential advantages over existing DDSs.15, 52-57 Owing to their 
versatile functionality- different reactive groups can be attached to the surface and the linkers 
can have different functional groups which allow post synthetic modification58-60- the drug 
release kinetics and biological behaviour of MOFs can be modified by post-synthetic 
modifications.61-63 
Their properties and cytotoxicity can be tuned through the thoughtful choice of metals and 
linkers, and they are easily degraded in the body, avoiding side effects from accumulation.43 
Additionally, due to their remarkable porosity, some of them present exceptional high drug 
loadings compared to other DDSs.24 
In summary, the fine control of MOFs’ cytotoxicity, drug payload, release and degradation 
kinetics, cellular internalisation and colloidal stability can be achieved through their structure 
and surface engineering, making them promising candidates as DDSs and magnetic 
resonance imaging (MRI) contrast agents. 
1.2. Metal-Organic Frameworks (MOFs): A Coordination Chemistry Point of 
View 
Metal-Organic Frameworks (MOFs) are a class of hybrid macromolecules where metal ions 
or metal clusters, called secondary building units (SBUs), are linked by multidentate spacer 
ligands through Werner-type coordination chemistry, forming three dimensional, crystalline, 
porous structures.64-66 This class of hybrid materials have nearly infinite tunability due to the 
relatively unlimited choice of metals and organic bridging ligands. Therefore, a tremendous 
number of MOFs have been reported, and well-studied models such as MOF-5,67 ZIF-8,68 
(Zeolitic Imidazole Framework-8), the MIL family,69 (Materials of Institut Lavoisier), or the UiO 
family, (Universitetet i Oslo),70 have been a platform for the synthesis of more complex 
derivative MOFs (Figure 1.2). 




Figure 1.2. a) The MIL family, big and small cages (bottom) hybrid supertetrahedra (middle) in 
functional of the organic linker (top). Iron polyhedra, carbon and oxygen are represented in orange, 
black and red, respectively.71 b) ZIF-8 structure, Zn bluish purple, N dark blue, C grey, H white.72 c) 
MOF-5 structure where terephthalate ligands link the SBUs (Zn4O clusters) (top) and IRMOF-8, 
analogue of MOF-5, in which extended ligands bridge the SBUs (bottom). The yellow spheres 
represents the porosity of the framework.73 
Iron-based MOFs of the MIL family have received widespread attention for healthcare 
applications due to the low toxicity of iron.15, 71, 74-76 Particularly, in MIL-101 (iron-terephthalate), 
which exhibits an extremely large surface area of 5900 cm2g-1, the SBUs are composed of 
iron (III) trimers, which are connected together via six terephthalate (1,4-
benzenedicarboxylate, BDC) ligands and a μ3-oxo ligand. The SBUs are connected by bdc 
linkers forming a ‘super tetrahedron’ where the metallic centres have an octahedral 
environment.69 The supertetrahedra are arranged forming two highly porous cages with pores 
of 29 Å and 34 Å diameter. XL analogues of MIL-101 and MIL-100 (Benzene tricarboxylic acid, 
BTC, as linker) have been synthesised by Horcajada et al (Figure 1.2a).71  
Zeolitic Imidazole Frameworks (ZIFs) are a class of MOFs that are isomorphic with zeolites. 
They are composed of tetrahedrally-coordinated transition metal ions, such as Fe, Co, Cu or 
Zn, connected by imidazole ligands.77, 78 ZIF-8, illustrated in Figure 1.2b, is composed of Zn 
ions and 2-methylimidazole ligands, and has a Langmuir surface area of 1,810 m2g-1, high 
thermal stability (up to 550°C),72 and remarkable chemical resistance to boiling alkaline water 
and organic solvents compared to other MOF structures.79 Although, due to its acidic 
instability, ZIF-8 has been studied as an anticancer DDS,80 its potential cytotoxicity hinders its 
biomedical applications.43  
[Zn4O(BDC)3]n, commonly known as MOF-5 or IRMOF-1, (IR stands for isoreticular), is shown 
in Figure 1.2c. Its structure can be viewed as a derivative of a cube, whose eight corners, 
Zn4O SBUs, are linearly linked by BDC ligands, and it has been widely studied for several 
applications. Based on the MOF-5 net, IRMOF-10, also known as MOF-10, has the same 
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topology. It is formed by Zn4O nodes linked by 4,4´-biphenydilcarboxylate (BPDC) ligands.67, 
81 IRMOF-16 is also its analogue, possessing p-terphenyl-4,4´-dicarboxylate ligands in this 
case. Logically, the pore size of the series of MOFs increases as the length of the bidentate 
linkers does.82 
Zirconium-based MOFs have recently acquired a notable interest as DDS and MRI contrast 
agents83 due to their biocompatibility84 and higher chemical stability compared to late transition 
metal based MOFs,85-87 which provides more favourable degradation and drug release 
kinetics. 
The first Zr MOFs were reported by Lillerud et al. in 2008.70 In the UiO series of isoreticular 
MOFs, for which UiO-66 was first discovered, the SBUs consist of six zirconium cations 
forming an octahedron. Each cation is coordinated in a square-antiprismatic geometry by μ3-
O, μ3-OH and carboxylate groups. The [Zr6O4(OH)4(RCO2)12] octahedral clusters are linked by 
linear dicarboxylate ligands into extended, highly porous materials with the ideal formula 
[Zr6O4(OH)4(RCO2)6]n. These Zr6 clusters and derivatives serve as secondary building units 
(SBUs) in the vast majority of Zr MOFs reported to date (Figure 1.3 a).83, 88-90 
 
Figure 1.3. a) UiO-66 SBU.91 b) UiO family of isoreticular MOFs with extended linkers in which porosity 
increases with the length of the organic linker.92 
The archetypal member of the series, UiO-66, in which the linker is BDC, exhibits a surface 
area of 1200 m2g-1 and a pore volume of 0.5 cc/g when free of defects. Its octahedral and 
tetrahedral pores have sizes of 11 and 8 Å, respectively, with pore windows of 3 and 5 Å.70 
A range of ligands have been used to form an isoreticular series, with porosity increasing with 
ligand length (Figure 1.3 b) until interpenetration occurs with phenylene-bis-ethynylbenzoate 
linkers.93, 94 The use of dicarboxylate linkers with anchored pendant functionalities along with 
the excellent chemical stabilities of the series has allowed various postsynthetic modification 
(PSM) protocols to be developed. 58, 60, 88, 95 




Figure 1.4. Zr MOFs linkers discussed during this Chapter.  
Zirconium MOFs containing tricarboxylate or tetracarboxylate linkers have been also 
synthesised. For example, planar tetracarboxylates such as tetrakis(4-
carboxyphenyl)porphyrin combined with 6-connected Zr6 SBUs gives PCN-223 where solvent 
molecules or modulators cap the free coordination sites, and with 12-connected Zr6 SBUs 
gives PCN-224; additives to synthesis tune the formation of the different MOFs.26, 96 Similarly, 
the structurally related 1,3,6,8(tetrakis(p-benzoate)pyrene ligand, when linked by 8-connected 
Zr6 SBUs, leads to both NU-901 and NU-1000 MOFs.97 
A wide variety of other Zr MOFs are known, but this thesis is focused on the above examples, 
shown in Figure 1.4, due to their potential for use in biomedical applications. 
1.3. Synthesis of Zr MOFs: Coordination Modulation  
The synthesis of Zr MOFs is usually carried out under solvothermal conditions,98-103 although 
other synthetic routes have also been reported.83, 98, 104, 105 Solvothermal synthesis is sensitive 
to several factors, such as pH, concentration, temperature, pressure, reaction time or 
stoichiometry among others. These parameters can be tuned to adjust the crystallisation 
process and obtain MOFs of various sizes.  
The coordination modulation protocol- first reported by Fisher and co-workers for Zn MOFs106- 
in which monodentate ligands (modulators) with similar chemical functionality to the 
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multidentate organic linkers are introduced to the synthetic process, has been widely used as 
a tool to control size and enhance MOFs properties such as crystallinity. 92, 100, 107-109 
Fisher et al studied the modulated synthesis of MOF-5 (Zn-terephthalate) in presence of 4-n-
decylbenzoic acid.106 The particles were synthesized by mixing a pretreated solution 
containing a molecular precursor providing the SBUs, which causes persistent nucleation and 
growth, and a solution containing the ligand. Following the process with time-resolved light 
scattering (TR-SLS) and small angle neutron scattering (SANS) among other techniques, the 
authors provided rationale insights of MOF-5 coordination modulation process, comparing it 
with the solvothermal induced process. The crystallization process was affected by the molar 
ratio of the components, resulting in lower crystallization process when an excess of the 
building units or modulator was used. SANS and light scattering results showed that the 
presence of the modulator does not affect the morphology and nature of the final particles in 
this case. 
The addition of monodentate ligands, such as acetic acid, benzoic acid and derivatives among 
others, influences the coordination equilibrium through competition with the multidentate 
bridging MOF linkers for the metal clusters coordination sites during the crystallisation 
process, in some cases favouring the crystal growth of certain crystal faces and enabling the 
synthesis of alternative morphologies (Figure 1.5).110 
 
Figure 1.5. Comparison of conventional and coordination modulation MOF synthesis. Selective crystal 
faces modulation results in direct MOF synthesis of different morphologies.110 
In this process, the monodentate ligands can act in two different ways. On the one hand, if it 
acts as a crystal growth promoter the size of the crystal will depend on the concentration of 
the modulator.102, 111, 112 On the other hand, if it acts as a capping agent, its functionality will 
be confined to the surface, being permanently coordinated to metal sites and thus inhibiting 
crystal growth.107, 113 Therefore, this technique can be wisely used to control not only the 
particle size of the MOFs100 - scaling down the size of DDSs to <200 nm is imperative for 
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intravenous administration in order to ensure circulation through small capillaries without 
blockage - but also the surface chemistry during the synthetic process (Figure 1.6 a). 
However, the role and effect of the modulator during synthesis is difficult to predict. 114 
For example, Kitagawa et al reported the acetic acid modulated synthesis of a copper 
framework [{Cu2(ndc)2(dabco)}n] (ndc=1,4-naphthalene dicarboxylate; dabco=1,4-
diazabicyclo[2.2.2]octane).110 In this anisotropic framework the dicarboxylate ligands link the 
copper clusters forming two-dimensional lattices, which are further connected by the amine 
pillar ligands forming a three dimensional framework. It was found that addition of acetic acid 
resulted in face selective modulation. One of the coordination modes (ndc carboxylate -
copper) was inhibited by the capping of acetate groups, while the dabco nitrogen -copper 
coordination was favored, allowing the formation of nanorods. Lui and Guo studied the effect 
of both acid-base environment of the reaction medium and the addition of capping agents to 
a copper-BTC MOF, HKUST-1 (where HKUST-1 stands for Hong Kong University of Science 
and Technology), synthesis under hydrothermal conditions (water/ethanol) using different 
modulators: sodium formate, sodium acetate and triethylamine (TEA).115 The addition of 
carboxylate salts (capping agents) to the reaction mixture drastically reduced the particle size 
compared to the unmodulated MOF. For example, upon addition of 1 equivalent of sodium 
formate the MOF particle size was reduced from 20 micrometers (when unmodulated) to 300 
nm, and further decreased as the equivalents of capping agent were increased, until the fourth 
equivalent, where new peaks appeared in the PXRD diffraction pattern, indicating the 
formation of a new phase. 
Increasing the pH of the reaction mixture leads to faster deprotonation of the linkers. Thus a 
basic modulator can speed up the crystallization process affecting the nucleation and growth 
processes through both coordination and deprotonation equilibriums (Figure 1.6 b).107 
HKUST-1, modulated with addition of TEA, which does not have a carboxylate coordination 
site to act as capping agent, resulted in nano crystals with a size of 200-250 nm, which were 
packed forming hierarchical octahedral-shape crystals with a diameter of 2.5-3 
micrometers.115 




Figure 1.6. a) Ideal attachment of functionalised monocarboxylate modulator, inhibiting crystal 
growth.61 b) Schematic representation of pH effect in nucleation and crystal growth of MOFs depending 
of pH and capping agents.107 
Coordination modulation of Zr-based MOFs has been widely studied, showing different 
behaviors upon addition of modulators. The first study of Zr MOFs coordination modulation 
was performed by Behrens et al., who used benzoic acid, acetic acid and water as modulators 
of Zr MOFs of the UiO family, demonstrating size-control by varying the amount of modulator 
added.100 Benzoic acid affected both size and morphology of UiO-67 crystals, enhancing 
crystallinity and increasing crystallite size with the amount of benzoic acid added during 
synthesis. The authors attributed the size increase to the in-situ formation of Zr-benzoic acid 
complexes, which reduce the nucleation rate. In contrast to other carboxylate containing 
modulators, which act as capping agents,113 benzoic acid did not get permanently attached to 
UiO-66 Zr6 clusters after synthesis, acting as a guest and getting trapped in the MOF pores 
(Figure 1.7).100 




Figure 1.7. a) PXRD patterns of UiO-67 modulated with different equivalents of benzoic acid.SEM 
images of UiO-67 modulated with b) 0, c) 3 and d) 30 equivalents of benzoic acid, showing a transition 
from amorphous aggregates to individual octahedral micro crystals.100 
Modulators are known to induce missing linker and missing cluster defects in Zr MOFs by 
capping SBUs and replacing multidentate ligands throughout the bulk of the material.92 
Despite defects representing a type of structural ‘’ imperfection’’ they can result in improved 
properties, such as boosting the MOFs porosity. Defects can modify a number of physical 
properties, including chemical and mechanical stability (Figure 1.8).103, 108, 116-118 
 
Figure 1.8. Schematic representation of ideal and defective (missing linkers of missing clusters) UiO-
66 structures. Missing cluster defect yields in the reo topology in which one missing cluster is 
compensated by 12 trifluoroacetate modulators, while 8 missing linkers are compensated by 16 
trifluoroacetate modulators.92 
The first detailed investigation of missing linker defects was reported by the Zhou group, using 
acetic acid as a modulator of UiO-66 synthesis.116 In contract to HKUST-1 AcOH modulated 
synthesis,115 enhanced crystal growth and promoted defects were found upon UiO-66 AcOH 
modulation.116 An increase in surface area and pore volumes (ranking from 0.44 cc/g to 0.65 
cc/g) was observed as AcOH concentration increased. Interestingly, when the reaction time 
was increased from one to two days, the pore volume increased to 1 cc/g. Color change was 
observed as porosity increased, indicating that changes in the electronic band structures were 
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occurring. Through inelastic neutron scattering experiments, acetate groups were observed, 
indicating partial incorporation of acetic acid to the MOF structure as a compensation for 
missing linkers (Figure 1.9).116 
 
Figure 1.9. a) Representation of missing linker defects. b) Color change as missing linker defects 
increase as a consequence of acetic acid addition.116 
Similarly, Vermoortele et al reported extremely porous UiO-66 when modulated with 
trifluoroacetic acid (TFA), with missing linkers compensated by modulators attachment, and 
used them for catalytic purposes.119 Farha and co-workers reported the effect of introducing 
hydrochloric acid to UiO-66 and UiO-67 MOFs synthesis, resulting in highly defective samples 
with hysteresis loops characteristic of mesoporous materials.99 Indeed, the MOFs had 4 out 
of 12 missing linkers, as determined by TGA and N2 adsorption and desorption measurements 
among other techniques, resulting in 8-connected nodes instead of 12-connected nodes.  
Missing cluster defects were first reported by Goodwin et al, showing that using formic acid 
as a modulator of UiO-66 synthesis results in nanoregions of missing clusters with 8-
connectivity, denominated reo topology, within UiO-66 (Figure 1.8).116  
Taking into account the wide variety of defects induced by the modulation of UiO-66 using 
different monocarboxylates as modulators, Lillerud and co-workers performed a detailed 
coordination modulation study based on the acidity of monocarboxylate modulators- acetic 
acid (pKa 4.8), formic acid (pKa 3.8) difluoroacetic acid (pKa 1.24) and trifluoroacetic acid (pKa 
0.23)- introduced to UiO-66 synthesis.92 The authors found an increase in porosity as the 
concentration of modulator increased, but more importantly as the pKa of the modulator 
decreases, ultimately resulting in mesoporosity when 6 equivalents of TFA are added to the 
synthetic mixture. The incorporation of formate as compensating ligand for missing linkers 
was identify in the acid-digested proton nuclear magnetic resonance (1HNMR), even when 
formic acid was not used during synthesis, but coming from DMF hydrolysis during synthesis. 
Incorporation of the modulators used during synthesis was also observed, more noticeable for 
lower pKa carboxylates. The authors found evidence that missing clusters were the most 
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predominant defects when monocarboxylates are used as modulators of UiO-66, which are 
compensated by the attachment of the former (Figure 1.10).92 
 
Figure 1.10. UiO-66 a) nitrogen adsorption and desorption isotherms b) surface area c) incorporation 
of modulator - depending on modulators’ pKa and the number of equivalents of modulator  added during 
UiO-66.92 
Importantly for healthcare applications, Mirkin et al have found that the pKa of the modulator 
also affects the colloidal stability of the MOF as a consequence of the defects induced through 
modulator attachment, generating highly charged nanoparticles (measured by zeta potential), 
which when dispersed in a solvent suffer from higher repulsion between each other (See 
section 1.6).120 
In summary, the coordination modulation protocol can be used to tune size, crystallinity, 
porosity, surface chemistry and colloidal stability of MOFs among other properties. It is clear 
that more acidic monocarboxylates have a stronger effect due to the higher competition for 
the metal clusters coordination sites, yielding in highly porous (defective), and consequently, 
colloidal stable nanoMOFs. Since modulators attachment to the Zr clusters is also governed 
by their pKa, one-pot synthesis surface functionalisation could be achieved by coordination 
modulation.  
1.4. Metal Organic Frameworks as Carriers for Drug Delivery: Background 
Since 2006, when Ferey and co-workers reported the first study of iron-based MOFs for 
applications in biomedicine,55 a tremendous amount of work has been developed towards 
MOFs various potential uses in healthcare.121 Iron MOFs are probably the most widely studied 
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MOFs for healthcare applications to date; this is largely due to iron being well tolerated by the 
body, with rat oral lethal dose 50% (LD50) of 30 gkg-1, while their high porosity enables very 
large drug loadings.15, 34 
The MIL family has raised special interest for healthcare applications and a remarkable 
amount of high quality research has been focused on their biological applications. 15, 74, 75, 122 
Antivirals such as azidothimidinetriphosphate (AZT-TP) and cidofovir (CDV) have been 
trapped into MIL-101(Fe) and MIL-101-(Fe)-NH2 with remarkable high loadings (> 40 % 
w/w).15 This could be explained due to the fact that the open metal sites have high affinity for 
the phosphates presents in the CDV and AZT-TP, as Doxorubicin loadings, which does not 
have phosphate groups, were remarkably lower (ca. 10 % w/w). On the other hand, NMOFs 
with smaller pores, such as MIL-53 and MIL-88A, have smaller drug payloads (<1 % w/w) due 
to the fact that the molecules do not have access to the pore, likely staying on the surface.15 
Lin and co-workers synthesised MIL-101(Fe)-NH2, Fe3-(μ3-O)Cl(H2O)2(BDC)3 and an 
analogue containing a mixture of BDC (82.6%) and 2-aminoterephthalic acid (NH2-BDC) 
(17.4%).57 The pendant amino functionality was used to covalently attach a fluorescent dye 
(boron dipyrromethene, BODIPY) or a cisplatin prodrug through amide formation. BODIPY 
and cis-platin release under simulated physiological conditions was shown to be fast, 
suggesting MOF instability. Thus, silica coating was used to enhance their stability and to 
satisfactorily slow down the drug release. To selectively direct the MOFs uptake to cancer 
cells, a targeting peptide for angiogenic tumours, c(RGDfK) was postsynthetically attached to 
the silica shell (Figure 1.11).57 
This example highlights the importance of MOF design and post-synthetic functionalisation for 
drug delivery applications, and it proves the high potential of selected NMOFs to selectively 
deliver contrasts agents and anticancer drugs to cancer cells. However, silica coating has 
cytotoxic disadvantages,36, 123 and its in vivo potential is truncated by their rapid excretion.14, 
50 
 




Figure 1.11. Schematic representation of MIL-101-NH2 post-synthetic modifications for drug delivery.57 
Zirconium-based MOFs have recently acquired a notable interest for biomedical applications, 
as Zirconium is a biocompatible metal: the human body typically contains about 300 mg of 
Zirconium, and the recommended daily ingestion is 3.5 mg per day. The lethal dose (LD50) of 
zirconyl acetate in rats, as determined by in vivo experiments, has been found to be 4.1 gkg-
1, which is comparable to iron.84 Additionally, the hard Lewis acid/base coordination nature of 
Zr-carboxylate bonds makes them more chemically and mechanically stable than iron, and 
other MOFs.86, 87, 90, 96, 108, 124 
For example, core-shell iron oxide-MOF nanoparticles have been proposed as dual anti-
cancer therapeutics and MRI contrast agents.125 Fe3O4@UiO-66-NH2 core (150 nm)-shell (2, 
25, 50 nm) nanoparticles were synthesised through growth of UiO-66-NH2 on Fe3O4 surface, 
which was terminated with carboxylic acid groups. The core-shell NMOFs exhibited strong 
superparamagnetic behaviour, suggesting their use as optimal T2-contrast agents retaining 
the core iron oxides properties, only with minor decrease in saturation magnetisation from 
69.7 emu/g to 51.6 emu/g, consequence of the MOF coating. Fe3O4@UiO-66-NH2 has high 
transverse relaxivity (r2) of 255.9 Mms-1, 125 considerably higher than some clinical Fe-based 
T2-weighed contrast agents.126 
Examples of Zr MOFs for healthcare applications are emerging in the literature and will be 
further discussed during the course of this Chapter.  
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1.5. Surface Modifications of Zr MOFs for Drug Delivery 
The surface chemistry of a given DDS governs its interaction with the media, improving 
stability and dispersion, and providing the possibility of targeted carriers. As such, surface 
modifications are of great interest for the development of efficient DDSs, however, the multiple 
synthetic steps – synthesis, drug loading and surface modification – and the requirement for 
orthogonality between them, can hinder the efficient manufacture of DDSs. Surface 
modification of MOFs can be performed during synthesis, by the coordination modulation (CM) 
protocol, or postsynthetically (PS). Postsynthetic surface modification can be categorised into 
(i) coordinative PSM, whereby the coordination chemistry of metal clusters at the particle 
surface is used to attach functionality, for example by surface ligand exchange, or (ii) covalent 
PSM, usually performed using the linker functionality as a platform for further reactions, such 
as click chemistry. 60, 61 
1.5.1. Postsynthetic Surface Modifications of Zr MOFs Based on Coordination 
Chemistry 
Zirconium SBUs are susceptible to nucleophilic attack. Hence zirconium MOFs can be 
functionalised through coordination to Zr6 SBUs, and thus nucleophilic functional groups such 
as carboxylates,127 phosphates,26 and imidazoles,128 among others have been used to confine 
functionalities to the surfaces of Zr MOFs directly through coordination to the unsaturated Zr 
positions available on the surface (Table 1.1). This type of PSM typically requires size 
selectivity in order to address only the outer MOF surface, as if the reagents can penetrate 
the porosity, the inner surface of the MOF can also be functionalised during the process. The 
new functionality may coordinate to unsaturated Zr SBUs or displace surface linkers in a 
process previously termed surface ligand exchange. 
The solvent-assisted ligands exchange (SALE) protocol has been used to introduce linkers to 
MOFs structures that were not able to be successfully formed during one-pot synthesis. For 
example, Wang et al. have shown that a carboxyl-functionalised diiodo-substituded BODIPY 
(I2-BDP) can be postsynthetically incorporated onto the surfaces of UiO-66, by heating the two 
in DMF at 65 °C for 24 h, without compromising the topology or porosity of the crystal.23 The 
optical properties of the BODIPY functionality led to the MOF being studied for photodynamic 
therapy (PDT) and thus it was termed UiO-PDT. Comprehensive characterisation showed that 
the content of I2-BDP in the 70 nm nanoparticles of UiO-66-PDT was around 30% w/w, with 
the measured BET surface area of 1422 m2g-1 confirming the anchoring of I2-BDP at the 
external surfaces rather than loaded in the pores. Park et al have taken a similar approach to 
attach two different surface molecules – a porphyrin and a dithienylethene – to UiO-66 
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nanoparticles in a range of ratios.129 Again, these optically active conjugate materials were 
assessed for PDT. 
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In 2014, Lin131 and Shi24 independently reported the use of phosphate groups to coordinate 
biomolecules to the available zirconium clusters on the surfaces of MOFs. Shi et al took 
advantage of the phosphate affinity for the Zr SBUs of UiO-66 to attach the amino-
biphosphonate Alendronate (AL) for the treatment of bone cancer.24 The resultant MOF, AL-
UiO-66, had very high drug loadings (51.4% w/w) compared to previously reported DDS (37 
w/w %). The sample was fully characterised and showed a drastic decrease in porosity after 
loading, while FT-IR spectra showed appearance of shifted AL characteristic vibration bands 
and new signals attributed to P-O-Zr stretching. The combination of the results suggests that 
AL was coordinated to the Zr positions in the outer and inner surface of the MOF, which was 
confirmed by O1s XPS spectrum of the materials, explaining the high drug payloads as a 
consequence of the high affinity of Zr clusters for AL. The authors also functionalised UiO-66 
surface with fluorescent molecules of flavin mononucleotide (the phosphorylated form of 
vitamin B2) using the same principle, thus forming UiO-66-FMN, which was used to explore 
intracellular imaging. The difference in size of flavin mononucleotide compared to alendronate 
ensured that the flavin was confined to the surface as it could not penetrate the pores.24 
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Lin and co-workers studied the attachment of small interfering RNA (siRNA), through the 
phosphate groups present on its backbone, to the Zr4+ cations present on UiO-68-NH2 surface, 
after loading the pores with a cis-platin prodrug. The authors further used this highly 
specialised MOF named siRNA-UiO-Cis for siRNA and cis-platin co-delivery. (Figure 1.12)131 
 
Figure 1.12. Schematic representation of siRNA-UiO-Cis synthesis and drug loading.131 
Later, in 2015, Mirkin and co-workers studied the use of phosphate coordinating groups in 
order to functionalise the surface of three different zirconium MOFs, UiO-66, UiO-67 and BUT-
30 (in which (4,4ʹ-ethylene-1,2-diyl)dibenzoic acid is the MOF linker), with a phospholipid 
through PSM.130 Importantly, in this isoreticular family of MOFs the density of zirconium 
clusters present in the surface decreases as the length of organic linker increases, and thus 
the content of 1,2-dioleosyl-sn-glycero-3-phosphate (DOPA), determined by ICP-MS, was 
higher for DOPA-UiO-66 and lower for DOPA-BUT-30. Similarly, the surface selectivity of the 
functionalisation, driven by the size of the DOPA units, was confirmed when smaller DOPA-
functionalised nanoparticles of each MOFs, in which the surface to bulk ratio is higher, had 
higher DOPA content. In other words, it was found that DOPA density correlates with the 
density of metal nodes in the outer surface. The samples were fully characterised, showing 
that after DOPA functionalisation the MOFs maintained their porosity, with FT-IR shifts again 
suggesting Zr-O-P coordination.130 
This protocol was later extended by Mirkin et al. into a general procedure for functionalising 
Zr MOFs with oligonucleotides through phosphate coordination.132 A number of Zr MOFs with 
different topologies and connectivity were examined, and a correlation was again found 
between surface SBU density and surface oligonucleotide coverage. The connectivity of the 
Zr SBU also mediates surface coverage; MOFs with more highly connected clusters have 
more surface defects due to coordinative unsaturation, allowing greater binding of surface 
phosphates.132 
More recently, the zirconium-phosphonate interaction has been exploited for the synthesis of 
Zr-based MOFs grafted by phospholipid bilayers (PBLs). In this case, a porphyrin MOF, PCN-
223, was postsynthetically coated with 1,2-dioleoyl-sn-glycero-3-phospho-choline (DOPC) in 
order to create a monolayer via coordination Zr-O-P, forming nanoPCN-223@DOPC, which 
was further coated with cholesterol and DOPC, creating a hydrophobic system in which coated 
Chapter 1: Introduction 
20 
 
MOFs and DOPC chains further self-assemble into supported MOFs-PBLs, so called 
nanoPCN-223@DOPC/DOPC (Figure 1.13).26 The formation of PBLs was confirmed by 
negative staining with uranyl acetate, due to strong interaction between phosphate and uranyl 
groups, among other characterisation techniques, such as FT-IR spectroscopy, Zeta potential 
measurement and X-ray photoelectron spectroscopy (XPS).  
 
Figure 1.13. Representation of nanoPCN-223@DOPC and nanoPCN-223@DOPC/DOPC synthesis.26 
Beside phosphate groups, the use of imidazole coordinating agents has recently been 
reported for the bio applications of a Zr-fumarate MOF.128 Once more, the use of a Lewis base, 
in this case the imidazole groups present in the histidine residues (His-tags) of several peptide 
sequences, was used to address Zr-MOFs surface with bio molecules. It was proved that the 
higher the number of histidine residues in the peptide, the higher the binding to the MOF and 
thus the authors used a series of peptides containing 6 histidine residues (H6-Tags) to coat 
Zr-fumarate surface to further study their bio applications.  
1.5.2. Postsynthetic Surface Modifications of Zr MOFs Based on Covalent Chemistry 
Surface functionalisation can also be achieved through covalent postsynthetic modification, 
through chemical transformation of pendant functionalised groups present in the organic 
linkers of MOFs. In 2010, the amino group of UiO-66-NH2, in which terephthalic acid is 
substituted by 2-aminoterephthalic acid during synthesis, was first used for PSM. 88, 89 The 
amino group was reacted with a series of anhydrides and the conversion was monitored by 
1HNMR spectroscopy of acid digested samples. It was proved that higher conversion rates 
were obtained for smaller anhydrides, as a consequence of reaction with amino groups 
present in the core of the structure, while larger anhydrides were limited to functionalisation at 
the surface, a consequence of the size selectivity of the process to achieve only outer surface 
functionalisation. Since then, the amino functionality has been widely used for PSM for a 
variety of applications, including drug delivery (Table 1.2).  
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Table 1.2. Literature examples of Zirconium MOFs functionalised by covalent PSM 
MOF Surface coating Surface 
modification 
protocol 




































































UiO-68-N3 1. Nucleobase 
acting as substrate 
 
2. DNAzyme 













For example, poly(N-isopropylacrylamide) (PNIPAM) chains have been attached to the amino 
groups present in UiO-66-NH2 through amide coupling with polymer chains terminated with 
activated N-hydroxysuccinimide (NHS) esters, forming the surface functionalised UiO-66-
PNIPAM (Figure 1.14).133 
 
 
Figure 1.14. (a) Scheme of controlled release using UiO-66- PNIPAM, based of PNIPAM thermo 
responsive behaviour (open and close forms). (b) Schematic representation of UiO-66-NH2 PSM, 
leading to UiO-66-PNIPAM formation.133 
Chapter 1: Introduction 
22 
 
In 2014, Mirkin et al. synthesised a UiO-66 analogue containing an azide group on its linker, 
UiO-66-N3, and subsequently covalently attached dibenzylcyclooctyne (DBCO) functionalised 
DNA to the MOF through copper-free strained-alkyne click chemistry (Figure.1.15).134 Through 
radio labelling, the authors confirmed that PSM occurs only on the outer surface, as expected 
due to size-selectivity. 
Recently, Willner and co-workers have reported the synthesis of UiO-68-NH2, and its 
postsynthetic transformation to UiO-68-N3.30 The NMOF was loaded with an anti-cancer drug 
Doxorubicin (DOX) or with fluorescent dyes, and subsequently, the azide functionality was 
reacted with various DBCO-functionalised DNA moieties through postsynthetic copper-free 
click chemistry. Sequential addition of a single oligonucleotide strand on the MOF surface 
followed by hybridisation with complementary strands allowed a diverse range of surface 
functionality, including pH-responsive sequences, aptamers, and DNAzymes.30 
 
Figure 1.15. (a) Synthesis of UiO-66-N3 (Zr6O4OH4(C8H3O4-N3)6) nanoparticles. (b) DNA 
functionalization of UiO-66-N3 nanoparticles, utilizing DNA functionalized with dibenzylcyclooctyne 
(DBCO). (c) Strain promoted click reaction between a metal–organic framework (MOF) strut and DNA. 
Zirconium atoms = blue; oxygen atoms = red; carbon atoms = black; azide groups = green. Hydrogen 
atoms are omitted for clarity.134 
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Controlled supramolecular interactions can also be used to surface modify MOFs. Hong et al. 
reported the synthesis of a radioactive version of UiO-66 (89Zr-UiO-66), which they further 
functionalised with pyrene-derived PEG (PY-PGA-PEG) through π-π stacking interactions 
with the organic linkers of UiO-66 structure.135 The py-derived PEG chains also contained a 
maleimide residue, which was used to further functionalise the MOF with a nucleolin-targeting 
peptide (F3) through postsynthetic modification with one of its cysteine residues. The authors 
found that the PEG units, due to their flexible structure, were partially blocking the porosity of 
the MOF, as a consequence of π-π stacking with organic linkers present inside the structure. 
The authors postulated that to control the distribution of PEG on the MOF’s surface, covalent 
attachment might be needed.135 
Other approaches, such as liposome encapsulation136 or silica coating and subsequent 
surface functionalisation based on reactions with silica siloxane groups,63, 137 have also been 
reported for other MOF systems. Although silica coating provides further MOF stability under 
simulated physiological conditions, higher cytotoxic effects and a higher accumulation in the 
body in the body are usually drawbacks of this approach. To the best of my knowledge, this 
approach has not been used for the surface functionalisations of zirconium MOFs, possibly 
because their water stability is higher than for other MOF systems.  
A combination of the coordination, covalent, and supramolecular approaches has also been 
used to functionalise PCN224.138 The amino acid Nα,Nα-bis(carboxymethyl)-l-lysine was 
attached to the surface by coordination of its three carboxylates, followed by covalent amide 
conjugation with a bifunctional linker with an activated NHS ester and a DBCO unit. 
Subsequent copper-free click chemistry allowed conjugation of azide-modified DNA, 
complementary strands of which were attached to lanthanide-based upconverting 
nanoparticles (UCNPs). Complementary base-pair recognition resulted in the formation of 
MOF-UCNP composites.  
In summary, a wide range of surface modifications, either through coordination or through 
covalent chemistry, have been performed on Zr MOFs in order to enhance their properties as 
DDSs, such as colloidal dispersion, physiological stability and biodistribution among others. 
The vast majority of the surface modifications are performed postsynthetically, using bulky 
surface reagents to avoid inner surface modifications. Among the different coordinating 
groups, it is more likely that those with a higher affinity to Zr, related to a lower pKa, will create 
stronger bonds with the zirconium clusters, which might protect the MOFs surface from 
degradation and improve their colloidal dispersion to a higher extent. 
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1.6. Colloidal Dispersion of Zr MOFs under Simulated Physiological Conditions  
To ensure the safe and efficient use of MOFs in medicinal applications, they must be stable 
towards aggregation and hydrolysis in aqueous solvents. Good water dispersion is vital for in 
vivo treatment, as blood is an aqueous, phosphate-containing fluid, and aggregation could 
result in harmful capillarity blockage.  
It is important to take into account that the ultimate aggregation that NMOFs will suffer in the 
blood current is difficult to predict. In vitro studies using phosphate buffered saline (PBS) or 
water as dispersants have been widely used in order to evaluate their behaviour in aqueous 
media, as well as the effect of the presence of phosphates on their colloidal stability. Other 
dispersants, such as growth media, serum, or PBS spiked with diverse proteins, have been 
exploited to study the presence of blood containing proteins in the dispersion of NMOFs.74-76  
Fairen-Jimenez et al have recently studied the colloidal stability of the UiO family of zirconium 
MOFs in PBS and growth media.139, 140 It was found that all MOFs highly aggregate in PBS, 
whereas no major aggregation was found when dispersed in growth media, possibly as a 
consequence of the formation of a protein corona on the NMOFs’ surface. This phenomena 
has also been proved for other MOF systems.74, 76 
Surface modifications are known to play a crucial role in the hydrolytic stability and colloidal 
dispersion of MOFs and DDSs in general, as they govern the interactions with the media in 
which DSS are dispersed. For example, UiO-66-N3 nanoparticles in water aggregate quickly 
upon NaCl addition, however, UiO-66-N3-DNA conjugated nanoparticles are colloidally stable 
in aqueous solutions of up to 0.4 M NaCl, possibly due to the steric and electrostatic barriers 
provided by the DNA surface coating.134 UiO-66-Cis was found to be colloidal stable by DLS 
measurements, and minor increase in the hydrodynamic diameter was found for siRNA@UiO-
Cis, which the authors attribute to siRNA coating.131 
Surface modification with the phospholipid L-DOPA can even enable the dispersion of 
hydrophilic Zr MOFs (UiO-66, UiO-67 and BUT-30) in low polarity media such as CHCl3. Thus, 
UiO-66-DOPA, UiO-67-DOPA and BUT-30-DOPA migrated from the aqueous to the organic 
phase upon liquid-liquid extraction (Figure 1.16 a).130 




Figure 1.16. a) UiO-66 and UiO-66-DOPA suspended in an aqueous phase and after being transferred 
to a chloroform phase after DOPA functionalization. SEM image of drop-casted colloidally stable UiO-
66- DOPA in CHCl3. Scale bar: 1μm.130 b) Aggregative behaviour of PCN223 before (right) and after 
PBLs coating (left). 26 
The colloidal stability and dispersion of bare PCN-223 nanoparticles, nanoPCN-223@DOPC 
and nanoPCN-223@DOPC/DOPC was assessed in a series of solvents, such as water, PBS 
and biological growth media RPMI-1640 and DMEM. The hydrodynamic size of bare 
nanoPCN-223 drastically increased with time in water, and more importantly in PBS. PCN-
223@DOPC was found to be highly hydrophobic, aggregating in water, possibly due to the 
acyl chains of DOCP, but the MOFs coated with phospholipid bilayers did not significantly 
aggregate in water or PBS over a period of 7 days, highlighting the power of surface 
modifications (Figure 1.16 b).26 
Hong and co-workers found slight changes on aggregative behaviour when UiO-66 was 
dispersed in water before and after supramolecular py-PGA-PEG functionalisation. The 
hydrodynamic diameter of UiO-66 (ca. 220 nm) was slightly higher than the size observed by 
SEM, and relatively increased for UiO-66-py-PGA-PEG-F3 (ca.250 nm). These results 
suggest that, although many factors are involved in MOFs aggregative behaviour, surface 
functionalisation through covalent attachment might be more efficient at enhancing colloidal 
stability of UiO-66 than using π-π interactions, possibly due to the higher stability of the coating 
using the former protocol.135 
Mirkin and co-workers have recently reported that the monocarboxylic acid modulator used 
during UiO-66 synthesis plays a crucial role in the MOFs polydispersity.120 Modulators with 
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lower pKa values are more likely to be deprotonated during synthesis, and so increased 
competition with the organic linker for the zirconium positions induces the formation of defects. 
These defects increase the surface charge (measured by zeta potentials), hence increasing 
the repulsion between nanoparticles and enhancing their colloidal stability. UiO-66 samples 
modulated by formic acid (FA, pKa = 3.77), dichloroacetic acid (DCA, pKa = 1.36) and 
trifluoroacetic acid (TFA, pKa = 0.23) were colloidally stable in water, as determined by DLS, 
and did not show any aggregation by scanning tunnelling electron microscopy (STEM). In 
contrast, when acetic acid (AcOH, pKa 4.76) is used as a modulator for the synthesis of UiO-
66 (the BDC linker has a first pKa of 3.51 and a second of 4.82) the resultant particles were 
considerably aggregated (Figure 1.17).120 
 
Figure 1.17. Overall results of colloidal stability of UiO-66 as a function of modulator acidity (pKa) and 
molar concentration. Formic acid FA (black), Acetic acid AA (green),dichloroacetic acid DCA (red), and 
TFA (blue). A) STEM size measurement (B) DLS size measurement, where the purple region in B 
corresponds to highly aggregated samples where particle size cannot be determined by DLS. C) and 
D) STEM image and digital photographs of UiO-66 dispersed in H2O synthesized with UiO-Acetic acid 
and (D) dichloroacetic acid (0.58 M) respectively (Scale bars C = 200 nm and D = 500 nm), showing 
the difference in aggregation. (E) Zeta potential measurements.120 
Thus, based on the results available in the literature, it is evident that the use of a low pKa 
modulator during MOFs synthesis highly enhances their colloidal dispersion, while high 
improvements are also found through surface modifications.  
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1.7. Stability of Zr MOFs under Simulated Physiological Conditions 
As zirconium, among other metals, has a greater affinity for phosphates than for carboxylates, 
phosphates present in the body can also attack the zirconium positions, inducing degradation 
and thus resulting in uncontrollable release of the drug.85 Hence, MOFs degradation kinetics 
have been widely studied in PBS. 
It is well-know that the stability of MOFs towards phosphates depends on many factors, but 
clearly surface coating is one of the most important, as it can shelter metal clusters from 
phosphate attack. Compared to the amount of work that has been performed to determine 
and to enhance the drug release kinetics of Zr MOFs (see Section 1.8), there are few studies 
in the literature that discuss the degradation kinetics of the Zr MOFs, despite the fact that the 
drug release might be a consequence of carrier degradation. Monitoring linker release by 
UV/Vis spectroscopy yields more detailed real-time information than ex situ diffraction 
techniques, and has shown that UiO-66 degrades rapidly in PBS. 
Although initial degradation could yield in burst drug release, final degradation of a DDS is of 
vital importance, as otherwise long-term accumulation of the DDS could induce unwanted side 
effects and toxicity.  
Fairen-Jimenez et al. revealed rapid degradation of benzoic acid modulated UiO-66 in PBS, 
releasing 80% of the bdc linker during the first hour, but not in water, where less than 10% of 
the linker was released after 7 days.139 The samples were characterised after different 
exposure times in PBS, confirming the formation of a phosphate corona by FT-IR 
spectroscopy, a consequence of phosphate attacking the Zr units and displacing the bdc 
linkers. Similar high degradation rates in PBS were found for other members of the UiO-66 
isoreticular series, which could result in unwanted uncontrollable release of drugs.  
Coating PCN-223 with phospholipid bilayers (PBLs) drastically improved the resistance of this 
zirconium MOF towards phosphates.26 The authors measured the stability of bare MOF, 
nanoPCN-223@DOPC and nanoPCN-223@DOPC/DOPC towards various chemicals, finding 
that both mono- and bi-layer coated nanoparticles were stable towards common cations and 
anions, as well as in serum. The sensitivity of Zr MOFs towards phosphate was illustrated by 
the rapid corrosion and linker release displayed by bare nanoPCN-223 in PBS, for which 90% 
of the linker was released in the first hour of PBS exposure, while PCN-223 coated with PBLs 
releases less than 3% of the organic linker after 7 days in PBS, strongly suggesting that PBLs 
act as a barrier to block phosphate attack (Figure 1.18).26 




Figure 1.18. Enhanced phosphate stability of TEM images of (a) bare nanoPCN-223 and (b) PBLs 
coated nanoPCN-223 particles in PBS solution with 2-day incubation time. (c) Powder XRD patterns 
for coated nanoPCN-223. d) Degradation profiles of bare and PBLs coated PCN-223 in PBS buffer. 26 
1.8. Drug Release Kinetics of Zr MOFs 
For DDSs to be effective, premature release of therapeutic cargo should be minimised, 
allowing the drug to travel to the location of the disease within the body before delivering the 
payload. For MOFs, release of cargo can occur by diffusion out of the pores or through 
degradation of the MOF itself, with unwanted early release – the so-called “burst release” 
phenomenon – a major issue to overcome.33 If the guest molecules are partially located on 
the MOF surface premature release is also likely to be observed. The chemical stability and 
ease of functionalisation of Zr MOFs has facilitated the development of many strategies to 
allow controlled or even stimuli-responsive release. 
As hydrolytic stability is implicit in control of cargo release, similar strategies to those 
discussed above have been employed overcome burst release in Zr MOFs. Attaching cargo 
to the surfaces and defect sites of Zr MOFs by coordination provides the possibility of pH or 
phosphate induced cleavage and release. For example, Lachelt and co-workers studied the 
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release of fluorescent peptides, attached to Zr-fumarate surfaces using His-tag imidazole 
coordination, into HEPES buffered glucose (HBG) at different pH values over 24 h by 
photometric determination.128 HBG does not contain phosphates, so the role of pH can be 
assessed independently. At pH 7.4 the coating was stable, while at pH 5 the peptide was 
partially released, and at pH 3 was completely cleaved from the surface of Zr-fum. Although 
imidazole ions present in histidine residues have pKa values around 6, and thus detachment 
at pH 5 due to imidazole protonation would be expected to be more pronounced, the authors 
suggest that incomplete detachment could be due to the lowered pKa value when His-tags are 
attached to the zirconium units. The coordination of the drug alendronate through its 
phosphate groups to UiO-66 resulted in pH responsive drug release from UiO-66-AL, which 
released 43% of AL in PBS at pH 7.4 over 60 hours, and 59% of AL under the same conditions 
but at pH 5.5.24 
Physically modifying drug-loaded MOFs to sterically protect the surface from hydrolysis is also 
an effective approach to control drug release. Fairen-Jimenez et al. have applied an 
amorphisation approach to trap calcein, a fluorescent model drug molecule, within UiO-66 by 
grinding. Full release of calcein from amorphous UiO-66 took 30 days rather than 2 days for 
crystalline UiO-66.29 The release of Diclofenac sodium (DS) from ZFU-800, a member of the 
isoreticular UiO-66 series linked by 3,3ʹ-(2-fluoro-1,4-phenylene)diacrylic acid, was monitored 
in PBS by Jian et al. DS payloads of 59% w/w were obtained, and its release in PBS (pH 7.4) 
at 37 °C displayed a burst effect, with an immediate 10% release, followed by full release over 
two days.141 The effect of pressure on the drug release kinetics was investigated by applying 
different pressures (10 MPa and 30 MPa) to drug loaded samples for one minute, compacting 
the MOFs into slices, which were further broken for the drug release experiments. 
Interestingly, the sample was still crystalline after the process. The authors observed a 2.5 
fold decrease in the release rates for the lowest pressure, maintaining the release up to 5 
days, and when the highest pressure was applied, the release was prolonged to 8 days, with 
no burst release for either sample. Whilst bulk crystallinity was maintained, pressure-induced 
amorphisation at particle surfaces could sufficiently block pores and slow down release. 
Thermal amorphisation has also been used to prolong the drug release times of NU-1000 and 
NU-901.25 These zirconium MOFs have remarkably high storage capacities – with calcein 
loadings of 41.6% w/w and 37.0% w/w, respectively – due to their high porosity (SBET = 2320 
and 2500 m2g-1, respectively), but their larger pore cavities can at the same time result in rapid 
drug release. Calcein was confirmed to be located in the pores, as the loaded samples had 
drastically reduced porosities. Temperature treatment (180°C) was performed in order to 
collapse the structure and to hinder calcein release through the pore cavity. In contrast to the 
mechanical amorphisation protocols performed on the UiO-66 family, although the intensity of 
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the Bragg peaks had decreased, they could still be observed clearly in the PXRD pattern, 
indicating only partial structure collapse. (Figure 1.19) 
 
Figure 1.19. Effect of temperature treatment in NU-1000 and NU-901 drug release kinetics. a) and b) 
PXRD patterns. c) and d) Drug release profiles in PBS.25 
The effect of thermal treatment on the drug release kinetics was clear; after 4 hours cal@NU-
1000 had released ~28% of its calcein, but after thermal treatment only 10% was released in 
the same time period. The release kinetics were slowed to the 7th day, when the profiles for 
thermally amorphised and pristine calcein-loaded NU-1000 overlap at around 80% release, 
and continue to release the full amount up to 7 weeks. On the other hand, only a minor effect 
on calcein release kinetics was found upon thermal treatment of NU-901. 25 
Incorporation of surface functionality can also block the release of cargo molecules. PNIPAM 
is thermosensitive polymer, which adopts a closed, globular mode at higher temperatures, 
and opens to a coil formation at lower temperatures. Thus, Kokado and Sada reported the on-
off thermoresponsive release of three different molecules – resorufin, caffeine and 
procainamide – from UiO-66-PNIPAM in water. 133 
The release kinetics at 25°C were slightly improved compared to the precursor UiO-66-NH2, 
which released ca. 95% of resorufin after few hours. Drug release from the PNIPAM-
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functionalised MOF was pronounced at 25° C, when the polymer is in its open coil form, 
exhibiting a burst release of more than 50% of the different molecules in the first few hours 
and 80-90% release after 1 day. The release kinetics were remarkably reduced at 40°C, with 
an initial release of only 10-20 % of the cargo molecules in the first hours and no subsequent 
release. As the drugs were loaded after PSM, the small amount of drug released initially at 
40°C could be a consequence of minor surface drug location. By changing the temperature 
during the course of the drug release experiment, UiO-66-PNIPAM drug release was switched 
on and off by external stimuli. It is important to point out that this temperature responsive 
behaviour was only achieved when the degree of PNIPAM coating was high enough to ensure 
significant surface coverage, as UiO-66-PNIPAM with 4.2% w/w PNIPAM did not present 
thermoresponsive behaviour (Figure 1.20).133 
 
Figure 1.20. Release behaviour of guest molecules (resorufin, caffeine, procainamide) from UiO-66-
PNIPAM in water at 25 °C and 40 °C for seven days. Stepwise release-and-halt behaviour of resorufin 
from UiO-66-PNIPAM in water by temperature variation. The release ratio was determined from the 
absorbance at 572 nm.133 
Willner et al studied the reorganisation of DNA on the surface of UiO-68 in response to pH 
and metal ions as mechanisms for the release of doxorubicin and several dyes.30 To induce 
pH responsive release, cytosine-rich DNA sequences were attached to the MOF surface, and 
the authors attributed the enhanced release of the molecules into PBS at pH 5 compared to 
that at pH 7.4 to the reorganisation of the cytosine-rich DNA into an i-motif structure that 
allowed cargo to be released, rather than linker protonation and structure decomposition. 
Metal ion (Mg2+ and Pb2+) responsive release was probed by attaching “DNAzyme” sequences 
through hybridisation with surface sequences. Upon metal-ion binding, these DNAzymes are 
released from the MOF and should result in uncapping and release of trapped cargo. The 
doxorubicin-loaded MOF was further functionalised with a DNA containing both an Mg2+ 
dependent DNAzyme sequence and an adenosine triphosphate (ATP) aptamer unit, based 
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on the fact that ATP concentrations are higher in cancerous cells than in healthy ones. 
Release was only slightly enhanced upon increase of Mg2+, but a two-fold increase was 
promoted through cooperation of Mg2+ and ATP addition. It should be noted that the phosphate 
units of ATP may also become involved with coordination to the Zr6 SBUs at the surface of 
the MOF.30 
The stability of Fe3O4@UiO-66-NH2 core-shell NPs has been investigated at different pHs 
(4.0, 5.0, 6.0, 7.4, 8.0) finding no significant changes in the crystallinity (PXRD) or morphology 
(SEM) of the samples.125 DOX was loaded into the core-shell Fe3O4@UiO-66-NH2 by stirring 
in PBS during 24 hours. DOX loading capability increases as the thickness of MOF shell does. 
Surprisingly, DOX loadings as high as 66.3 w/w % were achieved. DOX fluorescent quenching 
upon Fe3O4@UiO-66-NH2 addition strongly suggested interaction between the MOF and DOX. 
The authors suggested π-π stacking, hydrogen bonding between DOX atoms and UiO-66-
NH2 amino group, and attachment to the available Zr positions through DOX carboxylic group, 
being tha later confirmed through UV-Vis and X-ray photoelectron spectroscopy. 
DOX@Fe3O4@UiO-66-NH2 DOX release was investigated at various pHs (4.0, 5.0, 6.0, 7.4), 
finding a pH dependence with no burst release, only releasing a ca. 40 % of DOX at pH 4.0 
after 45 days. 125 
In general, all zirconium MOFs have pH responsive drug release as a consequence of 
hydrolysis, which is favourable for anti-cancer treatment, as the cytoplasm of cancer cells is 
more acidic than for healthy cells. If we compare the release kinetics of different drugs from 
UiO-66, it comes to mind that drugs attached to the Zr clusters (such as Alendronate)24 are 
released with a more favourable rate than drug stored in the pores (such as caffeine or 
resorufin).133 The importance of surface coating is obvious and has different effects depending 
on its nature. For example, surface coatings which can compete with phosphates during 
degradation highly enhance the stability of the samples through coordination equilibrium, and 
protecting polymers attached to the NMOFs surface also sterically protect them from 
degradation, although to a lower extent, as once the coating has been displaced, degradation 
occurs at a normal rate. Protocols to collapse NMOFs porosity around loaded molecules – 
such as mechanical amorphisation, temperature treatment, or applied pressure – have also 
induced more desirable release fates, although their effect in colloidal stability is not 
pronounced, indicating that surface coatings are more suitable to enhance both stability and 
dispersion. Thus, an appropriate strategy could be to perform surface coating after 
amorphisation.  
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1.9. Biocompatibility of Zr MOFs 
The therapeutic efficiency of any DDS is strictly correlated to its ability to cross the cell 
membrane and successfully deliver the drug to the various cell compartments.44, 45, 142 Both 
cell internalisation rates and routes are of crucial importance for efficiency OF  drug delivery, 
as well as low toxicity oF the DDS and its counter parts.42, 43 Importantly, the DDS should avoid 
immune system recognition, and thus not be internalised by immune system cells such as 
macrophages.143, 144 Hence, surface modifications to enable targeting and thus avoid immune 
system recognition while enhancing dispersion, stability and drug release kinetics – which are 
imperative for efficient DDS- are of great importance with the ultimate aim of enhancing 
NMOFs therapeutic efficiency. 
Nanoparticle’s cellular internalisation depends on many factors, including size, morphology 
and surface chemistry among others,45, 142, 145, 146 and attempts have been made to enhance 
uptake and also control the endocytosis mechanisms of MOFs.140, 147 Nanoparticles are 
generally internalised by cells through active transport such as endocytosis, including clathrin-
mediated,148, 149 caveolae-mediated,150, 151 non-mediated endocytosis, and 
macropinocytosis.152 While nanoparticles internalised through clathrin-mediated endocytosis 
are finally delivered to lysosomes, which can result in degradation and inefficient cytosolic 
release of the cargo, nanoparticles internalised through caveolae-mediated endocytosis can 
escape lysosome capture, typically resulting in faster cytosolic release and hence potentially 
higher therapeutic efficiency.151 For MOFs, fluorescent linkers or cargo molecules are usually 
used to monitor endocytosis through confocal microscopy and fluorescence-activated cell 
sorting (FACS) (See Chapter 4 for full discussion). 
In vitro cell proliferation experiments, such as MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), and MTT, (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, assays after incubation of cells with the DDSs, are 
used as key initial evaluators of the effect of factors such as surface modification and drug 
loading on their therapeutic effect and biocompatibility. These assays are based on the cellular 
internalisation of certain tetrazolium compounds and their cellular transformation into 
formazan products. The formazan products have a characteristic absorbance, which is 
measured by UV-Vis and compared to a control of untreated cells, indicating the methabolic 
activity of cells with and without treatment, and consequently the cell proliferation. 
The biocompatibility and therapeutic efficacy of empty Zr MOFs has been investigated before 
and after surface modifications (See Chapter 5 for full discussion).53, 54, 56, 153, 154 For example, 
the archetypal Zr MOF UiO-66 has been proven not to induce remarkable cytotoxicity in HeLa 
cervical cancer cells, with a half inhibitory concentration (IC50) of 1.50 ± 0.15 mgmL-1 after 24 
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hours of exposure.29 ZJU-800 has been also proved non-cytotoxic in rat neuroblastic 
pheochromocytoma PC12 cells after incubation with a solution of 0.1 mgmL-1 of NMOF during 
24 hours.141 
The biocompatibility of bare PCN-223 towards SMMC-7721 (human hepatocellular 
carcinoma) and HeLa cervix cancer cells was enhanced after PBLs coating, with nanoPCN-
223@DOPC/DOPC being non-cytotoxic at concentrations of 0.4 mgmL-1, while treatment with 
the same concentration of bare MOF decreased cell viability to ca. 70%, even though its cell 
internalisation efficiency is lower than for the coated MOF.26 
The potential of Zr-fum as DDS was investigated by attaching- through H6-Tag- various pro-
apoptotic peptides (Bak, Bad, KLK) and a cytochrome c protein (CytC) to the NMOF surface, 
which due to their membrane impermeability are not able to efficiently cross the cells 
membrane by themselves. Thus, a decrease on HeLa cells viability when treated with the 
NMOFs was considered a consequence of efficient cytotsolic release of the attached peptides. 
The authors compared the effects produced on cells growth to those obtained when incubating 
cells with free peptide or naked Zr-fumarate during the same period of time, 48 hours. The 
peptide or protein conjugated MOFs induced remarkably higher cytotoxicity on cells (ca. 40% 
cells viability) compared with the free peptide (ca. 90%), while naked MOF did not exhibit any 
cytotoxicity, confirming the high potential of Zr-fumarate as a DDS.128 
Although a wide variety of in vitro and in vivo studies of Zr MOFs as anticancer DDSs are 
present in the literature, and are discussed in Chapter 5, the examples discussed during this 
section highlight the high potential of Zr MOFs as DDSs, embodied by their efficient cargo 
release, colloidal stability and cellular internalisation.  
A considerable number of in vivo studies have been performed with a wide variety of MOFs, 
showing tumour remission after their intravenous administration. However, the potential of 
MOFs and other nanocarriers as DDSs is limited by the fact that they often accumulate in the 
liver and spleen, possibly due to macrophage recognition and internalisation.52, 135 
As such, from an ethical point of view, the need to find a rationalisation between the effect of 
the intrinsic characteristics of NMOFs, such as surface chemistry, on their properties (colloidal 
dispersion and physiological stability), and on their cellular internalisation, which is strictly 
related to their therapeutic efficacy, is inherently clear, providing if so the possibility of reducing 
early-stage animal testing while maximizing the potential application of MOFs as DDSs. Thus, 
finding insights to facilitate the thoughtful design of surface chemistry of MOFs, which should 
be efficiently internalised by cancer cells while able to avoid the immune system recognition 
and subsequent accumulation, might reduce unnecessary animal testing.  
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1.10 Conclusions and Future Work 
The high potential of Zr MOFs as DDSs has been highlighted in the context of their 
biocompatibility and amenable functionalisation, which further improves Zr MOFs properties 
such as colloidal dispersion in aqueous solvents, physiological stability and drug release 
kinetics. The latter, due to the nature of the metal-linker coordination bond, are sensitive to 
pH changes, an enormous advantage for anticancer DDSs, given that extracellular pH is ~7.4, 
and intracellular pH of cancer cells (~5.5) is more acidic than for healthy cells (~6.8).  
Examples of Zr MOFs surface functionalisations, subsequent properties and therapeutic effect 
are constantly emerging in the literature, and many reports have been published during the 
course of this thesis. However, one-pot functionalisations are still scarce in the literature, and 
to the best of the author’s knowledge, simultaneous surface functionalisation and drug loading 
during synthesis has not been achieved so far.  
This thesis will focus on the development of surface functionalisation protocols of UiO-66, both 
during synthesis and postsynthetically, the study of the MOFs’ properties, and correlation 
between cellular internalisation fates and routes with their therapeutic efficiency. 
The use of carboxylate containing surface reagents and a carboxylate containing anticancer 
metabolic target (dichloroacetic acid, DCA) as modulators of UiO-66 synthesis will be explored 
with the aim of obtaining surface-functionalised drug-loaded MOFs by one-pot syntheses, and 
empty surface-functionalised MOF analogues.  
The surface functionalities of certain modulators will be used to postsynthetically modify the 
MOFs surface through covalent chemistry with protecting polymers. Coordinating surface 
reagents (e.g the former carboxylate modulators) will be postsynthetically attached to the MOF 
surface, in order to compare the MOFs properties - colloidal dispersion and stability - 
depending on both surface coating type (targeting unit, polymers etc) and synthetic mode (e.g 
coordination modulation of postsynthetically).  
Additionally, the DCA modulated synthesis will be applied to the UiO family of isoreticular 
MOFs (including UiO-66 and its bromo, nitro and amino derivatives, Zr-Naphthalene and UiO-
67). DCA has a low pKa and hence its attachment to the Zr clusters should be pronounced, 
inducing defects and a consequent high surface charge, which was found desirable for 
colloidal dispersion by a separate group120 during the course of this PhD.  
Further discussion of examples of cellular internalisation of MOFs present in the literature will 
be provided during Chapter 4, and the endocytosis routes and fates of bare and surface 
functionalised calcein-loaded UiO-66 will be studied in order to find a correlation with their 
therapeutic efficacy. Rationalisation of literature examples of in vitro studies of Zr MOFs with 
Chapter 1: Introduction 
36 
 
their properties and cellular internalisation will be provided in Chapter 5. The biocompatibility 
of the empty surface-functionalised and bare MOFs will be assessed, and the therapeutic 
efficiency, anticancer selectivity of the DCA-loaded surface functionalised MOFs will be 
studied in a series of cancerous and healthy cell lines, including a study of the macrophage 
uptake, cytotoxicity and reactive oxygen species production.  
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2.1 Introduction  
The high drug loading and excellent biocompatibilities of metal-organic frameworks (MOFs) 
have led to their application as drug delivery systems (DDSs).1-3 Nanoparticle surface 
chemistry dominates both biostability and dispersion of DDSs while governing their 
interactions with biological systems, cellular and/or tissue targeting, and cellular 
internalisation, leading to a requirement for versatile and reproducible surface 
functionalisation protocols. Although a considerable amount of work has been performed to 
modify the bulk structure and internal pore spaces of MOFs,4-11 only few studies have 
addressed their external surface chemistry, usually through surface-selective postsynthetic 
modification protocols designed for specific MOFs and surface substrates.12-17 
Effective cell internalisation and intracellular drug release are vital characteristics of effective 
nanoparticulate DDSs.18-22 Nanoparticles are generally internalised through active transport 
mechanisms such as endocytosis, however, if they are small enough (<20 nm), nanoparticles 
can be internalised by passive diffusion, enabling direct release of cargo into the cytosol.23 
Cell internalisation pathways are closely related to both particle size and surface chemistry.22, 
24, 25 It has been recently reported that 50-600 nm nanoparticles of UiO-66, the zirconium 1,4-
benzenedicarboxylate (bdc)26 MOF with ideal formula [Zr6O4(OH)4(bdc)6]n, and its -Br, -NO2, 
and -NH2 functionalised derivatives undergo HeLa cancer cell internalisation primarily through 
clathrin-mediated endocytosis, while isoreticular MOFs with more hydrophobic, extended 
linkers, such as 2,6-napthalenedicarboxylate and 4,4′-biphenyldicarboxylate, are partially 
internalised through caveolae-mediated endocytosis and release their cargo into the cytosol, 
thus enhancing therapeutic efficiency.27 
The size and shape of NMOF particles can be tuned by introducing modulators – monotopic 
capping agents such as benzoic acid - to their syntheses.28-33 It is well known that 
monocarboxylic acid modulators can be attached to Zr MOFs surface and defect sites during 
synthesis, boosting their porosity.34-37 Coordination modulation offers the prospect of 
decorating the external surfaces of MOFs with desirable functionality during the synthetic 









Despite the clear need to develop reproducible and versatile protocols to modify the outer 
surfaces of MOFs, few studies have addressed this issue so far, and even though it has been 
reported that drugs can be introduced into MOFs during synthesis, achieving one pot-
syntheses to create drug containing nanoparticulate MOFs (NMOFs) with functionalised 
surface is still a challenging goal. 
UiO-66 was chosen as the object of study as it has excellent biocompatibility38 which, together 
with its well-characterised structure,26 ability to cross the cell membrane39, 40 and pH 
responsive drug release,40, 41 makes it a great candidate for nanoparticle-conjugated anti-
cancer drug delivery. Additionally, it is well known that monocarboxylic acid functionalised 
modulators can be attached to its surface and defect sites during synthesis, yielding highly 
porous nanoparticles.36, 42, 43  
With this ultimate aim, a protocol to introduce various surface reagents and an anticancer 
metabolic target (Figure 2.1a) to UiO-66 external surface and defect sites during its synthetic 
process has been conceived. Functionalised p-benzoic acid modulators, p-
azidomethylbenzoic acid (L1) and p-propargyloxybenzoic acid (L2), have been chosen as 
modulators due to their structural similarities compared to the bdc linker, and the fact that, if 
attached to the Zr6 clusters of UiO-66, the desired functionalities should point outwards, 
resulting in accessible reactive groups as platforms for further postsynthetic modifications on 
its surface (Figure 2.1b).  
 
Figure 2.1. a). Scope of modulators utilised in UiO-66 modulated synthesis. b) Schematic 
representation of UiO-66-L1 synthetis, in which modulator L1 gets attached to the Zr6 clusters on UiO-
66 surface during synthesis. c) Synthesis of DCA-loaded, surface modified MOFs obtained through 
coordination modulation (CM) 
Additionally, more complex carboxylate containing molecules such as vitamin B9 folic acid 
(FA) and vitamin B7 biotin (Biot) will be used to modulate UiO-66 synthesis. Particularly, FA 
has been widely used as a targeting unit for cancer cells, as most of them overexpress the 
folate receptor (FR) on their cell membrane surface, enhancing and directing the uptake of 




the DDSs to cancer cells. In order to study the modulating capability of the selected 
modulators, the modulated samples were compared with unmodulated or AcOH modulated 
UiO-66. 
Dichloroacetic acid (DCA), a small molecule that inhibits pyruvate kinase dehydrogenase, 
targeting the metabolism of cancer cells (See section 5.1.3 for full discussion), has been 
chosen as a modulator of UiO-66, in order to synthesise drug-containing surface 
functionalised MOFs buy one-pot synthesis. The lower pKa value (1.36) of dichloroacetic acid 
means that considerable amounts could be attached to UiO-66 Zr positions at defect sites 
during synthesis, even in the presence of other functionalised modulators (Figure 2.1c). 
Additionally, this concept of defect loading of drugs that act as modulators during synthesis 
could be applied to any therapeutic molecule containing carboxylate groups, such as 
doxorubicin.  
The DCA-modulated protocol will be extended to the UiO series of isoreticular Zr6 MOFs 
(Figure 2.2), which includes the use of terephthalic acid, functionalised terephthalic acid 
derivatives containing bromo, nitro or amino pendant functionalities and extended linkers such 
as 2,6 naphthalenedicarboxylic acid, and 4,4’ biphenyldicarboxylic acid, forming the MOFs 
UiO-66, DUT-52 and UiO-67 respectively. These MOFs and their linkers do not induce 
cytotoxicity to HeLa cervix cancer cells for concentrations up to 1 mgmL-1. 
Different synthetic conditions will be applied with the aim of controlling particle size and 
obtaining smaller (< 20 nm) - in order to enable passive diffusion of the drug containing MOFs 
into cancer cells with the ultimate goal of enhancing their therapeutic efficiency - and bigger 
(ca. 100 nm) nanoparticles to allow comparison of their cytotoxicity depending on both size 
and surface chemistry during Chapter 5. 
 
 
Figure 2.2. Structures of linkers used in the preparation of the UiO series of Zr MOFs. 





Attaching a small molecule with anticancer activity to MOFs metal clusters, creating defective 
structures, should allow the possibility of introducing a second drug into the MOF pores for 
multimodal treatments. For example, cisplatin prodrugs containing axial DCA ligands have 
been reported to be more effective than cisplatin, and able to overcome cisplatin resistance. 
Similarly, DCA is known to enhance the anticancer effect of 5-fluorouracil (5-FU) and to reduce 
resistance. Hence, the smaller DCA@UiO MOFs will be postsynthetically loaded with 5-FU in 
order to study their cytotoxic activity during Chapter 5.  
2.3 UiO-66 Modulated Synthesis and Characterisation 
Characterisation of the chemistry at the external surfaces of MOFs is complicated by the 
surface comprising a small fraction of the bulk material, although general guidelines can be 
followed. Nuclear magnetic resonance (NMR) spectroscopy of digested samples can give 
insights into the composition of the sample; the molar ratio of surface components compared 
to the linker can be estimated based on the intensities of resonances assigned to protons of 
both the linker and surface reagents, although defectivity hampers efforts to obtain mass 
fractions of surface functionality. Reactivity of linkers or functionalised modulators can also be 
assessed. Thermogravimetric analysis (TGA) can provide information on the gravimetric 
content and nature of the coating. If new mass loss events are observed at a higher 
temperature than those of free surface reagents, coordinative attachment to the Zr positions 
rather than simple electrostatic forces or surface adsorption is suggested. Similarly, the 
shifting of characteristic signals in Fourier transform infrared (FT-IR) spectra resulting from 
the coordination surface reagents, and/or appearance of new signals corresponding to 
coordination bonds between Zr and surface reagents, indicate attachment through 
coordination. Porosity should not be significantly affected by surface functionalisation, 
although addition of mass at the surfaces may result in lower gravimetric gas uptake and 
surface areas. If the modified MOF has much lower porosity (or is non-porous), it is an 
indication that the surface reagents are also coordinated in the inner porosity or simply stored 
in the pores as guests. Scanning electron microscopy (SEM) may also show the physical 
effects of surface modification; large polymers may induce “rounding” of particle surfaces. It 
is important to note that in order to confirm surface coating content and mode, the correlation 
of a number of techniques is required. 
  




2.3.1 The Use of Functionalised Benzoic Acid Derivatives as Modulators  
UiO-66 nanoparticles were synthesised via solvothermal conditions37 (Section 2.6) by adding 
1, 3 or 5 equivalents of the desired modulator (L1 or L2) with 7 v/v % acetic acid (AcOH) as 
co-modulator, yielding in highly crystalline nanoparticles, as confirmed by PXRD (Figure 2.3), 
with enhanced crystallinity compared to unmodulated or AcOH modulated samples. An 




Figure 2.3. Stacked PXRD patterns of UiO-66 modulated with a) L1 and b) L2. 
The modulator (L1 or L2) content in the UiO-66 samples was calculated using 1H NMR 
spectroscopy of samples digested in D2SO4 / DMSO-d6. By comparing intensity of one of the 
aromatic signals of the modulator (d, 2H) to the resonance of the aromatic protons of the bdc 
linker (s, 4H), it is possible to determine modulator content. 
Typical 1H NMR spectra are shown in Figure 2.4, which corresponds to UiO-66-L1 (5 eq), and 
UiO-66-L2 (3 eq). The integral ratios confirm that L1 is present in 13.3% molar ratio when 
compared to the linker, BDC, and L2 is present in 6.8% molar ratio. In this way, the content of 
both L1 in UiO-66-L1 and L2 in UiO-66-L2 could be determined (Table 2.1). 
 





Figure 2.4. a) 1H NMR spectrum (D2SO4 / DMSO-d6, 293 K) of UiO-66-L1 (5 eq), showing the presence 
of the modulator L1. b) 1H NMR spectrum (D2SO4 / DMSO-d6, 293 K) of UiO-66-L2 (3 eq), showing the 
presence of the modulator L2.  
 
Table 2.1. Modulator content in UiO-66 samples determined by 1H NMR spectra. 
Modulator L1 (1 eq) L1 (3 eq) L1 (5 eq) L2 (1 eq) L2 (3 eq) L2 (5 eq) 
Mol % versus bdc 5.6% 8.3% 13.3% 1.2% 6.8% 17.1% 
 
FTIR spectra of the samples revealed an increase in the intensity of the N3 vibration band at 
1100 cm-1 as the number of equivalents in UiO-66-L1 syntheses increases, while vibration 
bands characteristic of C-C triple bonds were observed for UiO-66-L2 (Figure 2.5).  
 
Figure 2.5. FTIR spectra of modulated UiO-66 samples showing the presence of functional groups of 
a) L1 and b) L2 in the synthesised MOF. 




The effect of modulator incorporation on particle size was examined by SEM imaging. For 
UiO-66-AcOH (Figure 2.6), particles were roughly spherical aggregates of very small crystals, 
with a diameter of around 200 nm. 
 
 
Figure 2.6. SEM images of UiO-66-AcOH. 
For UiO-66-L1 samples, the morphology is noticeably different, being roughly octahedral 
crystallites of 100-200 nm in size regardless of the number of equivalents of L1 included in 
the synthetic mixture (Figure 2.7). UiO-66-L1 synthesised with 5 equivalents of L1 had an 
average particle size of 147 ± 30 nm, determined by ImageJ software. 
 
 
Figure 2.7. SEM images of a) UiO-66-L1 (1 equiv), b) UiO-66-L1 (3 equiv), and c) UiO-66-L1 (5 equiv). 
In contrast, samples of UiO-66-L2 became larger and more polydisperse as more equivalents 
of L2 were included in the synthetic mixture (Figure 2.8), reaching sizes of ~600 nm for UiO-
66-L2 (5 equiv). UiO-66-L2 (1 equiv) has a reasonable particle size range of around 200-300 
nm, but as 1H NMR spectroscopic analysis showed very little incorporation of L2, UiO-66-L2 
(5 equiv) was used for proof-of-concept surface modification along with UiO-66-L1 (5 equiv) 
in Chapter 3. 
 





Figure 2.8. SEM images of a) UiO-66-L2 (1 equiv), b) UiO-66-L2 (3 equiv), and c) UiO-66-L2 (5 equiv). 
The quantities of organic components (either BDC or the modulator) present in UiO-66-L1 and 
UiO-66-L2 (all subsequent samples synthesised with 5 equivalents of modulator) were 
calculated by TGA measurements (Figure 2.9) and used for further degradation studies during 




Figure 2.9. TGA traces (recorded in air) of UiO-66-L1 and UiO-66-L2, compared to L1 and UiO-66-
AcOH. 
 




It has been previously reported that when UiO-66 (Zr6O4(OH)4L6 theoretical structure) is 
thermally degraded in air, the first mass loss step at 200-300 ºC corresponds to the zirconium 
clusters losing 2 molecules of water, adopting the Zr6O6L6 molecular formula, then, the ligand 
decomposition takes place near 500 ºC, leaving the residue ZrO2.44 Therefore, by comparing 
experimental mass loss of the last decomposition step with the weight percent of the linker in 
the [Zr6O4(OH)4Lx]n structure for different values of x, the number of ligands in the structure 






Table 2.2. Theoretical compositions of different defective UiO-66 samples. 
Number of linkers in Zr6O4(OH)4Lx Linker wt% 
X=6 59.2 wt% 
X=5 54.5 wt% 
X=4 49.1 wt% 
X=3 42.0 wt% 
 
It can be observed in Figure 2.9 that the last decomposition step of UiO-66-AcOH corresponds 
to 46.8 wt% of the sample, which matches a material with 2.5 ligands missing, leading the 
approximate composition [Zr6O4(OH)4L3.5]n, with either acetates, chlorides or solvents at defect 
sites. 
When L1 is introduced to the synthetic procedure, the material [Zr6O4(OH)4Lx(L1)y]n shows a 
similar decomposition profile to UiO-66-AcOH, indicating that L1 degrades together with the 
linker (BDC) but at a lower temperature, suggesting L1 is incorporated at the surfaces or the 
particles and at defects. As L1 has a similar molecular weight to the BDC linker the total 
organic content (BDC and L1) present in the sample has been estimated using the former 
theoretical calculations. In UiO-66-L1 the last decomposition step corresponds to 59.1% of 
the total weight of sample, suggesting a full complement of six linkers/modulators in the 
structure. Therefore, the UiO-66-L1 composition is expected to be close to [Zr6O4(OH)4L6-x 
L1x]n. UiO-66-L2 shows a more complex degradation profile, in which degradation of the last 
ligand step corresponds to 46.2 wt%. As its bioapplications, due to particle size, were not 
further studied (see Chapter 4 and Chapter 5), no in depth analysis of its thermal degradation 
was performed.  




The porosities of the samples were measured by N2 adsorption isotherms at 77 K, and the 
adsorption isotherms (Figure 2.10a) yielded the following information: 
UiO-66-AcOH: SBET = 1232 m2g-1; pore volume = 0.652 ccg-1. 
UiO-66-L1: SBET = 1565 m2g-1; pore volume = 0.762 ccg-1. 
UiO-66-L2: SBET = 1420 m2g-1; pore volume  = 0.702 ccg-1. 
 
 
Figure 2.10. a) Adsorption and desorption isotherms (N2, 77 K) of UiO-66-L1 and Ui-66-L2 modulated 
samples compared to UiO-66-AcOH. Filled symbols represent adsorption, empty symbols represent 
desorption. b) Pore size distribution (slit pore, N2 at 77 K on carbon, QSDFT equilibrium model) of UiO-
66-L1 and UiO-66-L2 modulated samples compared to UiO-66-AcOH.  
The surface areas for the samples modulated by 5 equivalents of L1 and L2 are enhanced, 
while the pore size distribution of these modulated samples (Figure 2.10b) is similar to the 
reported for UiO-66 (8 Å and 11 Å).26 These results, together with the pore volume 
determination and the surface area of the nanoparticles, unequivocally confirm that the 
modulators are attached to the surface and defects sites and not stored in the pores of the 
NMOFs.  
  




2.3.2 The Use of Biotin and Folic Acid as Modulators  
Four samples were initially prepared by coordination modulation, with biotin and folic acid 
added during synthesis. The samples are named, taking into account the addition (or not) of 
acetic acid as a co-modulator during synthesis, UiO-66-FA (CM), UiO-66-Fa-AcOH (CM), UiO-
66-Biot (CM), and UiO-66-Biot-AcOH (CM) (Section 2.6). Analysis by PXRD (Figure 2.11) 
shows that all the samples exhibit characteristic reflections to confirm the formation of UiO-
66.26 When acetic acid (7% v/v) is added to the reaction mixture as a co-modulator, the 
intensity of the peaks increased. It is notable that UiO-66-FA (CM) has a broad pattern with 
low intensity, suggesting small particle size or perhaps incorporation of folic acid, which is 
itself a dicarboxylic acid, into the structure as defects. 
 
 
Figure 2.11. Stacked PXRD patterns of the surface modified UiO-66 samples prepared by the direct 
coordination modulation approach. 
Due to the strength of the Zr-carboxylate bond, acidification and heating are needed to 
dissolve the MOFs for 1H NMR spectroscopy analysis. Hence, study of the acidified and 
heated 1H NMRs of their surface reagents (folic acid and biotin) is imperative, as the 
preparation conditions could result in structural composition changes, with different resonance 
signals and integration ratio than the non-acidified spectra prepared at room temperature. Full 
characterisation of the surface reagents 1H NMRs spectra is given in the appendix, while the 
MOFs 1H NMR spectra are compared to addified 1H NMR of their modulator.  




The 1H NMR spectra of the modulated samples after acid digestion show the presence of the 
modulator in all cases.Generally, when acetic acid is added as a co-modulator during 
synthesis, the quantity of incorporated modulator decreases. This could be explained due to 
the more acidic pH of the reaction mixture and therefore more gradual deprotonation of the 
modulators’ carboxylic acid groups, or due to competition between the two modulators for the 
Zr4+ cations during synthesis.28 Although the coordination modulation protocol and 
crystallisation process of these MOFs are still not fully understood, the role of the pKa of the 
different modulators is thought to play a crucial role.35, 37 
When only folic acid is used as the modulator in the synthesis of UiO-66-FA (CM), folic acid, 
which possesses two carboxylic acid groups, is significantly incorporated into the materials, 
with resonances assigned to folic acid easily identified in the 1H NMR spectrum (Figure 2.12) 
(See appendix for full characterisation of the effect of acid and heating in folic acid 1HNMR 
resonance signals). Analyses based on the intensities of the different resonances of the folic 
acid alkyl protons (G, H, I, and J) were consistent, and the integral ratios confirm folic acid is 
present with a 28.0% molar ratio when compared to the bdc linker, while the folic acid content 
determined by UV-Vis spectra of the digested samples, was 13.6% w/w (Section 2.6)  
 
Figure 2.12. Stacked partial 1H NMR spectra of UiO-66-FA (CM), bottom, and folic acid, top, in D2SO4/ 
DMSO-d6 with signal assignment.  
Although still appreciable, folic acid resonances in the 1H NMR spectrum of UiO-66-FA-AcOH 
(CM) have lower intensity, hindering their analysis (Figure 2.13). The lower incorporation when 
AcOH is added as the co-modulator of the synthesis was expected, and the content of folic 
acid dropped from 28% molar ratio in UiO-66-FA (CM) to 12% molar ratio in UiO-66-FA-AcOH 




(CM), or in other words the incorporation of folic acid decreased by 57% when acetic acid is 
present, based on 1H NMR spectroscopic analysis. The incorporation determined by UV-Vis 
spectroscopy was 7.0% w/w, around 50% lower than for UiO-66-FA (CM), and in great 
agreement with the 1H NMR spectroscopy results.  
 
Figure 2.13. Stacked partial 1H NMR spectra of UiO-66-FA-AcOH (CM), bottom, and folic acid, top, in 
D2SO4/ DMSO-d6. 
The presence of biotin in both UiO-66-Biot (CM) and UiO-66-Biot-AcOH (CM) was also 
confirmed by 1H NMR spectroscopy of the acid-digested samples (Figures 2.14 and 2.15, 
respectively, See appendix for full biotin acidified 1HNMR discussion). Its incorporation was 
however considerably lower than folic acid, possibly due to the difference in the pKa values of 
their carboxylic acid groups.37 
Biotin content was estimated through analysis of alkyl proton resonances; B, C, and D 
(equivalent for a total of 6H) and A (2H) which were compared to the aromatic resonance for 
bdc. Integral ratios confirmed the presence of biotin in UiO-66-Biot (CM) in a 7% molar ratio 
compared to bdc, while UiO-66-Biot-AcOH (CM) shows very little incorporation of biotin, with 
the resonances observable, but too weak to allow quantification. 





Figure 2.14. Stacked partial 1H NMR spectra of UiO-66-Biot-AcOH (CM), bottom, and biotin, top, in 
D2SO4/ DMSO-d6 with signal assignment, showing disappearance of resonances for exchangeable N-
H protons upon acidification. 
 
Figure 2.15. Stacked partial 1H NMR spectra of UiO-66-Biot-AcOH (CM), bottom, and biotin, top, in 
D2SO4/ DMSO-d6. 
While the carboxylic acid groups of the linker bdc have pKa values of 3.54 and 4.46, the 
carboxylic acid groups of folic acid have pKa values of 3.5 and 4.3, and the pKa of the biotin 
carboxylic acid is 4.5. The pKa values of the linker and the two modulators are close, but folic 
acid has slightly lower values and also two sites of attachment, possibly explaining why its 
incorporation is higher.  
Different features in the TGA profiles of the modulated samples were observed when 
compared to unfunctionalised UiO-66 (Figure 2.16).  
The folic acid modulated UiO-66 samples showed TGA profiles with additional mass loss 
features around 300-400°C compared to unfunctionalised UiO-66. These events occur at a 
higher temperature than for folic acid itself, strongly indicating its attachment to the MOF rather 




than being stored in the pores. Due to the gradual thermal degradation of folic acid, 
quantitative determination of the mass fraction is not possible using TGA. When only folic acid 
is added as the modulator of UiO-66 synthesis the metal residue at 800 °C is lower than when 
acetic acid acts as the co-modulator consistent with higher incorporation of folic acid observed 
in the 1H NMR and UV-vis spectra. The linker degradation occurs, although in a more gradual 
way, at a similar temperature to UiO-66.  
When biotin is used as the modulator of UiO-66 synthesis only minor incorporation was 
observed by 1H NMR spectroscopy, decreasing with the addition of AcOH as a co-modulator. 
Similar TGA profiles to UiO-66 were obtained (Figure 2.16), in which new mass loss events 
are also observed around 300-450 ºC.  
 
 
Figure 2.16. TGA traces of MOFs surface modified through coordination modulation compared with the 
surface functionality and unfunctionalised UiO-66, for a) UiO-66-FA (CM), b) UiO-66-FA-AcOH (CM), 
c) UiO-66-Biot (CM), and d) UiO-66-Biot-AcOH (CM). 
The FT-IR spectra of the folic acid modulated samples showed new peaks in the carboxylic 
acid region (1700 cm-1), matching with a major peak in the FT-IR spectrum of folic acid, 




although slightly shifted as a possible consequence of its coordination to the Zr positions 
(Figure 2.17).  
 
Figure 2.17. FT-IR spectra of the folic acid modulated MOFs compared to bare UiO-66 and the surface 
functionality, for a) UiO-66-FA (CM), and b) UiO-66-FA-AcOH (CM). 
When biotin is used as the modulator of UiO-66 synthesis, new characteristic peaks also 
appear in the same region of the FT-IR spectrum, suggesting coordination and incorporation 
of biotin into the UiO-66 samples (Figure 2.18). 
 
Figure 2.18. FT-IR spectra of the biotin modulated MOFs compared to bare UiO-66 and the surface 
functionality, for a) UiO-66-Biot (CM), and b) UiO-66-Biot-AcOH (CM). 
The porosity of the samples was studied using N2 adsorption and desorption measurements 
(Figure 2.19). UiO-66-FA (CM) was the only sample with lower porosity compared to UiO-66, 
but it is also the sample with the highest modulator incorporation and a possibly defective 
structure, as indicated by the broad PXRD pattern. Folic acid possesses two carboxylic acid 
groups with a similar arrangement to fumaric acid, which is also capable of forming a UiO-66 
topology MOF known as Zr-fumarate.32 The surface area of UiO-66-FA (CM) is similar to that 
reported for Zr-fumarate, indicating that folic acid could be partially incorporated as the linker 
of UiO-66-FA (CM). As folic acid is bigger than UiO-66 pore, its incorporation in the pore 




cavities is unlikely. Folic acid incorporation determined by UV-Vis (13.6% w/w), and estimated 
by 1H NMR (28% molar ratio), is considerably large for it to be found only in the outer surface, 
and it is likely distributed throughout the particles in a defective manner, as indicated by the 
featureless pore size distribution. 
 
 
Figure 2.19. a) N2 adsorption isotherms (77 K) of the MOFs surface modified by coordination 
modulation. Closed symbols for adsorption, empty symbols for desorption. b) Pore size distributions 
calculated form the isotherms. 
UiO-66-FA (CM): SBET = 753 m2g-1; pore volume= 0.405 ccg-1 
UiO-66-FA-AcOH (CM): SBET = 1377 m2g-1; pore volume= 0.672 ccg-1 
UiO-66-Biot (CM): SBET = 1129 m2g-1; pore volume= 0.578 ccg-1 
UiO-66-Biot-AcOH (CM): SBET = 1227 m2g-1; pore volume= 0.578 ccg-1 
When acetic acid is added as the co-modulator in the synthesis of UiO-66-FA-AcOH, as the 
amount of incorporated folic acid decreases, so increases the surface area of UiO-66-FA-
AcOH (CM). Biotin modulated samples exhibit similar porosity to UiO-66,26 with slightly higher 
porosity when AcOH is used as the co-modulator, again suggesting surface attachment and 
consequent creation of defects.37, 42, 43, 45  
  




SEM imaging was used to study the size and morphology of the folic acid and biotin modulated 
samples (Figure 2.20). 
 
Figure 2.20. SEM images of a) UiO-66-FA (CM), b) UiO-66-FA-AcOH (CM), c) UiO-66-Biot (CM), and 
d) UiO-66-Biot-AcOH (CM). 
On the one hand UiO-66-FA (CM) forms very small nanoparticles, thus its size was difficult to 
determine by SEM. The smaller size when only folic acid is added as the modulator indicates 
that it acts as a capping agent, with an average size of 35.9 ± 13.2 nm, determined by ImageJ 
software. On the other hand, when AcOH is the co-modulator, UiO-66-FA-AcOH (CM) 
particles are not homogeneous in size and different populations can be observed by SEM, 
one with bigger particles around 2 µm and another with small poorly defined nanoparticles. 
This could be explained once again by competition or pH variability, highlighting the complexity 
and variability of the coordination modulation process. Therefore, for further drug delivery 
experiments, UiO-66-FA (CM) was chosen.  
The role of the modulator in particle size and morphology is remarkably important when 
studying the differences between folic acid or biotin modulated samples. UiO-66-Biot (CM) 
particles consist of small interpenetrated crystallites with an individual size of around 120 nm, 
growing among each other extensively. When AcOH is also added to the reaction mixture, 
UiO-66-Biot-AcOH forms individual crystallites of 157.2 ± 15.8 nm with defined edges; for this 
reason it was chosen for biological testing.  
 




2.3.3 The Use of Dichloroacetic acid (DCA) as Modulator  
DCA is a pyruvate D-kinase inhibitor,46-48 which is over expressed in cancerous cells.49, 50 Its 
hydrophilic nature hinders its cell uptake;51 as its cytotoxic effects on cancer cells depend on 
effective cytosolic release and mitochondrial localisation making it an ideal mechanistic probe 
molecule for cell uptake.  
DCA@UiO-66, DCA@UiO-66-L1 and DCA@UiO-66-L2 were synthesised according to 
previous methods,37 using dichloroacetic acid as a modulator in place of acetic acid. The lower 
pKa of dichloroacetic acid compared to acetic acid ensures it is incorporated into the MOFs in 
significant quantities at defect sites. The samples were obtained as phase pure fine powders 
with high crystallinity, as confirmed by PXRD (Figure 2.21). 
 
Figure 2.21. Stacked PXRD patterns of DCA-loaded UiO-66 samples prepared by coordination 
modulation. 
The presence and quantity of DCA and the functionalised modulators L1 and L2, compared 
to the ligand bdc, were assessed by 1H NMR spectroscopy of samples digested in D2SO4 / 
DMSO-d6.  
From the 1H NMR spectrum of digested DCA@UiO-66-L1 (Figure 2.22 a), the content of 
functionalised modulator, L1, and DCA was estimated to be 5.7 mol % and 32.4 mol %, 
respectively, compared to bdc. Similarly, in the 1H NMR spectrum of digested DCA@UiO-66-
L2 (Figure 2.22 b), the presence of L2 and DCA was confirmed, showing a molar integral ratio 
of 4.4 mol % and 33.2 mol %, respectively, compared to the bdc linker. 
 





Figure 2.22. a) 1H NMR spectrum of DCA@UiO-66-L1 digested in D2SO4 / DMSO-d6. The resonance 
at 6.6 ppm corresponds to the HOOCCHCl2 proton in DCA. b) 1H NMR spectrum of DCA@UiO-66-
L2 digested in D2SO4 / DMSO-d6. The resonance at  = 6.6 ppm corresponds to the HOOCCHCl2 proton 
in DCA. 
It can be observed that for the two DCA functionalised modulated samples, the modulator 
content is remarkably lower than when the samples are co-modulated with acetic acid (Section 
2.3). The difference in the pKa values of acetic acid (4.8) and dichloroacetic acid (1.4) might 
explain the different features of the samples when using the same functionalised modulator 
and either DCA or AcOH as co-modulators.35, 37 The lower pKa of DCA means that it will be 
more easily deprotonated in the reaction mixture, and therefore the competition with the 
functionalised modulators and linker will be higher, resulting in lower incorporation of 
functionalised modulator. Indeed, the pKa values of benzoic acid derivatives are in general 
close to the pKa values reported for bdc (3.54 and 4.46).35 It has also been reported that 
incorporation of modulator as capping defects in UiO-66 increases as their pKa decreases.37 
The size of the nanoparticles was analysed by SEM imaging (Figure 2.23) showing that the 
samples are composed of nanoparticles with regular size.  





Figure 2.23. SEM images at different magnifications of a) DCA@UiO-66, b) DCA@UiO-66-L1, and c) 
DCA@UiO-66-L2. 
The size of the NMOFs differs slightly among the different functionalised modulators used 
during synthesis. Indeed, when no co-modulator is used, DCA@UiO-66 nanoparticles are 
typically 77 ± 24 nm in size, and the size is maintained or increased when the functionalised 
modulators are added, being 100 ± 15 nm for DCA@UiO-66-L1 and 77 ± 11 nm for 
DCA@UiO-66-L2. The size distributions are also in general more homogeneous when a 
functionalised co-modulator is present during synthesis.  
An additional DCA decomposition step is clearly noticeable in the TGA profiles of the samples 
(Figure 2.24) at temperatures of around 250-350 ºC. Interestingly, this decomposition step 
when found within the UiO-66 structure generally starts at a higher temperature than the one 
reported for DCA as a free molecule (194 °C),52 thus indicating that it is attached to the 
structure through coordination of its carboxylic acid group to Zr6 secondary building units.  
The mass fraction of DCA can be determined by TGA, as shown in Table 2.3, and is quite 
similar across the samples. The chlorine atoms of DCA also allow its quantification by 
inductively coupled plasma mass spectrometry (ICP-MS). The values for DCA loading from 
ICP-MS (after deduction of the chlorine content of a blank sample of UiO-66 to account for 
residual chloride from the ZrCl4 starting material) correlate very well with those from TGA. 
 





Figure 2.24. TGA traces for DCA-modulated MOFs compared to the empty materials for a) DCA@UiO-
66, b) DCA@UiO-66-L1, and c) DCA@UiO-66-L2. 
 
Table 2.3. TGA residues and DCA loading values from TGA and ICP-MS for the DCA-loaded samples. 
Sample TGA residue at 
800°C (% w/w) 
DCA content (TGA / 
ICP) % w/w 
DCA@UiO-66 41.3 17.0 / 16.9 
DCA@UiO-66-L1 43.7 15.9 / 15.5 
DCA@UiO-66-L2 36.6 18.7 / 18.9 
 
FT-IR spectra were collected to monitor the nature of DCA incorporation after coordination 
modulation (Figure 2.25). Although some of the signals associated with its functional groups 
are masked by UiO-66 vibration bands, new ones can easily be identified. Firstly the new band 
around 1750 cm-1, partially overlapping with UiO-66 carboxylic acid vibration bands, is 
attributed to the DCA carbonyl stretch. Importantly, it can be observed that in all the UiO-66 
samples the signal is shifted to slightly lower values, indicating attachment through the 
carboxylic acid group of DCA rather than pore storage. Also, the band associated to the C-Cl 
stretch (800 cm-1) is appreciable with no shifting observed. 





Figure 2.25. FT-IR spectra of DCA-loaded MOFs compared to the UiO-66 and DCA, for a) DCA@UiO-
66-L1, b) DCA@UiO-66-L2, and c) DCA@UiO-66. 
Even though they are of low intensity, due to the relatively small incorporation of functionalised 
modulator determined by 1H NMR spectroscopy, signals associated with the functional groups 
of the modulators were observed in the FT-IR spectra. For example DCA@UiO-66-L1 exhibits 
the characteristic azide band (2100 cm-1) of the modulator L1, while DCA@UiO-66-L2 FT-IR 
shows the alkyne characteristic vibration bands of L2. 
Nitrogen adsorption and desorption isotherms were collected at 77 K in order to evaluate the 
porosity of the samples and ultimately determine DCA location in the structure (Figure 2.26).  
 





Figure 2.26. a) N2 adsorption isotherms (77 K) of the DCA-loaded MOFs. Closed symbols for 
adsorption, empty symbols for desorption. b) Pore size distributions calculated form the isotherms. 
DCA@UiO-66: SBET = 1488 m2g-1; pore volume= 0.686 ccg-1 
DCA@UiO-66-L1: SBET = 1510 m2g-1; pore volume= 0.759 ccg-1 
DCA@UiO-66-L2: SBET = 1299 m2g-1; pore volume= 0.701 ccg-1 
The samples exhibit higher porosity than defect free UiO-66. Indeed, apart from DCA@UiO-
66-L2, which has the lowest surface area, the BET surface areas are around 20% higher than 
UiO-66 (1200 m2g-1), all of them with pore volumes more than 30% higher than that reported 
for UiO-66 (0.4 ccg-1).26 Additionally, TGA and PXRD were performed after nitrogen uptake, 
confirming that the high porosity of the samples is not a consequence of DCA desorption 
during sample activation (heating to 120 ºC for 20 h). 
The high porosity is therefore a consequence of the defects induced during synthesis due to 
both DCA and functionalised modulator attachment, as competition with the linker during the 
nucleation process could lead in incorporation not only in the surface as a capping agent, but 
also in the core of the structure. As it only possess one site of attachment, this will lead to 
missing linkers in the structure, and/or missing clusters, and therefore empty space that 
enhances the overall porosity.37 
In fact, the pore size distribution of UiO-66 usually shows two main defined pores, octahedral 
(11 Å) and tetrahedral (8 Å),26 while when DCA modulates UiO-66 synthesis, the simulated 
pore size distribution differs from the expected (Figure 2.26b). All the DCA modulated samples 
show similar pore size distributions, where bigger pores are observed. This is again a 
consequence of the attachment of DCA in the core of the structure, deriving on defected 
samples.  




During the course of this investigation, an investigation of the effect of modulator pKa on UiO-
66 properties was published, including the use of DCA as a modulator.35 The authors reported 
that, when using DCA (and other low pKa carboxylic acids) as a modulator, the number of 
defects induced during synthesis results in materials that form stable colloidal dispersions in 
water, with size distributions very close to those determined by SEM. DLS measurements of 
our own DCA modulated samples collected in water (Figure 2.27) confirm this, showing stable 
colloidal dispersions of particles that are initially monodisperse, with the same particle sizes 
as found by SEM, but with some minor aggregation over time (Section 2.6). 
 
Figure 2.27. DLS profiles in water of a) DCA@UiO-66, b) DCA@UiO-66-L1, and c) DCA@UiO-66-L2.  
The importance of these finding is based not only in the fact that with only one synthetic step 
both an anticancer drug and a functionalised modulator can be successfully attached to the 
UiO-66 structure, yielding highly crystalline and porous nanoparticles with the appropriate size 
for drug delivery, but also in the fact that this high porosity could potentially be used to store 
a second drug in the pore, especially interesting for treatments with multiple drugs. 
Additionally, the fact that DCA is attached rather than stored should ensure no major release 
of the drug during the following postsynthetic surface modification process (See Chapter 5), 
and more favourable release kinetics, possibly reducing the burst effect, during drug delivery 
experiments.  




2.3.4 Co-Modulated Synthesis of DCA-containing, Surface Modified UiO-66 
The coordination modulation protocol using DCA as co-modulator of UiO-66 synthesis was 
further extended to include the presence of either folic acid or biotin as functionalised 
modulators, to produce surface-modified, DCA-loaded UiO-66 in a single step.  
Different amounts of folic acid and DCA were employed and samples are named based on 
the molar ratio of each component to bdc added during synthesis: DCA10@UiO-66-FA0.25 (CM) 
(10 equiv DCA, 0.25 equiv folic acid), and DCA5@UiO-66-FA1 (CM) (5 equiv DCA, 1 equiv 
folic acid). As previously observed, when adding 10 equivalents of DCA to the reaction 
mixture, both folic acid and biotin co-modulated samples are highly crystalline and phase pure 
by PXRD (Figure 2.28). When the equivalents of DCA and folic acid are adjusted to increase 
folic acid content, DCA5@UiO-66-FA1 (CM) maintains characteristic reflection peaks, but they 




Figure 2.28. Stacked PXRD patterns of surface-modified, DCA-loaded UiO-66 prepared in one-pot co-
modulated syntheses. 
1H NMR spectroscopy was used once again to determine the content of the modulators in the 
acid-digested samples (See appendix for discussion of the modulators’ acidified 1HNMR). The 
1H NMR spectrum of acid-digested DCA10@UiO-66-FA0.25 (CM) enabled determination of 
most of the characteristic signals of DCA and folic acid (Figure 2.29). While the intensity of 




DCA proton resonance at  = 6.6 ppm is high and enables easy analysis – 42.6% molar ratio 
compared to the bdc linker – the intensities of the signals assigned to folic acid are low and 
the integral ratios are difficult to estimate, but suggest a folic acid content of <5% molar ratio 
compared to bdc. 
 
 
Figure 2.29. 1H NMR spectrum of DCA10@UiO-66-FA0.25 (CM) digested in D2SO4 / DMSO-d6. The 
resonance at  = 6.6 ppm corresponds to the HOOCCHCl2 proton in DCA. 
This could be easily explained once again by the difference of the pKa values of the two 
modulators; 1.4 for DCA while 3.5 and 4.3 for the carboxylic acid groups of folic acid. 
Therefore, the competition between modulators during the nucleation process, together with 
the higher number of equivalents of DCA added, will enhance incorporation of DCA over folic 
acid.  
Thus, the ratio of DCA: FA was adjusted during synthesis in order to increase folic acid content 
in the sample. As expected, the 1H NMR spectrum acid-digested of DCA5@UiO-66-FA1 (CM) 
(Figure 2.30) showed an increased content of folic acid, and accordingly, a relatively smaller 
incorporation of DCA. 
 





Figure 2.30. 1H NMR spectrum of DCA5@UiO-66-FA1 (CM) digested in D2SO4 / DMSO-d6. The 
resonance at  = 6.6 ppm corresponds to the HOOCCHCl2 proton in DCA. 
The DCA content was estimated to be 32.4 mol % compared to bdc, while analysis of the 
resonances assigned to the alkyl protons of folic acid confirmed ~15-20 mol % incorporation 
of folic acid. Folic acid content in the samples was further determined by UV-Vis spectroscopy 
of the digested samples, as described previously, being 3.6% w/w for DCA10@UiO-66-FA0.25 
(CM) and 26.7% w/w for DCA5@UiO-66-FA1 (CM). 
Although biotin signals are appreciable in the 1H NMR spectrum of acid-digested DCA@UiO-
66-Biot (CM), shown in Figure 2.31, very little incorporation of biotin was determined. The low 
intensity of the biotin signal at  = 1.2 ppm and its poor definition does not allow proper 
analysis. However, an incorporation of < 2 mol % compared to bdc was estimated from the 
signal at  = 2.1 ppm (t, 2H), which integrates accordingly to the rest of the identifiable biotin 
signals. DCA presence was confirmed with a 43.8% molar ratio compared to bdc.  
 





Figure 2.31. 1H NMR spectrum of DCA@UiO-66-Biot (CM) digested in D2SO4 / DMSO-d6. The 
resonance at  = 6.6 ppm corresponds to the HOOCCHCl2 proton in DCA. 
TGA profiles of the DCA modulated samples (Figure 2.32) show the appearance of a new 
decomposition step attributed to DCA decomposition. In general, it can be observed that DCA 
folic acid co-modulated samples have a considerably smaller metal residue than when UiO-
66 synthesis is only modulated with DCA, and the DCA content measured by TGA correlates 
closely to that measured by ICP-MS (Table 2.4). In fact, when the DCA:FA ratio is 5:1, and 
higher incorporation of folic acid is determined by 1H NMR spectroscopy, the degradation 
profile has a more gradual character, in agreement with results found for previously 
synthesised folic acid containing UiO-66 samples (Section 2.3.2). The fact that DCA 
decomposes at a higher temperature (250–350 °C) than the one reported in the literature (194 
°C) indicates that DCA is attached to UiO-66 structure,52 possibility on the surface (outer and 
inner due to its small size) and in the defect sites.  
 





Figure 2.32. TGA profiles of a) DCA5@UiO-66-FA1 (CM), b) DCA10@UiO-66-FA0.25 (CM) and c) 
DCA@UiO-66-Biot (CM). d) Comparison of the DCA-loaded UiO-66 samples with and without folic acid, 
with empty UiO-66. 
 
Table 2.4. TGA residues and DCA loading values from TGA and ICP-MS for the DCA-loaded, surface 
modified samples. 
Sample TGA residue at 
800°C (% w/w) 
DCA content (TGA / ICP) 
% w/w 
DCA10@UiO-66-FA0.25 (CM) 35.8 19.6 / 18.9 
DCA5@UiO-66-FA1 (CM) 32.9 12.1 / 11.8 
DCA@UiO-66-Biot (CM) 38.1 19.0 / 20.7 
 
Nitrogen adsorption isotherms (Figure 2.33) found the samples synthesised using 10 
equivalents of DCA to be highly porous, with surface areas of 1661 m2g-1 and 1357 m2g-1 for 
folic acid and biotin NMOFs respectably. These findings, together with TGA and FT-IR results, 
unequivocally confirm that DCA and the functionalised modulators are attached to available 
zirconium positions of UiO-66. In agreement with the nitrogen uptake of UiO-66-FA (CM), 
when the DCA:FA ratio is reduced to enhance folic acid incorporation, a lower surface area, 




close to that reported for Zr-fumarate,32 is obtained, although the pore volume is similar to the 
one reported for UiO-66.  
 
 
Figure 2.33. a) N2 adsorption isotherms (77 K) of the DCA-loaded, co-modulated MOFs. Closed 
symbols for adsorption, empty symbols for desorption. b) Pore size distributions calculated form the 
isotherms. 
DCA10@UiO-66-FA0.25 (CM): SBET = 1661 m2g-1; pore volume = 0.943 ccg-1 
DCA5@UiO-66-FA1 (CM): SBET = 844 m2g-1; pore volume = 0.485 ccg-1 
DCA@UiO-66-Biot (CM): SBET = 1357 m2g-1; pore volume = 0.859 ccg-1 
The isotherms when adding 10 equivalents of DCA present different features depending on if 
folic acid or biotin are also added to the synthesis, highlighting once more the important role 
that the modulator plays during synthesis. DCA5@UiO-66-FA1 presents a second uptake 0.92 
P/P0, characteristic of filling inter-particle voids, while DCA@UiO-66-Biot exhibits a hysteresis 
between 0.86 and 0.52 P/P0, characteristic of mesoporous samples. The high degree of 
defects could be a consequence of DCA and biotin incorporation, leading to absence of linkers 
or even metal clusters. 
The pore volumes of the samples synthesised with 10 equivalents of DCA are remarkably 
higher than UiO-66 (0.5 ccg-1), being 0.943 ccg-1 and 0.859 ccg-1 for folic acid and biotin 
respectively. The pore size distribution shows distorted pores compared to UiO-66 (8 Å and 
11 Å). The pores of the three samples are similar in size, showing two major peaks with no 
clear definition. This is once again due to defects induced during synthesis when incorporating 
modulators to UiO-66 structure.  
 




SEM imaging shows that when UiO-66 is modulated using both DCA and biotin as modulators, 
small crystallites of 166 ± 22 nm are obtained for the synthetic conditions used (Figure 2.34).  
 
Figure 2.34. SEM images of a) DCA10@UiO-66-FA0.25 (CM), b) DCA5@UiO-66-FA1 (CM), and c) 
DCA@UiO-66-Biot (CM). 
A decrease of particle size was observed when the ratio of DCA to folic acid was adjusted, 
from 158 ± 23 nm to 91 ± 29 nm for for DCA10@UiO-66-FA0.25 and DCA5@UiO-66-FA1 
respectively. This could be a consequence of folic acid acting as capping agent and therefore 
inhibiting crystal growth, yielding smaller nanoparticles.  
To summarise, DCA modulation yields in highly defected, colloidal stable nanoparticles with 
high DCA content. Through extensive characterisation, it has been proven that DCA gets 
attached to the unsaturated metal cluster nodes during synthesis. Due to its low pKa, DCA 
gets highly incorporated into the MOF structure, even in the presence of other functionalised 
modulators. The synthetic protocols are versatile and offer many options to create highly 
specialised drug-containing surface-functionalised MOFs in one synthetic step, being able to 
tune MOF content and particle size through modulators ratio adjustment. 
  




2.4. DCA Modulated Synthesis of the UiO Family of Isoreticular MOFs 
Due to these encouraging results, and in order to study the cytotoxicity of UiO type 
DCA@MOFs based on functionalised and extended linkers (Chapter 5), the DCA modulation 
protocol was applied to the UiO series of isoreticular MOFs, shown in Figure 2.35.  
DCA@MOFs synthesis was performed following the former coordination modulation protocol, 
using a 1:1 ratio of ZrCl4 and linker and adding 10 equivalents of DCA to the syntheses, 
together with 1 equivalent of HCl.  
 
 
Figure 2.35. a) Structures of linkers used in the preparation of Zr MOFs. b) Schematic of UiO-66 with 
DCA capping defects. 
SEM imaging (Figure 2.36) showed the DCA@UiO-66 derivate MOFs to be around 75-150 
nm in diameter, with particle size distributions (Figure 2.37) showing that DCA@UiO-66 and 
DCA@ UiO-66-NH2 are slightly smaller than DCA@UiO-66-Br and DCA@UiO-66-NO2. On 
the other hand, DUT-52 and DCA@UiO-67 formed microcrystals, and will not be discussed 
during this thesis. Particle size data is presented in Table 2.5. 





Figure 2.36. SEM images of DCA@UiO-66, DCA@UiO-66-Br, DCA@UiO-66-NO2 and DCA@ UiO-
66-NH2 
 
Figure 2.37. Particle size distribution histogram for the larger DCA-loaded terephthalate MOF samples. 
PXRD patterns (Figure 2.38) show highly crystalline and phase pure MOFs with the UiO-66 
topology.  





Figure 2.38. Stacked PXRD patterns of the larger DCA@UiO-66 MOFs. 
The samples’ porosity was analysed by N2 adsorption and desorption measurements (Figure 
2.39a), which ultimately confirmed DCA incorporation through binding to the Zr6 clusters, as 
the samples present higher BET surface areas and pore volumes (Table 2.5) than those 
previously reported in the literature for pristine materials.41 The pore size distributions show 
defective pores (Figure 2.39b), again as a consequence of DCA attachment and defect 
induction.  
 
Figure 2.39. a) Comparison of N2 uptake isotherms (77 K) for larger DCA-loaded UiO-66 MOF samples. 
Filled symbols indicate adsorption, empty symbols desorption. b) Pore size distributions, calculated 
from the N2 uptake isotherms, for larger DCA-loaded UiO-66 MOFs, showing the expected pores for 
UiO-66 samples but with some larger, defect-based pores. N2 on carbon at 77 K, slit pore, QSDFT, 
equilibrium model. 
1H NMR spectra of the acid digested samples again show high DCA incorporation (ca. 30 mol 
% compared to linker), while TGA analysis enabled quantification of DCA loading (ca. 250–




375°C) and an estimation of the structural composition. A comparison of the TGA traces for 
the four DCA@UiO-66 derivative MOFs with an empty UiO-66 MOF can be found in Figure 
2.40. The estimated DCA content in weight percent is given in Table 2.5. 
 
Figure 2.40. Comparison of the TGA profiles of the DCA@UiO-66 MOFs with empty UiO-66. 
The experimental DCA and linker mass losses were compared to those calculated for 
theoretical model structures where DCA replaces linkers, in each case being close to the 
theoretical structure [Zr6O4(OH)4(L)4(DCA)2(OH)2]n, indicating defective structures  
Table 2.5. Pertinent physical properties of the larger DCA-loaded terephthalate MOFs 
Sample Size / nm % DCA w/w BET SA  
/ m2g-1 
Pore volume / 
ccg-1 
DCA@UiO-66  77 ± 24 17.2 1510 0.76 
DCA@UiO-66-Br  131 ± 30 16.7 1016 0.56 
DCA@UiO-66-NO2  121 ± 27 16.2 985 0.52 
DCA@UiO-66-NH2  81 ± 26 16.9 1189 0.83 
 
To promote cytosolic release through passive diffusion, the previous DCA modulated synthetic 
conditions were tuned with the aim of obtaining smaller, DCA-loaded nanoparticles (< 20 nm) 
of the UiO family of Zr6 MOFs.  
Solvothermal reaction of ZrOCl2, which has a more similar structure to the Zr6 SBUs, with 2.5 
eq of linker, to promote nucleation, and 18.2 eq of dichloroacetic acid yields solids whose 




PXRD patterns (Figure 2.41) show Bragg peaks characteristic of the UiO-66 topology.26, 41 
When terephthalate linkers are used, the diffraction patterns have broad, low intensity peaks, 
suggesting small and defective particles, consequence of DCA attachment to the Zr6 clusters 
in place of linkers. 
 
Figure 2.41. Stacked PXRD patterns of DCA@MOFs. 
SEM imaging was used to study the morphology and size of the NMOFs, showing that while 
the DCA@UiO-66 small derivatives are indeed small nanoparticles (Figures 2.42) of slightly 
different sizes depending on the linker, DCA@DUT-52 and DCA@UiO-67 are composed of 
bigger nanoparticles (Figure 2.43). The particle size distributions are shown in Figure 2.44, 
and the average particle sizes and standard deviations are given in Table 2.6.  
 
Figure 2.42. SEM images DCA@UiO-66small derivative MOFs. 






Figure 2.43. SEM images of a) DCA@DUT-52 and b) DCA@UiO-67. 
 
Figure 2.44. a) Particle size distribution histogram for DCA@UiO-66 small samples. b) Particle size 
distribution histogram for DCA@DUT-52 and DCA@UiO-67. 
The porosity of the samples was determined by N2 sorption/desorption isotherms. The four 
terephthalate MOFs present type IV isotherms (Figure 2.45) with H2 hysteresis loops, which 
are typical of interconnected networks of pores with different size and shape and suggest 
highly defective structures.53 The fact that the hysteresis closes before 0.9 P/P0 in all cases, 
in contrast to H3 hysteresis loops, which are typical of aggregates of particles, strongly 
suggests that the hierarchical porosity is a consequence of attachment of DCA modulators 




and resulting missing linker and cluster defects, although some contribution of inter-particle 
space should also be considered. 
Comparison of the N2 uptake isotherms (Figure 2.46) with those of DCA@DUT-52 and 
DCA@UiO-67 shows that while the uptakes in the micropore region for the small samples are 
lower than typical UiO-66 materials,41 the defectivity induces pore volumes similar to 
DCA@UiO-67, ranging from 0.8 to 1.2 ccg-1 as a consequence of the additional, defect-
induced mesoporosity. This difference is also borne out in the pore size distributions (Figure 
2.47) which show well defined micropores of expected size for DCA@DUT-52 and DCA@UiO-
67 but remarkably bigger pores in the case of DCA@UiO-66 small samples, consequence of 
their mesoporosity. The BET surface areas and pore volumes are given in Table 2.6. 
 
Figure 2.45. N2 uptake isotherms (77 K) for a) DCA@UiO-66 small, b) DCA@UiO-66-Br small, c) 
DCA@UiO-66-NO2 small, and d) DCA@UiO-66-NH2 small. Filled symbols indicate adsorption, empty 
symbols desorption. 





Figure 2.46. Comparison of N2 uptake isotherms (77 K) for all the MOFs synthesised using the ZrOCl2 
protocol. Filled symbols indicate adsorption, empty symbols desorption. 
 
Figure 2.47. Pore size distributions, calculated from the N2 uptake isotherms, of the MOFs synthesised 
by the ZrOCl2 protocol, showing the mesopores of the defective DCA@UiO-66 small derivative MOFs. 
N2 on carbon at 77 K, slit pore, QSDFT, equilibrium model. 
1H Nuclear magnetic resonance (NMR) spectra of acid-digested samples of the DCA@MOFs 
(D2SO4 / DMSO-d6) show significant quantities of DCA in all cases. The 1H NMR spectrum for 
digested DCA@UiO-66 small is shown as an exemplar in Figure 2.48, compared to DCA@UiO-
66 (ca.100 nm). The resonance at  = ~6.5 ppm corresponds to the -CCl2H proton of DCA, 
and it can be observed that the smaller and more defective derivative has higher DCA content. 




It is not possible to quantitatively determine DCA loading values from the NMR spectra alone, 
as the exact composition of the MOF will depend on defectivity and the replacement of MOF 
linkers with capping DCA molecules. However, estimating the molar ratio of DCA compared 
to the ligand gives a qualitative assessment of the extent of DCA incorporation (Table 2.6). 
 
Figure 2.48: Partial stacked 1H NMR spectra (D2SO4 / DMSO-d6) of digested DCA@UiO-66 small (red) 
and DCA@UiO-66 (black), showing the higher relative intensity of DCA for the smaller analogue MOF.  
Table 2.6. Pertinent physical characteristics of the DCA@MOFs synthesised using the ZrOCl2 
procedure 
Sample Size / nm DCA mol % to 
Linker 
% DCA w/w BET SA / 
m2g-1 
Pore volume   
/ ccg-1 
DCA@UiO-66 small 12.8 ± 3.6 30.3 26.2 891 0.87 
DCA@UiO-66-Br small 30.2 ± 7.9 34.6 19.3 639 0.81 
DCA@UiO-66-NO2 small 21.7 ± 5.3 34.5 21.5 901 1.12 
DCA@UiO-66-NH2 small 12.5 ± 2.9 45.5 26.4 990 1.21 
DCA@DUT-52 232 ± 30 34.1 14.1 764 0.42 
DCA@UiO-67 196 ± 32 18.6 6.6 2241 0.99 
 
Thermogravimetric analysis (TGA) of the DCA@MOFs shows significant mass loss events 
from 250–375 °C compared to pristine materials (Figure 2.49), allowing quantification of DCA 
content (Table 2.6). 
DCA mass loss events within the MOF occur at a higher temperate that free DCA thermal 
decomposition (198°C),52 as a consequence of its attachment to the Zr clusters. Mass loss 
events occurring before 225 °C are characteristic of DMF incorporation and water loss from 
the structure,44 which is observed for both empty and DCA-containing MOFs, more notably for 
empty MOFs, as DMF coming from the synthetic process can get incorporated to the Zr6, as 
well as formic acid from DMF hydrolysis during the reaction.37 However, DCA mass loss 




events from 250–375 °C can be easily identified in the trace and the first derivative, allowing 
DCA content to be quantified. 
The experimental DCA and linker mass loss correlate well with the theoretical composition 
[Zr6O4(OH)4(L)3(DCA)3(OH)3]n in the case of the DCA-loaded terephthalate MOFs, while 
DCA@DUT-52 is closer to [Zr6O4(OH)4(L)4(DCA)2(OH)2]n and DCA@UiO-67 to 
[Zr6O4(OH)4(L)5(DCA)1(OH)1]n, meaning that the terephthalate derivatives are considerably 
more defective, as was also suggested by PXRD and N2 adsorption analyses. 
 
Figure 2.49. TGA traces in air of DCA loaded MOFs compared to empty MOFs  




The particle size, aggregation and colloidal dispersion of the MOFs in water were measured 
by dynamic light scattering (DLS). The profiles for the small terephthalate nanoparticles are 
shown in Figure 2.50. 
 
Figure 2.50. DLS profiles in water for DCA@UiO-66 small derivative MOFs. 
The samples show a small degree of aggregation, except for DCA@UiO-66-NH2 small which 
shows very little aggregation, likely due to positive charge on the pendant amino groups of L4 
resulting in interparticle repulsion.54 The DLS profiles for DCA@DUT-52 and DCA@UiO-67 
are shown in Figure 2.51, and also show only a small degree of aggregation.  
Figure 2.51. DLS profiles in water for a) DCA@DUT-52 and b) DCA@UiO-67. 




Comparison of all samples (Figure 2.52) shows the difference in behaviour of the smaller and 
larger samples. 
 
Figure 2.52. Comparison of the first recordings in the DLS experiments for aqueous suspensions of all 
the MOFs synthesised using the ZrOCl2 protocol.  
It is expected that in biological systems, formation of a protein corona will limit aggregation 
further.27, 41, 55-57 To examine this, DLS experiments were carried out on the samples that 
showed some aggregation – the smaller terephthalate MOFs as well as DCA@DUT-52 and 
DCA@UiO-67 – when dispersed in phosphate buffered saline (PBS, pH = 7.4) that had been 
“spiked” with 2% w/w bovine serum albumin (BSA), to mimic biological conditions. All samples 
showed less aggregation and improved colloidal stability, and are compared with the 
analogous experiments in water in Figures 2.53 and 2.54. The smaller samples stabilised to 
around 100-150 nm aggregates, while DCA@UiO-66-NH2 small appeared to be monodisperse 
and correlated well with particle sizes determined by SEM. The amino functionality of L4 is 
expected to be protonated under these conditions, and so form a highly stable corona with the 
negatively charged BSA. The larger particles also formed stable dispersions close to the 
particle sizes determined by SEM, indicating that the MOFs will not be significantly aggregated 
during in vitro cytotoxicity studies. 





Figure 2.53. Comparison of the DLS profiles collected in water with those in 2% w/w BSA in PBS for 
a) DCA@UiO-66 small, b) DCA@ UiO-66-Br small, c) DCA@ UiO-66-NO2 small, and d) DCA@ UiO-66-NH2 
small. 
 
Figure 2.54. Comparison of the DLS profiles collected in water with those in 2% w/w BSA in PBS for 
a) DCA@DUT-52 and b) DCA@UiO-67. 
The larger DCA-loaded terephthalate MOFs were also well-dispersed in water, with only minor 
aggregation, showing size distributions (Figure 2.55) close to those determined by SEM.  





Figure 2.55. Comparison of the first recordings in the DLS experiments for aqueous suspensions of 
the larger DCA-loaded terephthalate MOFs of bigger size.  
It has been reported that DCA enhances the cytotoxic activity of anticancer drugs such as 5-
fluorouracil (5-FU) while reducing cancer cells resistance towards them. As such, the smaller, 
DCA-loaded Zr-terephthalate samples, along with DCA@DUT-52 and DCA@UiO-67, were 
postsynthetically loaded with 5-FU to generate multimodal DDSs.  
1H NMR spectra of acid digested samples showed that DCA was still present after loading, 
but only very low intensity signals were observed for 5-FU, indicating low loading. Additionally, 
due to the very low content of 5-FU, its FT-IR vibration bands are masked by the MOF signals 
in the FT-IR spectra of the 5-FU@DCA@MOF samples, and characteristic vibration bands of 
DCA can still clearly be observed in the spectra. 
Thermogravimetric analysis cannot distinguish between loaded DCA and 5-FU, although it 
suggests some loss of DCA during 5-FU loading for the small terephthalate MOFs. The 
loading of 5-FU, shown in Table 2.7, was calculated by UV-Vis spectroscopy, and found to 
range from 1.5–4.3% w/w (Figure 2.54). 





Figure 2.54. Release of 5-FU into methanol from the 5-FU@DCA@MOFs followed by UV/Vis 
spectroscopy to allow determination of 5-FU loading. Note that base line value was substracted from 
the absobance value.  
Knowing the loading of 5-FU in the MOFs, it is therefore possible to estimate the DCA loading 
using the TGA traces, if it is assumed that the mass loss in the temperature region (250–375 
°C) corresponds to thermal decomposition of both DCA and 5-FU, and therefore deduct the 
5-FU content, as determined by UV/Vis spectroscopy, from the total (Table 2.7). The 
terephthalate-based MOFs lose significant quantities of DCA during 5-FU loading, but still 
retain respectable, clinically relevant contents. 
Table 2.7. Estimation of DCA loading in the 5-FU@DCA@NMOFs by a combination of TGA analysis 
and UV/Vis spectroscopy. aValues in brackets are DCA loadings determined for the samples prior to 5-
FU loading for comparison. 
Sample % 5-FU  % TGA % DCAa 
5-FU@DCA@UiO-66small 1.9 24.1 22.3 (26.2) 
5-FU@DCA@UiO-66-Brsmall 3.8 16.9 13.1 (19.3) 
5-FU@DCA@UiO-66-NO2 small 4.3 13.0 8.7 (21.5) 
5-FU@DCA@ UiO-66-NH2 small 2.4 15.0 12.6 (26.4) 
5-FU@DCA@DUT-52 1.5 17.0 15.5 (14.1) 
5-FU@DCA@UiO-67 2.5 9.6 7.1 (6.6) 




2.5. Conclusions and Future Work 
In conclusion, it has been shown that carboxylate modulators can be attached to the Zr 
positions (at outer surface and defect sites) of UiO-66 during its synthesis, yielding crystalline, 
phase pure, highly porous nanoparticles, as a consequence of the defects that modulators 
attachment induces.37 The scope of modulators used during this study confirms the versatility 
of the protocol, being able to introduce functionalised p-benzoic acid and more complex 
modulators (i.e folic acid and biotin) to the NMOF structure during synthesis. Additionally, the 
resultant MOFs had the adequate particle size for drug delivery (<200 nm), and this surface 
functionalisation protocol could be applied to other areas such as gas capture or storage. 
The use of carboxylate-containing drug molecules as modulators for synthesis of UiO-66 
nanoparticles - in this study the PDK inhibitor dichloroacetic acid (DCA) - has been shown to 
be an efficient methodology to ensure high cargo loading at defect sites in one-pot syntheses. 
DCA modulation in particular generates colloidally-stable nanoparticles with high DCA-loading 
values that are amenable to further functionalisation without compromising porosity. 
Additionally, the low pKa of DCA ensures its high incorporation, even in the presence of other 
functionalised modulators, allowing the synthesis of highly specialised drug-containing 
surface-functionalised MOFs in one synthetic step. 
DCA modulation also served as a size-control protocol, as the DCA@UiO-66 derivative MOFs 
synthesised under the ZrCl4 conditions had homogeneous size distributions of ca. 100 nm, 
while the ones synthesised under the ZrOCl2 conditions had particle sizes of ca. 20 nm. It has 
been observed that, under the same ZrCl4 and ZrOCl2 synthetic conditions, electron-rich 
terephthalates yield in relatively smaller sizes (ca. 80 and 10 nm) than electron-poor 
terephthalates (ca. 125 and 30 nm), while extended linkers (more hydrophobic) form micro 
and nanocrystals of ca.200 nm. Due to the defects that DCA attachment induces, the high 
porosity of the NMOFs has been used to store a second drug (5-FU) for combined treatments. 
The materials presented during this chapter will be used in the subsequent chapters. For 
example, UiO-66-L1 and UiO-66-L2 will be used as platforms for postsynthetic modifications 
during Chapter 3, where the properties of all the surface-functionalised MOFs will be studied 
and compared with their precursors and bare MOFs synthesised under acetic acid modulated 
conditions. Calcein loading and postsynthetic modification of UiO-66-L1 and UiO-66-L2 (in 
which L2 is introduced postsynthetically) will be performed during Chapter 4, and the calcein-
loaded MOFs will be further used to study the effect of surface chemistry on their cellular 
internalisation fate and routes, while postsynthetic modification of the DCA analogues and the 
evaluation of the cytotoxicity of all the DCA-containing MOFs will be studied in Chapter 5.  





2.6.1. General Experimental Remarks 
Powder X-Ray Diffraction (PXRD): PXRD measurements were carried out at 298 K using a 
PANalytical X’Pert PRO diffractometer (λ(CuKα) = 1.4505 Å) on a mounted bracket sample 
stage. Data were collected over the range 5–45°. (University of Glasgow)  
Thermogravimetric Analysis (TGA): Measurements were carried out using a TA 
Instruments Q500 Thermogravimetric Analyser. Measurements were collected from room 
temperature to 800 °C with a heating rate of 10 °C / min under an air atmosphere. (University 
of Glasgow)  
Nuclear Magnetic Resonance Spectroscopy (NMR): NMR spectra were recorded on either 
a Bruker AVIII 400 MHz spectrometer or a Bruker AVI 500 MHz spectrometer and referenced 
to residual solvent peaks. (University of Glasgow)  
Gas Uptake: N2 adsorption isotherms were carried out at 77 K on a Quantachrome Autosorb 
iQ gas sorption analyser. Samples were degassed under vacuum at 120 °C for 20 h using the 
internal turbo pump. BET surface areas were calculated from the isotherms using the 
Micropore BET Assistant in the Quantachrome ASiQwin operating software. (University of 
Glasgow)  
Pore-Size Distribution: Pore size distributions were calculated using the N2 at 77 K on carbon 
(slit pore, QSDFT, equilibrium model) calculation model within the Quantachrome ASiQwin 
operating software. (University of Glasgow)  
UV-Vis Spectroscopy: UV-vis spectra were recorded using a Shimadzu UV-1800; analysis 
was carried out using the software UVProve. (University of Glasgow)  
Scanning Electron Microscopy (SEM): The powder samples were coated with Pd for 50 
seconds using Polaron SC7640 sputter coater and imagined using a Carl Zeiss Sigma 
Variable Pressure Analytical SEM with Oxford Microanalysis. Particle size distribution was 
analysed manually using ImageJ software. (University of Glasgow)  
Fourier Transform Infrared Spectroscopy: IR spectra of solids were collected using a 
Shimadzu Fourier Transform Infrared Spectrometer, FTIR-8400S, fitted with a Diamond ATR 
unit. (University of Glasgow)  
 




Dynamic Light Scattering: Colloidal analysis was performed by Dynamic Light Scattering 
(DLS) with a Zetasizer Nano ZS potential analyser equipped with Non-Invasive Backscatter 
optics (NIBS) and a 50 mW laser at 633 nm. (University of Glasgow)  
ESIMS: Electrospray Ionisation Mass Spectrometry was carried out on solution samples 
injected into a Bruker MicroTOFq spectrometer. (University of Glasgow). 
2.6.2. Materials and Synthesis 
All reagents unless otherwise stated were obtained from commercial sources and were used 
without further purification. The modulators L1 and L2 were synthesised by literature 
procedures, and the synthesis of UiO-66 – [Zr6O4(OH)4(C8H4O4)x]n – was adapted from a 
literature procedure.42 
p-Azidomethyl benzoic acid (L1) 
The commercially available 4-(bromomethyl)benzoic acid (5 g, 23.27 mmol, 1.0 eq) was 
dissolved in N,N-dimethylformamide, DMF, (150 ml) in a round 250 ml bottom flask. Sodium 
azide (3.8 g, 58.18 mmol, 2.5 eq) was added dropwise. The reaction mixture was heated at 
50 °C for 24 hours. The solvent was evaporated under vacuum. Following the literature 
procedure, p-azidomethyl benzoic acid (3.91 g, 22.1 mmol, 95%) was obtained pure as a white 
solid.58 
1H NMR (500 MHz, CDCl3) δ 4.48 (s, 2 H), 7.46 (d, J = 8.4 Hz, 2H), 8.16 (d, J = 8.3 Hz, 2H); 
13CNMR (126 MHz, CDCl3) δ 53.41, 128.7, 130.62, 130.91, 141.04, 167.51. 
The azide band (2130 cm−1) was identified by IR, and compared with the staring material. 
ESI-MS: calculated for C8H6N3O2 m/z = 176.0466; found m/z = 176.0455. 
p-Propargyloxy benzoic acid (L2) 
To a solution of methyl 4-hydroxybenzoate (5 g, 33 mmol, 1.0 eq) in acetonitrile (40 mL), 
K2CO3 (6.64 g, 49.5 mmol, 1.5 eq) was added. The mixture was heated to 50 °C for 30 min 
followed by dropwise addition of propargyl bromide (80% in toluene, 4.9 g, 3.53 ml, 33 mmol, 
1 eq). The mixture was allowed to react at the same temperature during 16 hours. Solvent 
was evaporated, the remaining liquid was quenched with water and extracted with chloroform 
(4 x 15 ml). The organic layers were combined and washed with water (2 x 10 ml) and brine 
(2 x 10 ml). Pure methyl p-propargyloxybenzoate was obtained as a white solid (8.11 g, 32 
mmol, 97%).59 




1H NMR (500 MHz, CDCl3) δ: 2.54 (t, J = 2.5 Hz, 1H), 3.88 (s, 3H), 4.74 (d, J = 2.5 Hz, 2H), 
6.99 (d, J = 8.5 Hz, 2H), 8.00 (d, J = 9.0 Hz, 2H); 13C NMR (126 MHz, CDCl3) δ: 51.86, 55.78, 
76.05, 77.79, 114.51, 123.42, 131.50, 161.11, and 166.64. 
Methyl p-propargyloxybenzoate (8 g, 32 mmol) was dissolved in a mixture of THF (45 ml) and 
MeOH (22.5 ml), an aqueous solution of NaOH 40% weight (25 ml) was added and the 
reaction mixture allowed to reflux for two hours. After cooling down, the organic solvents were 
distilled under vacuum yielding a clear solution, which was acidified with 6 M aqueous HCl. A 
white precipitate separated, was filtered and washed with abundant water, yielding after drying 
under vacuum pure p-propargyloxybenzoic acid (6.43 g, 27 mmol, 87.6%).59 
1H NMR (500 MHz, CDCl3) δ: 3.57 (t, J = 2.4 Hz, 1H), 4.86 (d, J = 2.4 Hz, 2H), 7.04 (d, J = 9.0 
Hz, 2H), 7.88 (d, J = 9.0 Hz, 2H), 12.41 (s, 1H); 13C NMR (126 MHz, CDCl3) δ: 39.91, 56.05, 
79.02, 79.14, 115.04, 124.11, 131.67, and 161.13. 
ESI-MS: calculated for C10H7O3 m/z = 175.0401; found m/z = 175.0399. 
UiO-66 Syntheses 
UiO-66 was synthesised by adaptation of a literature procedure to include different modulators 
as follows.42 For all samples, after cooling the reaction mixture, particles were collected by 
centrifugation (4500 rpm, 15 minutes), and washed (sonication centrifugation cycles) with 
fresh DMF (x1) and MeOH (x3). The NMOFs were dried for at least 24 hours under vacuum 
before analysis. For SEM, the samples were prepared as low concentration dispersions of 
nanoparticles in MeOH, which were allowed to dry in the oven at 60 ºC for 5 minutes.  
UiO-66 (Unmodulated) 
1,4-Benzenedicarboxylic acid (bdc) (448 mg, 2.7 mmol) was dissolved in 30 ml of DMF. In a 
separate vial, the metal precursor, zirconium chloride (629 mg, 2.7 mmol) was dissolved in 30 
ml of DMF. Both solutions were sonicated until complete dissolution and mixed together in a 
100 ml jar. The solution was heated to 120 ºC for 24 hours yielding UiO-66 nanoparticles. 
UiO-66-AcOH (Modulated with acetic acid) 
UiO-66 particles were modulated using the same procedure.42 Acetic acid (4.2 ml, 7% volume) 
was added after mixing both precursors solutions. The sample is named UiO-66-AcOH.  
UiO-66-L1 and UiO-66-L2 (Modulated with L1 or L2) 
1,4-Benzenedicarboxylic acid (448 mg, 2.7 mmol) plus one, three or five equivalents of 
modulator (L1 or L2), compared to metal precursor, were dissolved in 30 ml of DMF. In a 
separate vial, the metal precursor, zirconium chloride (629 mg, 2.7 mmol) was dissolved in 30 




ml of DMF. Both solutions were sonicated until complete dissolution and mixed together. 
Subsequently, acetic acid (4.2 ml, 7% volume) was added. The solution was heated to 120 ºC 
for 24 hours yielding UiO-66 nanoparticles. 
Synthesis of Folic Acid and Biotin Modulated UiO-66 
1,4-Benzenedicarboxylic acid (150 mg, 0.9 mmol) plus modulator, either biotin (100 mg, 0.41 
mmol, 0.45 equivalents compared to metal precursor) or folic acid (100mg, 0.23 mmol, 0.25 
equivalents compared to metal precursor), were dissolved in 10 mL of DMF. In a separate 
vial, the metal precursor, zirconium chloride (210 mg, 0.9 mmol) was dissolved in 10 mL of 
DMF. Both solutions were sonicated until complete dissolution and mixed together. 
Subsequently, acetic acid (1.4 mL, 7% v/v) was added when necessary. The solution was 
heated to 120 ºC for 24 h yielding UiO-66 nanoparticles. 
Synthesis of Dichloroacetic Acid (DCA) Modulated UiO-66 
DCA@UiO-66 synthesis was performed following the former coordination modulation 
protocol, adding 10 equivalents of DCA instead of AcOH (7% volume) to the syntheses, 
together with 1 equivalent of HCl. In the case of DCA@UiO-66-L1 and DCA@UiO-66-L2, 
equivalents of the modulator in question (L1 or L2) were dissolved together with the linker in 
DMF.  
Co-Modulated Synthesis of DCA-Loaded, Surface Modified UiO-66 
For the synthesis of DCA10@UiO-66-FA0.25 (CM), DCA5@UiO-66-FA1 (CM) and DCA@UiO-
66-Biot (CM) the former coordination modulation protocol was slightly modified, dissolving folic 
acid (FA, 0.25 or 1 equivalents compared to metal precursor) or biotin (0.4 equivalents 
compared to metal precursor) together with 1 equivalent of the linker in DMF. After mixing 
both precursor solutions, DCA (5 or 10 equivalents) was added. After gently mixing, the 












DCA Modulated Synthesis of UiO Family of Zr MOFs 
 
 
Figure 2.55. Linker of the UiO family of Zr MOFs synthesised in this thesis.  
In separate vials, zirconyl chloride octahydrate (213 mg, 0.66 mmol, 1 equivalent) and the 
linker in case, (1.65 mmol, 2.5 equivalents), shown in Figure 2.55, were dissolved in 25 mL of 
DMF. After mixing both precursor solutions, dichloroacetic acid (DCA) (1 mL, 5 mmol, 18.75 
equivalents compared to metal) was added to the reaction mixture, which after gently stirring, 
was placed in the oven at 120°C during 24h.  
After cooling down, the powders were collected by centrifugation, and washed with DMF (X2) 
and MeOH (X3) through dispersion centrifugation cycles.  
The resultant NMOFs were dried under vacuum at least 24 hours before analysis. 
Synthesis DCA@UiO-66 Derivatives of Bigger Size 
DCA@UiO-66 derivatives synthesis was performed following the former coordination 
modulation protocol, using 1 to 1 ratio of ZrCl4 and linker, adding 10 equivalents of DCA 
instead to the syntheses, together with 1 equivalent of HCl. After 24 hours, the reaction 
mixtures were cooled to room temperature and the NMOFs were collected with centrifugation 
and washed with DMF (x1) and MeOH (x3). 
 





40 mg of the DCA@NMOF in question were sonicated during 15 minutes in a 5-FU solution 
(3 mgmL-1 in MeOH), and then the dispersion was stirred during 3 hours at room temperature. 
The 5-FU@DCA@NMOFs were collected by centrifugation and washed with MeOH (x3) 
through dispersion centrifugation cycles to ensure no residual 5-FU was present on the 
surfaces of the particles. The resultant NMOFs were dried under vacuum at least 24 hours 
before analysis.  
5-FU UV-Vis Determination: 
Around 2.5 mg of samples were dispersed in 5 mL of MeOH and sonicated for 2 minutes in 
order to promote 5-FU release, followed by 30 minutes stirring at room temperature. The 
supernatant was collected by centrifugation, and a UV/Vis spectrum measured from λ = 200-
500 nm. The 5-FU content (λmax = 266 nm) in weight percent was calculated against a 
previously calculated calibration curve (note that the base line value was substracted from the 
absorbance value). Additionally, absorbance measurements of the linkers in MeOH were 
performed, confirming minor or no linker leakage from the MOFs that did not affect 5-FU 
determination.  
The calculations were performed using the exact mass of each MOF added. The samples 
were dispersed again and the measurements were repeated 2 hours after to ensure that 5-
FU release was completed.  
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Developing versatile and reproducible MOFs surface functionalisation protocols is crucial for 
their application in healthcare, particularly in anticancer drug delivery, as surface modifications 
can both enhance stability and dispersion in biological media, while decreasing the immune 
system recognition and providing the possibility of directing the DDS to damaged tissue 
through targeting.  
Coatings with different polymers have decreased immune system recognition and 
accumulation in the liver of DDSs, with promising in vitro and in vivo results in anticancer 
therapy.1, 2 For example, spherical polystyrene nanoparticles with covalently bound 
poly(ethylene glycol) chains on their surface were less sequestered by the liver than uncoated 
ones, and a correlation was found between the PEG surface density and their blood half-life, 
improving their stability under physiological conditions.3 PEG chains have also been bound to 
the surface of chemically cross-linked albumin nanospheres, reducing significantly their 
uptake by cell culture macrophages.4 Incorporation of polymers onto the external surfaces of 
NMOFs has been suggested as a route to enhanced stability and effective application in drug 
delivery.5, 6 In addition, MOFs have been targeted to cancer cells by attaching different 
targeting units to their surface, reducing their non-specific distribution.7, 8 
The Lewis acid character of MOFs’ metal centres offers the possibility of coordinating 
nucleophiles to the coordinatively unsaturated metal sites available on the outer surface of 
NMOFs,9, 10 and several polymer coatings, including oligonucleotides, have been added to the 
surfaces of MOFs by coordination to the metal clusters through one of the polymers’ ends.11-
13 The well-known surface ligand exchange (SLE) protocol – postsynthetically exchanging 
surface ligands for desired functionality – is also based on coordination chemistry.14-20 
Postsynthetic covalent modifications, performed on functionalised organic linkers, have been 
widely used in biological applications of NMOFs.21-23 Additionally, unsaturated carboxylic acid 
groups present on the MOF surface can also be exploited for postsynthetic covalent surface 
modifications.24 For example, a green fluorescent protein was coupled to surface carboxylate 
groups of different MOFs using a carbodiimide-mediated reaction,25 and then the protocol was 
applied to couple PEG5000-NH2 and Stp-10C,5 a derived oligoamino amide with proton-
sponge features. However, the low reactivity of the organic linker’s carboxylates hinders the 
application of this protocol, resulting in very low surface coatings (1-2% w/w).  
Silica coating has been widely used to increase MOFs’ water stability, to induce slow release, 
and to attach surface reagents through the siloxane groups.26, 27 Although this approach can 
dramatically enhance some MOFs properties, drawbacks exist in the fact that the silica coating 
can block pore access, and that some silica nanoparticles have been found to be toxic.28-30 






The need to find a rationalisation between the intrinsic characteristics of NMOFs, such as 
surface chemistry, and their therapeutic efficacy is inherently clear, providing if so the 
possibility of reducing early-stage animal testing through effective MOF engineering while 
maximizing the potential application of MOFs as DDSs.  
Thus, the different ways of functionalising the outer surface of UiO-66 nanoparticles will be 
explored, in order to characterise the effect of surface chemistry and coating mode on 
properties such as physiological stability and colloidal dispersion. Through thoughtful choice 
of surface reagents with different characteristics – hydrophilic or hydrophobic, targeting 
agents, negatively charged, positively charged or neutral – this thesis ultimately attempts to 
rationalise the effect of surface chemistry of UiO-66 on HeLa cell internalisation pathways 
(Chapter 4), therapeutic efficiency, selectivity of cytotoxicity (targeting) and in vitro immune 
response (Chapter 5). 
Different surface modification protocols will be assessed: (i) postsynthetic surface ligand 
exchange (PS), and (ii) click modulation, wherein functionalised modulators, previously 
introduced to UiO-66 structure during its synthetic process (Chapter 2), are covalently 
modified (Figure 3.1a). Different surface reagents (Figure 3.1b) which possess various 
coordinating groups – vitamin B9 folic acid (FA)31, vitamin B7 biotin (Biot)32, and a negatively 
charged anticoagulant, heparin (Hep)33 – that are well known to play different biological roles, 
have been selected to be coordinated to UiO-66 surfaces postsynthetically. The carboxylic 
acid functionalities of both folic acid and biotin allowed their direct incorporation during 
modulated syntheses, which was detailed in Chapter two, and thus the colloidal dispersion 
and physiological stability of both postsynthetically coated and modulated FA and Biot 
samples will be compared in order to gain insights into the different surface modification 
protocols effect on MOFs properties.  
The functionalities of p-azidomethylbenzoic acid (L1) and p-propargyloxybenzoic acid (L2), 
previously introduced to UiO-66 structure during its synthetic process in Chapter 2, will be 
used as a platform for postsynthetic surface modifications based on click chemistry during this 
chapter.  
Proof-of-concept postsynthetic surface modifications by Copper(I)-Catalyzed Azide-Alkyne 
Cycloaddition (CuAAC) will be performed between  the modulated MOFs (UiO-66-L1 and UiO-
66-L2) and1-dodecyne and 1-azidodecane respectively. Additionally, the amphiphilic 
propargyl-terminated poly(ethylene glycol) (PEG Mn = 500 and 2000), the hydrophobic 
propargyl-terminated poly-L-lactide (PolyLact, Mn = 2000) and the hydrophilic azide-
terminated poly-N-isopropylacrylamide (PNIPAM, Mn = 15000) have been selected as 





protecting polymers to click to UiO-66-L1 and UiO-66-L2 surface, but in this study, UiO-66-L2 
is prepared by surface ligand exchange from UiO-66-L1, and not through coordination 
modulation, in order to maintain appropriate particle size for further endocytosis studies 
(Chapter 4) and cytotoxicity assessment (Chapter 5). Thus, the properties that different 
surface coatings provide to UiO-66 and the potential and reproducibility of different protocols 
to introduce different functionalities will be evaluated.  
 
Figure 3.1 a) Synthetic scheme for the surface modified MOFs, highlighting MOFs obtained through 
postsynthetic exchange (PS) and click modulation. b) Chemical structures of the surface functionality 
attached to the MOFs by SLE. (top) and by (CuAAC) (bottom). 
  





3.3 UiO-66 Surface Functionalisations 
3.3.1 UiO-66-L1 and Ui-66-L2 Postsynthetic Covalent Surface ModificationS 
At first, proof-of-concept postsynthetic surface modifications will be performed between the 
modulated MOFs (UiO-66-L1 and UiO-66-L2) and 1-dodecyne and 1-azidodecane 
respectively. Then, surface modifications for drug delivery applications will be performed using 
propargyl-terminated PEG, propargyl-terminated PolyLact and azide-terminated poly-N- 
PNIPAM as surface reagents.  
3.3.1.1. Alkyl-Modified UiO-66: Proof-of-Concept Surface Modifications 
After confirming, in Chapter 2, that the functionalised modulators are incorporated into the 
MOF structure, postsynthetic modification by Copper(I)-Catalyzed Azide-Alkyne Cycloaddition 
(CuAAC) was attempted. Various catalysts were tested, including CuI and a mixture of CuSO4 
and sodium ascorbate, resulting in loss of the sample crystallinity each time. An efficient and 
economic approach, using CuI and 2 equiv of acetic acid and DiPEA each as an in situ 
stabilising ligand for Cu(I),34 was tolerated by the MOF structure, as confirmed by PXRD, and 
allowed further functionalisation of the NMOFs.  
Proof-of-concept reactions using this catalyst were carried out between UiO-66-L1 and 1-
dodecyne (Figure 3.2a), as well as between UiO-66-L2 and 1-azidodecane. Sample integrity 
throughout the process was confirmed by PXRD (Figure 3.2b).  
 
 
Figure 3.2. a) Schematic of the click modulation protocol in the preparation of UiO-66-L1-dodecane.  
b). Stacked PXRD profiles of UiO-66-L1 and UiO-66-L2 before and after surface alkylation. 
 
1H NMR spectra of acid digested samples of UiO-66-L1-dodecane and UiO-66-L2-decane 
suggested significant conversions of the modulators into the respective triazole products; 
while the low modulator content makes analysis difficult, additional aromatic signals are 





present alongside peaks for the alkyl groups. Full conversion would not be expected, as some 
modulators will be located at inaccessible internal defect sites rather than on the particle 
surface. High-resolution electrospray ionisation mass spectrometry (HRESI-MS) analysis of 
the digested MOFs (Section 3.7) showed peaks for the products of the CuAAC reaction 
between modulators and surface functionality as follows: 
 
UiO-66-L1-dodecane. Calc C20H30N3O2 [M+H]+: m/z = 344.2333; found: m/z = 344.2319. 
UiO-66-L2-decane. Calc C20H28N3O3 [M-H]–: m/z = 358.2136; found: m/z = 358.2131. 
 
The conversion of the functional groups of the modulators was monitored by FTIR 
spectroscopy, including comparison of the spectra of the surface modified NMOFs with 
pristine samples where the modulator had been reacted with the respective surface 
component in solution (Figure 3.3). The low overall content of modulator in the samples means 
the signals are quite weak. For UiO-66-L1-dodecane, the N3 signal (~2100 cm-1) of L1 
decreases considerably upon reaction, while the C-H region (2700-3000 cm-1) shows signals 
for the surface alkyl unit. In the IR spectrum of UiO-66-L2-decane, the signal around 3250 cm-
1 for the acetylene functionality of L2 is lost, and again new signals appear in the C-H region 
(2700-3000 cm-1). Unfortunately, the signals expected for the triazole unit are masked by 
peaks from UiO-66 itself.  
 
 
Figure 3.3. FTIR spectra comparing a) UiO-66-L1 before and after reaction with 1-dodecyne, as well 
as the product of the CuAAC reaction between L1 and 1-dodecyne, and b) UiO-66-L2 before and after 
reaction with azidodecane, as well as the product of the CuAAC reaction between L2 and azidodecane. 
Stacked IR spectra showing the disappearance of the azide stretch and appearance of C-H signals 
after the CuAAC surface reaction has taken place on UiO-66-L1. 
 





N2 adsorption isotherms measured at 77 K (Figure 3.4) confirmed that the porosity of the 
samples after fuctionalisation with alkyl chains were both maintained, with surface areas 
slightly decreasing - 1168 m2g-1 for UiO-66-L1-dodecane and 1262 m2g-1 for UiO-66-L2-
decane - compared to their precursors, UiO-66-L1 (1565 m2g-1) and UiO-66-L2 (1420 m2g-1). 
Surface functionalisation with alkyl chains increases the mass of the particles, and so a 
decrease in gravimetric surface area is expected. The pore volumes are 0.623 ccg-1 and 0.587 
ccg-1 for UiO-66-L1-dodecane and UiO-66-L2-decane respectively.  
 
Figure 3.4. N2 adsorption isotherms (77 K) of the MOFs, showing a decrease in gravimetric uptake as 
additional mass is incorporated onto their surfaces. Closed symbols represent adsorption, empty 
symbols desorption. 
Thermogravimetric analysis was used to investigate the incorporation of surface functionality. 
For UiO-66-L1-dodecane, additional mass loss events are obvious in the TGA traces recorded 
in air (Figure 3.5a) and under nitrogen (Figure 3.5b). These mass loss events occur at 
temperatures higher than the decomposition of the isolated product of the CuAAC reaction 
between L1 and dodecane, indicating covalent attachment to the NMOF, and a surface 
functionality component of around 10% w/w.  
Similar TGA analysis was carried out on UiO-66-L2 and its functionalised analogue UiO-66-
L2-decane. In both the TGA traces recorded in air (Figure 3.6a) and under nitrogen (Figure 
3.6b), there is a high temperature mass loss event corresponding to covalently attached 
surface functionality, with a weight content of around 10% w/w.  
 






Figure 3.5. a) Comparison of TGA traces in air of UiO-66-L1 before and after reaction with 1-dodecyne. 





Figure 3.6. a) Comparison of TGA traces in air of UiO-66-L2 before and after reaction with 1-
azidodecane. b) Comparison of TGA traces in nitrogen of the MOFs as well as the isolated “clicked” 
material L2-decane. 
SEM imaging was used to examine the morphology and size of the NMOFs after surface 
modification. In both cases, it can be seen that particle size and morphology is retained after 
the click modulation protocol (Figure 3.7). 






Figure 3.7. SEM images of a) UiO-66-L1-dodecane and b) UiO-66-L2-decane. 
The full conjunction of the characterisation data proves that postsynthetic covalent 
modification (CuAAC) occurs only on the outer surface, and that the modulators (L1 and L2) 
introduced during synthesis are suitable platforms for postsynthetic surface modifications.  
 
3.3.1.2. UiO-66-L1 Postsynthetic Covalent PEGylation 
For drug delivery purposes, poly(ethylene glycol) chains (PEG) were chosen for UiO-66 
coatings as they present an amphiphilic behaviour which resembles that of human cellular 
membranes.1 Furthermore, other nanoparticulate DDS have shown a decrease in their 
immune system recognition upon PEGylation compared to bare nanoparticles.2, 3 This is 
because the flexible and rapidly changing structure of the PEG, makes it difficult for the 
immune system to model an antibody around it. UiO-66-L1 was chosen for modification with 
propargyl-functionalised poly(ethylene glycol) chains of two different sizes, PEG550 (Mn = 
550) and PEG2000 (Mn = 2000), as it exhibits the appropriate size for drug delivery. 
PXRD analysis showed that the PEGylated NMOFs retained their crystallinity (Figure 3.8a). 
Full 1H NMR spectroscopic analysis of the acid digested products, UiO-66-L1-PEG550 and 
UiO-66-L1-PEG2000, is difficult due to the intensity of the polymer signals. However, a control 
experiment - stirring PEG2000-propargyl or PEG550-propargyl with UiO-66-L1 but without 





catalyst - revealed that, without Cu(I) catalyst, no polymer was present in the sample at all, 
confirming that covalent linkage is required for the PEG to remain attached to the MOF. 
Thermogravimetric analysis, shown in Figure 3.8b, confirms the incorporation of the PEG units 
and strongly indicates that covalent attachment is required for their incorporation, as no mass 
loss events corresponding to PEG units are seen in control samples where the MOFs are 
simply soaked in PEG solutions without a catalyst for the CuAAC conjugation protocol. The 
level of PEG incorporation was estimated to be 21.7% w/w and 23.1% w/w, for UiO-66-L1-
PEG550 and UiO-66-L1-PEG2000, respectively. 
 
 
Figure 3.8. a) Stacked PXRD patterns of UiO-66-L1 and its PEGylated derivatives. B) TGA profiles of 
UiO-66-L1-PEG550 and UiO-66-L1-PEG2000 compared with control samples of UiO-66-L1 that had 
been exposed to propargyl-functionalised PEGs without any Cu(I) catalyst. 
Whilst a series of peaks corresponding to covalently modified PEG550 (the molecules of 
different chain lengths are present in the starting material) are clearly visible in the HRESI-MS 
mass spectrum of UiO-66-L1-PEG550 (Figure 3.9), it was not possible to ionise the larger 
PEG2000 chains by ESIMS or MALDI-TOF. This was common to the precursors and to the 
digested MOFs. 
 






Figure 3.9. ESIMS of digested UiO-66-L1-PEG550 and a table of observed peaks for covalently 
modified PEG chains of different lengths.  
FTIR spectra were collected to monitor the functional group conversion and incorporation of 
the PEG units to UiO-66-L1. For both UiO-66-L1-PEG550 (Figure 3.10a) and UiO-66-L1-
PEG2000 (Figure 3.10b), there is a noticeable decrease in intensity of the azide signal around 
2300 cm-1, indicating conversion of the surface L1 units, and signals for the C-H functionality 
of the PEG chains are observed.  
 
Figure 3.10. FTIR spectra comparing a) UiO-66-L1-PEG550 with the two starting materials used in its 
synthesis, and b) UiO-66-L2-PEG2000 with the two starting materials used in its preparation. 
A decrease in N2 uptake upon PEGylation was observed, with BET surface areas of 865 m2g-
1 for UiO-66-L1-PEG550 and 521 m2g-1 for UiO-66-L1-PEG2000 the consequence of the 
incorporated mass of the PEG chains (Figure 3.11). The pore size distribution of UiO-66-L1-
PEG550 corresponds with that reported for UiO-66, but in the case of UiO-66-L1-PEG2000, 





the adsorption and desorption isotherms reveal a Type IV isotherm, typical of mesoporous 
materials, but with no closure point. In the case of nitrogen adsorption at 77 K the lower closure 
point is usually located around p/p0~0.42, and any hysteresis recorded bellow this point has 
been attributed to irreversible changes such as swelling of the adsorbent or surface 
impurities.35 A similar, phenomenon has been found by Farha et al. upon UiO-66 
functionalisation with the phospholipid DOPA, although to a lesser degree.11 The fact that 
PEG2000 chains are considerably bigger in size than DOPA explains why it is more 
pronounced in this case.  
 
Figure: 3.11) N2 uptake isotherms (77 K) of the PEGylated MOFs compared to their precursor UiO-
66-L1. Closed symbols represent adsorption, empty symbols desorption. B) Pore size distributions of 
the PEGylated MOFs compared to their precursor UiO-66-L1. 
Interestingly, the physical effects on nanoparticle morphology can be observed by SEM 
imaging (Figure 3.12). As the chain length of the surface functionality increases, the particles 
become more rounded in shape with less defined edges and vertices, as their surface features 
become dominated by the bulk of their capping polymers rather than the underlying MOF 
crystal structure.  
 






Figure 3.11. SEM images of a) UiO-66-L1-PEG550 and b) UiO-66-L1-PEG2000. 
The particle size distributions before and after PEGylation were analysed manually using the 
ImageJ software package (Figure 3.12). The average size of precursor UiO-66-L1 particles 
was found to be 146.6 ± 29.3 nm, which increased upon PEGylation to 160.2 ± 26.9 nm for 
UiO-66-L1-PEG550 and to 172.9 ± 36.8 nm for UiO-66-L1-PEG2000. This size increase is 
consistent with the increasing size of the surface polymer chains being installed on the 
nanoparticles’ surfaces, but the magnitude of the size change may be affected by the 
accompanying change in morphology from octahedral to roughly spherical particles upon 
surface modification.  







Figure 3.12. Particle size analysis from SEM micrographs for a) UiO-66-L1, b) UiO-66-L1-PEG550, 
and c) UiO-66-L1-PEG2000. 
3.3.1.3. UiO-66-L1 and UiO-66-L2 Postsynthetic Covalent Polymeric Coating 
After confirming successful surface functionalisation using the modulators’ (L1 and L2) azide 
and progargyl functionalities to covalently attach alkyl and PEG chains to UiO-66 surface, 
poly-L-lactide and poly-N-isopropylacrylamide were chosen as additional protecting polymers. 
Poly-L-Lactide is biocompatible and hydrophobic,36 which should boost its cell internalisation37 
and biocompatibility, while poly-N-isopropylacrylamide has a thermoresponsive behaviour, 
which should retained and embodied on the coated MOF drug release kinetics.6  
Surface ligand exchange was performed on UiO-66-L1 to exchange L1 with L2 on the particle 
surface and to retain particle size, to form UiO-66-L2. Acid-digested 1H NMR spectra (in 
D2SO4/ DMSO-d6) of UiO-66-L1 (Figure 3.13, bottom) confirmed the reproducibility of the 
synthetic protocol to introduce L1 during synthesis, with a 14.6% molar ratio compared to the 
linker in UiO-66 structure, in great agreement with previous results. After surface ligand 
exchange of L1 for L2, the 1H NMR spectrum of acid digested UiO-66-L2 (Figure 3.13, top) 
showed disappearance of resonances assigned to L1 and appearance of signals for L2 with 





a 27.0% molar ratio compared to the bdc linker. Minor traces of L1, probably present in the 
core of UiO-66-L1, are still present in the 1H NMR spectrum, but the low intensity (~2% molar 
ratio to bdc) hinders their analysis. 
 
Figure 3.13. Stacked partial 1H NMR spectra of acid digested (D2SO4 / DMSO-d6) samples of UiO-66-
L1 (bottom) and UiO-66-L2 (top), prepared from the former. 
Postsynthetic covalent modifications were performed following our CuAAC protocol. UiO-66-
L1 was reacted with propargyl-terminated poly-L-lactide (PolyLact, Mn = 2000 Da), while UiO-
66-L2 was reacted with azide terminated poly-N-isopropylacrylamide (PNIPAM, Mn = 15000 
Da), yielding UiO-66-L1-PolyLact and UiO-66-L2 PNIPAM, respectively. Analysis of the 
postsynthetically modified UiO-66 samples by PXRD showed that that their crystallinity is not 
affected by the postsynthetic surface functionalisation processes.  
The polymeric nature of poly-L-lactide and PNIPAM also hinders the analysis of UiO-66-L1-
PolyLact and UiO-66-L2-PNIPAM by 1H NMR spectroscopy, but again the presence of 
polymeric signals can be observed in both cases.  
Thermogravimetric analysis (TGA) of the surface-modified samples was compared with their 
precursors (either UiO-66-L1 or UiO-66-L2) and with authentic samples of the commercial 
surface reagents (Figure 3.14) prior to attachment in order to identify their characteristic 
features, based on which the surface moiety content can be estimated. However, due to the 
different, and in some case gradual, degradation profiles of most surface reagents, their exact 
determination is difficult.  





Degradation profiles more complex than UiO-66-L1 and UiO-66-L2 were observed for the 
polymer coated samples prepared by click modulation. In the case of UiO-66-L1-PolyLact, the 
MOF structure decomposes at a lower temperature than its precursor UiO-66-L1, as a 
consequence of the earlier degradation of the polymer. The fact that the polymer 
decomposition after attachment is more gradual, and starts at a higher temperature than the 
free reagent, indicates that is it covalently attached. Propargyl-terminated poly-L-lactide 
decomposes between 225-400 ºC, and the 10% w/w mass loss from UiO-66-L1-PolyLact in 
this temperature region is in concordance with the difference in metal residue compared to its 
precursor UiO-66-L1, suggesting approximately 10% w/w incorporation of the polymer. 
 
 
Figure 3.14. TGA traces of covalently surface modified MOFs compared with the surface functionality 
and the starting material for a) UiO-66-L1-PolyLact, and b) UiO-66-L2-PNIPAM. 
Similarly, when UiO-66-L2 is reacted with PNIPAM, as the polymer itself degrades at a lower 
temperature than the MOF, UiO-66-L2-PNIPAM thermally degrades at lower temperature than 
UiO-66-L2. Gradual mass loss from the polymer to the linker decomposition temperatures 
corresponds to a 3% w/w mass loss, similar to the difference of metal residue to the precursor 
sample. 
Control samples, in which either UiO-66-L1 or UiO-66-L2 were stirred under the previous 
CuAAC protocol conditions with the surface reagents but without the presence of the CuI 
catalyst, showed no major difference in the thermal stability of their structure or extra mass 
loss (Figure 3.15). A minor decrease in the metal residue of the samples was observed as a 
consequence of solvent incorporation during the process. Additionally, 1H NMR spectra of the 
control samples showed no presence of polymeric signals. These findings together confirm 
that the polymers are covalently attached to UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM 
rather than simply adsorbed on the outer particle surfaces. 







Figure 3.15. TGA traces of the polymer-coated samples compared to the starting materials and control 
reactions, where no catalyst for the CuAAC reaction has been added, to confirm that the polymers are 
covalently attached to the MOF. 
Additionally, the propargyl band of poly-L-lactide and the azide band of UiO-66-L1 are missing 
in the UiO-66-L1-PolyLact spectrum, suggesting covalent reaction (Figure 3.16). 
Unfortunately, other signals of the different moieties are masked by UiO-66 peaks and the IR 
spectrum of UiO-66-L2-PNIPAM is inconclusive.  
 
Figure 3.16. FT-IR spectra of the click modulated MOFs compared to the starting material and the 
surface functionality, for a) UiO-66-L1-PolyLact, and b) UiO-66-L2-PNIPAM. 





In order to analyse the porosity of the samples upon postsynthetic surface modification, N2 
adsorption and desorption isotherms were collected at 77 K (Figure 3.17). Only a small 
decrease in porosity after surface ligand exchange, in agreement with the moderately higher 
ligand content, was observed for UiO-66-L2, from 1591 m2g-1 for its precursor UiO-66-L1 to 
1349 m2g-1. It is still slightly more porous than non-defective UiO-66, confirming that L2 is 
attached to the surface and defect sites rather than stored in the pores. The isotherms of the 
surface modified samples showed retention of porosity and decreases in gravimetric surface 
areas, consistent with the addition of mass, with surface areas of 1129 m2g-1 and 1030 m2g-1 
and pore volumes 0.640 ccg-1 and 0.578 ccg-1 for UiO-66-L1-PolyLact and UiO-66-L2-
PNIPAM respectively. 
 
Figure 3.17. a) N2 adsorption isotherms (77 K) of the postsynthetically surface modified MOFs. Closed 
symbols for adsorption, empty symbols for desorption. b) Pore size distributions calculated form the 
isotherms. 
SEM imaging was used to study the morphology of the NMOFs upon surface modification. 
Compared to the precursors UiO-66-L1 and UiO-66-L2 (Figure 3.18), the covalently-modified 
samples are in general more rounded in shape as a consequence of surface modifications 
with large polymer chains (Figure 3.19). This effect is more remarkable for UiO-66-L2-
PNIPAM, due to the bigger size of PNIPAM.  






Figure 3.18. SEM images at different magnification of a) UiO-66-L1, and b) UiO-66-L2. 
 
Figure 3.19. SEM images at different magnification of a) UiO-66-L1-PolyLact, and b) UiO-66-L2-
PNIPAM. 
A size increase from 143 ± 31 nm and 142 ± 14 nm for UiO-66-L1 and UiO-66-L2 respective, 
to 177 ± 25 nm and 177 ± 24 nm from UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM 
respectively was found as a consequence of surface coating. A comparison of the particle size 
histograms is given in Figure 3.20. 






Figure 3.20. Comparison of particle size histograms for PolyLact and PNIPAM coated samples and 
their precursors.  
These results prove that covalent postsynthetic surface modification can be performed using 
L1 and L2 as surface reagents, and that click modulation protocol is versatile and reproducible.  
3.3.2. Postsynthetic Surface Coordination of UiO-66-L1 
Postsynthetic modifications based on coordination chemistry – surface ligand exchange17 – 
were performed on UiO-66-L1 using heparin, biotin, or folic acid as the reactants. The resultant 
materials are designated UiO-66-Hep (PS), UiO-66-Biot (PS) and UiO-66-FA (PS) to denote 
the postsynthetic functionalisation protocol. 
The 1H NMR spectrum of acid digested UiO-66-FA (PS) (Figure 3.21) showed the presence 
of some of the characteristic folic acid resonances. Some of the signals are again not present, 
possibly due to coordination of folic acid to the metals in solution or through deuterium 
exchange, and others exhibit very weak intensity (See appendix for full folic acid acidified and 
heated 1HNMR characterisation). Analyses were consistent, showing similar folic acid 
contents of approximate 40 mol % compared to bdc. The content of folic acid in UiO-66-FA 
(PS) sample was found to be 23.6% (w/w), as determined by UV-Vis. 






Figure 3.21. Stacked partial 1H NMR spectra of UiO-66-FA (PS), bottom, and folic acid, top, in D2SO4/ 
DMSO-d6.  
The 1H NMR spectrum of acid-digested UiO-66-Biot (PS) shows the presence of characteristic 
biotin signals (Figure 3.22). However, their low intensity compared to the linker in UiO-66 
hinders analysis, with an estimation of ~10 mol % incorporation of biotin on the surface of UiO-
66-Biot (PS) (See appendix for full biotin acidified 1HNMR characterisation). 
 
Figure 3.22. Stacked partial 1H NMR spectra of UiO-66-Biot (PS), top, and biotin, bottom, in D2SO4/ 
DMSO-d6. The inset highlights the characteristic alkyl region. 
The characterisation of UiO-66-Hep (PS) by 1H NMR spectroscopy was complicated as a 
consequence of the polymeric nature of heparin itself. In general for all the samples 





postsynthetically modified using coordination chemistry – UiO-66-FA (PS), UiO-66-Biot (PS) 
and UiO-66-Hep (PS) – it can be observed that signals assigned to the L1 modulator present 
in the precursor UiO-66-L1 have disappeared, presumably as a consequence of the exchange 
of the different functionality on the surface. The presence of the surface functionality is 
confirmed but full quantification if difficult as a consequence of low signal intensity compared 
to bdc and the possibility of missing linker defects. 
Additional mass loss events are noticeable in the samples functionalised by postsynthetic 
exchange that can be ascribed to the surface functionality (Figure 3.23). The multi-step 
thermal degradation profile of heparin itself hinders the analysis of UiO-66-Hep (PS) by TGA, 
although the presence of heparin is clearly noticeable. The major new mass loss (235-420 ºC) 
corresponds to 27.7% w/w of the sample, while the difference between the final residues 
compared with the precursor UiO-66-L1 is 16.4% w/w, confirming an increase in mass of the 
surface functionality even though L1 is lost from the precursor. However, heparin itself does 
not totally decompose, leaving a residue of ca. 37%. The fact that the main heparin 
decomposition step occurs in a more gradual manner for UiO-66-Hep (PS) than for free 
heparin indicates that heparin is attached to the UiO-66 structure, but quantification of the 
mass fraction of heparin is difficult.  
 
Figure 3.23. TGA traces of postsynthetically surface modified MOFs compared with the surface 
functionality and the starting material, UiO-66-L1, for a) UiO-66-Hep (PS), b) UiO-66-FA (PS), and c) 
UiO-66-Biot (PS). 
Folic acid also degrades gradually with temperature, changing therefore the degradation 
profile of UiO-66-FA (PS), and making quantification of the folic acid content by mass difficult. 
The gradual degradation from 120-450 ºC corresponds to a mass loss of 29.0%, while the 
difference in metal residues to a 16.7%. Although there is also a big difference in the TGA 
residue of the UiO-66-Biot (PS) and the precursor UiO-66-L1 (12% w/w), no notable additional 
features were observed in its degradation profile. Since biotin is clearly present in the acid-
digested 1H NMR spectrum, it can be concluded that it decomposes together with the bdc 
linker between 300-400 ºC.  





With the combination of 1H NMR spectroscopy and TGA, it can be concluded that the different 
surface reagents are present on the surfaces of UiO-66. In some cases, the degradation of 
the surface reagents occurs at higher temperatures than the free reagents, strongly 
suggesting attachment. Additionally, displacement of surface-attached L1 suggests the same.  
Minor changes in FT-IR spectra of the surface functionalised samples were observed (Figure 
3.24). In agreement with the 1H NMR spectra, the azide band present in UiO-66-L1 at ca. 2100 
cm-1 is no longer present in the IR spectra of UiO-66-FA (PS), UiO-66-Hep (PS) and UiO-66-
Biot (PS).  
 
 
Figure 3.24. FT-IR spectra of the postsynthetically surface modified MOFs compared to the starting 
material, UiO-66-L1, and the surface functionality, for a) UiO-66-FA (PS), b) UiO-66-Hep (PS), and c) 
UiO-66-Biot (PS). 
New IR bands, characteristics from heparin, are clearly present in the FT-IR spectrum of UiO-
66-Hep (PS). The bands at 1020 cm-1 are assigned to heparin sulfates, which are slightly 





shifted when compared to free heparin, as a consequence of coordination to the zirconium 
positions rather than electrostatic interaction. 
In order to analyse the porosity of the samples upon postsynthetic surface modification, N2 
adsorption and desorption isotherms were collected at 77 K (Figure 3.25), showing decreases 
in surface area consistent with the addition of mass. Compared to their precursor UiO-66-L1 
(SBET = 1591 m2g-1; pore volume= 0.791 ccg-1), a considerable decrease in porosity is 
observed, with surface areas of 891 m2g-1, 879 m2g-1 and 949 m2g-1, and pore volumes of 
0.453 ccg-1, 0.499 ccg-1 and 0.496 ccg-1 for UiO-66-Hep (PS), UiO-66-FA (PS) and UiO-66-
Biot (PS) respectively, meaning that although the MOFs are still porous after the surface 
modification, their pore access might be partially blocked by the surface functionality.  
 
Figure 3.25. a) N2 adsorption isotherms (77 K) of the postsynthetically surface modified MOFs. Closed 
symbols for adsorption, empty symbols for desorption. b) Pore size distributions calculated form the 
isotherms. 
Accordingly to the TGA profiles, the samples with the smallest surface areas correspond to 
those samples with lowest metal residue, and therefore have a greater mass content of the 
surface functionality. In other words, the decrease in gravimetric surface area is consistent 
with the amount of extra mass added to the NMOF. Additionally, the pore volumes and the 
pore size distributions of all the samples are similar to UiO-66, unequivocally confirming that 
functionalisation occurs on UiO-66 surface, not by blocking pores.  
SEM imaging was used to study the morphology of the NMOFs upon surface modification 
(Figure 3.26), showing a slightly increase in particle size, together with a change in 
morphology. UiO-66-FA (PS), UiO-66-Biot (PS) and UiO-66-Hep (PS) particle sizes analysed 
by imageJ are 168 ± 26 nm, 155 ± 34 nm and 175 ± 17 nm respectively (Figure 3.27).  






Figure 3.26. SEM images at different magnification of a) UiO-66-FA (PS), b) UiO-66-Hep (PS), and c) 
UiO-66-Biot (PS). 
 
Figure 3.27. Comparison of particle size histograms for the surface modified samples through 
postsynthetic coordination and their precursor.  
When UiO-66-FA is dispersed in MeOH, there is some randomly allocated material interlacing 
the NMOFs (Figure 3.28), presumably as a consequence of the detachment of folic acid during 
the sample preparation process. The sample does not have this material when the preparation 





avoids dispersion. This indicates that folic acid coating might not be so stable, and it is partially 
released during the sample dispersion. 
 
Figure 3.28. SEM images of UiO-66-FA (PS) a) non-dispersed, and b) dispersed with methanol. 
To summarise, coordination chemistry has been successfully utilised to introduce both folic 
acid, biotin and heparin to UiO-66-L1 outer surface postsynthetically, showing attached 
modulator L1 displacement. However, a more pronounced decrease in porosity, compared to 
samples functionalised during synthesis (coordination modulation) or by the click modulation 
protocol, was observed. This could be a consequence of major outer surface coverage and 
partial pore window blockage; as coordination modulation induces the creation of defects 
through the overall attachment of modulator to the inner and outer available Zr clusters, and 
the postsynthetic modification of these modulators occurs only in the outer surface due to size 
selectivity and to steric hindrance for the CuACC catalyst formation. Coordination chemistry 
offers a wide variety of possibilities to be explored for surface modifications.  
3.4. The Effect of UiO-66 Surface Chemistry on its Colloidal Dispersion 
In order to study the effect on MOF colloidal dispersion upon surface chemistry and coating 
mode, dynamic light scattering (DLS) measurements were performed before and after surface 
coating- either through coordination modulation, detailed in Chapter 2, or though postsynthetic 
modification, detailed during this chapter- and compared to samples synthesised under 
conventional AcOH modulated conditions. 
Particle size and aggregation in solution was measured on dispersions of 250 g of MOF per 
mL of dispersant (i.e MeOH, water or PBS 10x). Three consecutive recordings, each 
consisting on 14 runs, were performed with a waiting time of 1 minute, and no stirring was 
provided during the analysis.  
 





UiO-66-L1 and UiO-66-L2 aggregate in MeOH as a consequence of their hydrophilic surfaces, 
but the aggregation is however more pronounced for UiO-66-AcOH (Figure 3.29). A smaller 
degree of aggregation was found for UiO-66-L1, which exhibits stable colloidal dispersions 
with an average size of ~300 nm, while UiO-66-L2 aggregates further during the course of the 
experiment, from around 500-1000 nm, and shows a second population with a smaller degree 
of aggregation. This may be a result of their hydrophilic surfaces. 
 
Figure 3.29. DLS profiles in methanol of a) UiO-66-L1 and b) UiO-66-L2 (Synthesised by SLE on UiO-
66-L1).c) UiO-66-AcOH 
The effect of surface PEGylation is clear. The PEGylated samples show much smaller size in 
solution, with average diameters around 150 nm correlating well with SEM data, suggesting 




Figure 3.30. a) Dynamic light scattering (DLS) measurements of UiO-66 samples in methanol. b) Zoom 
in on DLS data for smaller particle sizes.  
 





When the surfaces of the NMOFs are modified through postsynthetic covalent attachment of 
polymers (poly-L-lactide or PNIPAM) the average hydrodynamic diameter of the functionalised 
samples also decreases compared to their precursors (Figure 3.31). The biggest improvement 
is in the case of UiO-66-L1-PolyLact, which shows a particle size close to the one determined 




Figure 3.31. DLS profiles in methanol of a) UiO-66-L1-PolyLact, and b) UiO-66-L2-PINIPAM. 
No drastic improvement was found for the samples postsynthetically modified using the 
surface ligand exchange protocol (Figure 3.32). In fact, UiO-66-Hep (PS) exhibited a higher 
degree of aggregation in methanol compared to its precursor UiO-66-L1. The decreasing 
diameter of UiO-66-Hep (PS) during the course of the experiment suggests precipitation or 
digestion of the MOFs as surface heparin detaches. On the other hand, UiO-66-FA (PS) and 
UiO-66-Biot (PS) have an average hydrodynamic diameter similar to their precursor in MeOH. 
While UiO-66-FA (PS) exhibits stable colloidal dispersions with no aggregation during the 
experiment, UiO-66-Biot (PS) further aggregates during the last recording.  
 






Figure 3.32. DLS profiles in methanol of a) UiO-66-Biot (PS), b) UiO-66-Hep (PS) and c) UiO-66-FA 
(PS). 
The differences in the particle sizes in the surface functionalised samples (FA and Biot) 
prepared by coordination modulation during Chapter 2 when acetic acid is used as co-
modulator is reflected in their DLS profiles (Figure 3.33). For example, UiO-66-FA (CM) forms 
stable aggregates with an average size of approximately 200-400 nm in MeOH, while UiO-66-
FA-AcOH (CM) forms bigger aggregates (500-900 nm) that further aggregate to a size of 750-
1750 nm during the course of the experiment. In contrast, UiO-66-Biot-AcOH (PS) forms 
smaller aggregates that UiO-66-Biot (CM), which shows significant aggregation to around 
4000 nm. UiO-66-Biot (CM) forms intergrown crystals, as observed by SEM. Thus, its DLS 
profile in MeOH shows two populations, one with average size 400 nm, possible single 
crystals, and other highly polydisperse (1500-6500 nm) corresponding to intergrown crystals. 
UiO-66-Biot-AcOH (CM), which was identified as monodisperse crystallites of about 200 nm 
in size, dispersed better in MeOH, with minor aggregation over the experiment.  
These results, combined with the particle size distributions from SEM, led to only take forward 
UiO-66-FA (CM) and UiO-66-Biot-AcOH (CM) for further experiments. 
 






Figure 3.33. DLS profiles in methanol of a) UiO-66-FA (CM), b) UiO-66-FA-AcOH (CM), c) UiO-66-Biot 
(CM), and d) UiO-66-Biot-AcOH (CM). 
When comparing the first recording of the different samples (Figure 3.34), apart from UiO-66-
Hep (PS), it can be seen that the postsynthetically surface functionalised particles are in 
general better dispersed than their precursors in MeOH, with more homogeneous 
distributions, especially for the samples covalently modified with polymers. The samples 
prepared by coordination modulation show similar or slightly greater aggregation than UiO-66 
(AcOH).  
 
Figure 3.34. Comparison of DLS profiles in methanol of all samples. 





DLS measurements were also carried out in water, but stable dispersions of the precursors 
UiO-66-L1 and UiO-66-L2 were difficult to generate. Initial aggregates of around 2500 nm in 
size were obtained for UiO-66-L1 followed by rapid further aggregation and precipitation, 
resulting in no signal populations (Figure 3.35). This slightly improved after surface ligand 
exchange with L2, which presented two different populations. The first had an average size of 
500 nm and the second around 5000 nm, increasing in intensity during the course of the 
experiment as a consequence of aggregation.  
 
 
Figure 3.35. DLS profiles in water of a) UiO-66-L1, and b) UiO-66-L2. 
The PEGylated samples showed much less aggregation, in particular UiO-66-L1-PEG2000, 
which has a much larger surface corona of water-compatible PEG chains and so stabilises 
small aggregates around 500 nm in size (Figure 3.36). 
 
Figure 3.36. Dynamic light scattering measurements of UiO-66 samples in water. 





During repeated DLS experiments run over 10 minutes, it was observed that UiO-66-L1-
PEG2000 gradually aggregated (Figure 3.37), from particles around 250 nm to around 500 
nm in diameter. Aggregates of UiO-66-L1-PEG550 across a broad size range around 1000 
nm had, in contrast, stabilised rapidly prior to measurement, again indicating the significant 
effect of larger PEG chains on hydrodynamic behaviour of the UiO-66 nanoparticles. 
 
Figure 3.37. Time dependent aggregation observed during DLS measurements for a) UiO-66-L1-
PEG550, and b) UiO-66-L1-PEG2000. 
 
Coating the NMOFs with other polymers enhanced their colloidal dispersion properties in 
water (Figure 3.38). Initial colloidal dispersions with size close to the one determined by SEM 
were obtained, followed by strong aggregation in the case of UiO-66-L2-PNIPAM. UiO-66-L1-
PolyLact was successfully dispersed and remained stable until the last measurement, where 
a second population appeared. 
 
Figure 3.38. DLS profiles in water of a) UiO-66-L1-PolyLact, and b) UiO-66-L2-PNIPAM. 





Minor improvements in the colloidal dispersion and stability in water were found for the 
postsynthetically-coated folic acid and biotin samples (Figure 3.39).  
 
Figure 3.39. DLS profiles in water of a) UiO-66-FA (PS), b) UiO-66-Hep (PS), and c) UiO-66-Biot (PS). 
Although UiO-66-FA (PS) also exhibits two different populations, no major aggregation or 
precipitation were found during the course of the experiment. UiO-66-Biot (PS) forms stable 
aggregates of 300 nm approximately during the first two recordings, but a second population 
of 4000 nm appeared due to aggregation during the third run. Once again, colloidal dispersion 
and stability were worst after heparin surface modification, as the sample precipitates during 
the course of the experiment, and a decreasing in size is observed due to sedimentation. It is 
likely the DLS response in the second and third runs is that of heparin (<50 nm) rather than 
the MOF.  
Aggregation of both modulated samples in water was observed during the course of the 
experiment (Figure 3.40). Initially, small UiO-66-FA (CM) particles formed colloidal dispersions 
of 200 nm in size and further aggregated to around 1000 nm for the last recording, as did the 
larger UiO-66-Biot-AcOH (CM) samples, which formed initial aggregates of around 500 nm. 
However, more stable colloidal dispersions that unfunctionalised UiO-66 were formed.  







Figure 3.40. DLS profiles in water of a) UiO-66-FA (CM), and b) UiO-66-Biot-AcOH (CM). 
Comparing all the samples (Figure 3.41), a similar trend is observed. In all cases, surface 
modification initially improves particle dispersity in water compared to precursor samples, but 
aggregation over the course of the experiments is an issue.  
 
 
Figure 3.41. Comparison of DLS profiles in water of all samples. 
DLS measurements were also carried in phosphate buffered saline (PBS), but it was again 
found difficult to generate stable dispersions of UiO-66-L1 and UiO-66-L2, as aggregation and 
precipitation during the course of the experiment were observed. In initial recordings, 
aggregates around 2000-4000 nm in size were found (Figure 3.42).  






Figure 3.42. DLS profiles in PBS of a) UiO-66-L1, and b) UiO-66-L2. 
On the other hand, stable colloidal dispersions of the postsynthetically surface functionalised 
nanoparticles, with different degrees of aggregation, were obtained in PBS (Figure 3.43). UiO-
66-FA (PS) forms aggregates of around 750 nm, which do not considerably aggregate further 
during the course of the experiment. Similar behaviour is seen for the other samples 
functionalised through the postsynthetic exchange protocol, with UiO-66-Hep (PS) showing a 
similar profile with no further aggregation with time, and UiO-66-Biot (PS) a smaller average 
diameter of ~600 nm. 
 
Figure 3.43. DLS profiles in PBS of a) UiO-66-FA (PS), b) UiO-66-Hep (PS), and c) UiO-66-Biot (PS). 
In agreement with the DLS results obtained when dispersing the sample in MeOH and water, 
the samples functionalised using covalent click chemistry shown a considerable improvement 
in PBS colloidal dispersion (Figure 3.44). Although both samples form slightly bigger 
aggregates with time, initial recordings show particle sizes corresponding to those determined 





by SEM for UiO-66-L1-PolyLact, which aggregates from 200 nm to 500 nm during the course 
of the experiment. In the case of UiO-66-L2-PNIPAM, slightly larger aggregates from 400 nm 
to 750 nm are formed during the course of the experiment.  
 
Figure 3.44. DLS profiles in PBS of a) UiO-66-L1-PolyLact, and b) UiO-66-L2-PNIPAM. 
Similar results were found when dispersing the modulated NMOFs in PBS (Figure 3.45). 
During the first recording, UiO-66-FA (CM) exhibits two populations, aggregates around 500 
nm and a small population very close to the size observed by SEM, which disappears for the 
last two recordings without further aggregation. UiO-66-Biot-AcOH (CM) forms stable 
aggregates of 1000 nm average size 
 
Figure 3.45. DLS profiles in PBS of a) UiO-66-FA (CM), and b) UiO-66-Biot-AcOH (CM). 
Comparing the first recordings of the functionalised samples and their precursors in PBS, the 
effect on colloidal dispersion based on surface chemistry is clearly noticeable, especially when 
using our previously reported ‘click modulation protocol’ to covalently attach polymers to UiO-
66 surface (Figure 3.46). In all cases, surface modification improves dispersity and reduces 
aggregation. 
 






Figure 3.46. Comparison of DLS profiles in PBS of all samples. 
The results suggest that surface modification enhances the stability and dispersion of NMOFs 
for drug delivery. However, the presence of different proteins, sugars and different moieties in 
the blood current that are known to be adsorbed onto the surfaces of NMOF will definitely 
have an effect on their colloidal stability and dispersion in vivo.38-40 In fact, it has been reported 
that NMOF aggregation is strongly decreased in growth media.41-43 During Chapter 2, the 
effect of adding BSA to PBS confirmed the further colloidal stability of MOFs in the presence 
of proteins due to the formation of a protein corona. It is important to consider that no stirring 
is provided during the course of the experiment, while the blood current is dynamic in its 
nature. Although here it is shown how to improve those properties through surface 
functionalisations, especially coating UiO-66 with polymers by the ‘’click modulation’’ protocol, 
the colloidal stability of the NMOFs in vivo conditions is still difficult to predict. However, it is 
important to point out that the samples synthesised previously under the DCA modulated 
conditions (Chapter 2) are colloidally stable in water and PBS, showing size distributions in 
great agreement with SEM, without aggregation during the course of the experiment. These 
samples are the ones which will be used as DDSs, as they contain a high loading of the the 
PDK inhibitor dichloroacetate, and surface modification is expected to further enhance their 
dispersion.  





3.5. The Effect of Surface Chemistry in UiO-66 Degradation Kinetics 
To be an efficient injectable treatment, the nanocarrier should be stable at the first stages of 
the treatment, ideally not being degraded in extracellular conditions (i.e. blood, pH 7.4) in order 
to avoid renal clearance of the drug, yet not persistent enough to be accumulated over longer 
treatment periods. The nature of the metal-linker coordination bonds in MOFs ensures total 
degradation of the structure at sufficiently acidic pH ranges due to linker protonation, but 
strongly coordinating molecules, such as phosphates, are also able to displace the linkers in 
the structure at extracellular pH.44, 45 Whilst the rapid degradation of MOFs under physiological 
conditions ensures no accumulation of the carrier after it has reached its target and released 
the drug, their instability towards phosphates, which are present in the blood, typically hinders 
NMOFs bioapplications due to fast release kinetics.46 If the initial degradation could be slowed 
down while maintaining their final clearance, NMOFs therapeutic efficiency will be enhanced. 
Several approaches, such as amorphisation42, 47, 48 or silica coating,26 among others, have 
been studied to improve their stability towards phosphates. 
To obtain the degradation profile of the different UiO-66 nanoparticles, around 10 mg of 
sample were dispersed in a dialysis bag with 10 ml of phosphate buffered saline (PBS) at pH 
7.4, and dialysed against 100 ml of PBS (10x) under magnetic stirring at room temperature. 
The release of the bdc linker, indicative of degradation, was measured by UV-Vis 
spectroscopy. The quantity of bdc (% w/w) present in the different UiO-66 samples was 
calculated based on the TGA measurements. 
A calibration curve of bdc in PBS pH 7.4 was performed (max = 241 nm) and shown in Figure 
3.47a. Solutions of bdc and L1 of the same concentration were measured revealing a 
maximum absorbance peak at 234 nm for L1 with a very similar extinction coefficient to bdc. 
When the absorbance of a solution of both bdc and L1 (1:1) was measured, a maximum peak 
absorbing at 238 nm was determined with a very similar extinction coefficient to bdc on its 
own (Figure 3.47b).  
 






Figure 3.47. a) Calibration curve of bdc absorbance at  = 241 nm in PBS at pH 7.4. b) UV-Vis spectra 
of PEG2000-propargyl (brown), L1 (pink), bdc (black), and a mixture of L1 and bdc (green). 
 
Due to the overlapping absorbance of L1 and bdc, the fact that the presence of L1 does not 
affect the bdc absorbance, and as the quantity of L1 present in sample (determined by 1H 
NMR) is very small compared to bdc, the bdc calibration curve in Figure 3.47a was used.  
Each measurement was taken in situ (from 210 nm to 330 nm) and the liquid was introduced 
back to the dialysis media before prior measurement. Each experiment was performed 
separately 3 times to determine the standard deviation and each calculation was performed 
with the exact mass of NMOF added. Non-linear fittings of the degradation profiles are given 
in the appendix. 
At first, comparison of the postsynthetically surface modified UiO-66 degradation profiles with 
their precursor UiO-66-L1 (Figure 3.48) shows the presence of an induction period, with 
variations depending on the surface reagent, as a consequence of the protection that the 
surface coating provides. Although a general enhancement in stability towards phosphate 
degradation were observed for all samples, after 2.5 h UiO-66-Hep (PS) has a faster 
degradation rate than its precursor, suggesting rapid loss of the surface polymer.  
 






Figure 3.48.Comparison of the degradation profiles in PBS of surface coated and uncoated UiO-66. a) 
during 24 hours, b) during 5 hours, highlighting the induction period of the surface coated samples. 
Error bars represent the standard deviation from triplicate experiments.  
Significant differences were noted for PEGylated samples compared to uncoated samples, 
and are plotted in Figure 3.49. There is a clear enhancement in stability for the PEGylated 
samples, which also degrade with a different kinetic profile (sigmoidal vs exponential), 
indicating that polymeric coating protects the MOFs surface from degradation.  
 
 
Figure 3.49. a) Degradation profiles of coated and uncoated UiO-66 nanoparticles in PBS pH 7.4, with 
b) an inset of the early time period. Error bars denote standard deviations from triplicate experiments. 
The effect of exposure of the UiO-66 nanoparticles to PBS buffer on their crystallinity was 
investigated by powder X-ray diffraction. In the general procedure, 20 mg of the UiO-66 
nanoparticles were dispersed in PBS buffer (pH 7.4, 20 ml) by sonication (5 minutes), and 
stirred for different contact times. Then, the nanoparticles were collected by centrifugation and 





washed with fresh water. After being dried for 24 h under vacuum, their crystallinity was 
analysed by PXRD (Figure 3.50).  
 
Figure 3.50. Stacked PXRD patterns of UiO-66 samples after different contact times with PBS buffer 
for a) UiO-66-L1-PEG550 and b) UiO-66-L1-PEG2000. 
The samples clearly exhibit different stabilities under the experimental conditions, with 
uncoated UiO-66 samples rapidly losing crystallinity, while the PEGylated samples remain 
highly crystalline after an hour. 
Similar features are observed for the postsynthetic covalent modifications with poly-L-Lactide 
and PNIPAM, which exhibit a sigmoidal profile versus the exponential profile of UiO-66-L1 
(Figure 3.51). The importance of these findings resides in the fact that after 1 h UiO-66-L1 has 
released the 55% w/w of its linker in the structure, while UiO-66-L1-PolyLact has only released 
the 27% w/w and UiO-66-L2-PNIPAM the 30% w/w, yet the degradation of the three samples 
is very close after 24 h. 
 
Figure 3.51. BDC release profiles measured by UV/vis spectroscopy of the click modulated, polymer 
coated UiO-66 samples. Error bars represent the standard deviation from triplicate experiments. 





Comparing the degradation of the postsynthetically coordinated and modulated folic acid and 
biotin containing samples (Figure 3.52), different trends can be also observed based on the 
mode of surface modification. 
 
Figure 3.52. BDC release profiles measured by UV/vis spectroscopy of the UiO-66 samples surface 
modified during coordination modulation. Error bars represent the standard deviation from triplicate 
experiments. 
An initial induction period plays an important role for all the coated samples, but is more 
noticeable for the postsynthetic modifications, with no bdc release for UiO-66-FA (PS) after 
15 minutes. In general, even if the stabilisation is higher at the beginning of the experiment for 
the postsynthetically coordinated samples, presumably due to complete zirconium 
coordination that hinders phosphate attack, after a short period of time the degradation rate 
becomes faster than for the modulated samples. In fact, after only 45 minutes UiO-66-Biot 
(PS) has released a similar amount of linker to UiO-66-Biot (CM) (ca. 25% each versus 55% 
for UiO-66-L1). In the case of UiO-66-FA (PS) it takes a longer period, 3.5 h to reach a similar 
degradation to UiO-66-FA (CM). 
Folic acid release can also be tracked by UV-vis spectroscopy during the course of the 
experiment (Figure 3.53). It is important to take into account that we previously determined a 
23.6% w/w and 13.6% w/w of folic acid for UiO-66-FA (PS) and (CM) respectively. In both 
cases folic acid releases faster than the linker of the structure and with a similar profile, 
suggesting it is located on or near the particle surface.  






Figure 3.53. Comparison of BDC and folic acid release profiles measured by UV/vis spectroscopy of 
the folic acid coated UiO-66 samples. Error bars represent the standard deviation from triplicate 
experiments. 
The conjunction of these results suggest that although initial enhancement of UiO-66 stability 
towards phosphates can be achieved by surface functionalisations, the choice of surface 
coating also plays an important role, both through the affinity of the coordination groups to the 
Zirconium positions and through the coating interaction with the aqueous media (i.e the highly 
water soluble heparin is less stable after 2.5 h). The mode of coating also plays an important 
role, as samples synthesised by coordination modulation are initially less stable than samples 
modified through postsynthetic coordination with the same surface reagents, possibly due to 
partial pore blockage, hindering the Zr positions from phosphate attack to higher extent. The 
click modulation protocol, in which polymers (i.e PEG, PolyLact and PNIPAM) coat UiO-66 
surface is also a successful tool to enhance MOF stability, more remarkably for the PEGylated 
samples. Importantly, similar degrees of degradation to the uncoated samples are obtained 
after 24 hours, indicating that although initial drug release should be decreased, accumulation 
in the body due to higher stability should not be an issue. 
  






In conclusion, a number of different functionalities have been assessed to UiO-66 surface, 
and different surface modification protocols – coordination modulation, postsynthetic 
exchange, and covalent click modulation – have been studied for the surface functionalisation 
of UiO-66 nanoparticles for use in drug delivery. 
Postsynthetic surface modifications on UiO-66-L1 based on coordination chemistry have been 
performed using L2, folic acid, biotin and heparin as surface reagents, showing L1 
displacement and surface reagent attachment to the available zirconium positions. Proof-of-
concept CuAAC covalent modifications between UiO-66-L1 and 1-dodecyne, and between 
UiO-66-L2 and 1-azidodecane, have proven functionalisation occurs only on the outer surface, 
and the ‘click modulation’ protocol has been further applied to covalently attach PEG (Mw= 
500 and 2000), Poly-L-Lactide (Mw= 2000) and PNIPAM (Mw 15000) chains to the outer 
surface of UiO-66 using modulators L1 and L2 as surface modification platforms.  
Importantly, in nearly all cases, surface functionalisation enhances properties such as colloidal 
dispersion and stability towards phosphate-induced degradation compared to bare UiO-66, to 
a different extent depending on the surface reagent and on the coating mode. For example,  
the heparin coated MOF performed poorly in colloidal stability, and its degradation kinetics 
were only improved over a few hours, while PEGylated, and other polymer-coated MOFs, in 
contrast were colloidally-stable and their degradation was highly improved, with induction 
times of an hour during which almost no degradation occurred. It has been noted than in 
general, covalent postsynthetic polymer coating with PEG, PolyLact and PNIPAM though the 
click modulation protocol provides higher colloidal stability than postsynthetic modifications 
based on coordination chemistry.  
Postsynthetically coating of UiO-66 with biotin and folic acid initially enhanced the stability of 
the MOF to a higher extent than when the same functionalities are introduced during synthesis 
by coordination modulation, possibly as a consequence of partial pore blockage when the 
coating is performed postsynthetically, hindering the external and internal surface from 
phosphate attack to a higher extent. However, after induction times of few hours, the samples 
prepared through coordination modulation have slower degradation kinetics than their 
postsynthetic analogues.  
The surface modification protocols detailed during this chapter will be also applied to 
postsynthetically functionalise UiO-66 surface after loading of a fluorescent molecule (Calcein) 
during Chapter 4. The calcein-loaded MOFs will be used to investigate HeLa cervical cancer 
cells internalisation of the bare and surface-coated MOFs, using confocal microscopy and flow 





cytometry, with ultimate aim of finding correlation between UiO-66 surface chemistry, cell 
internalisation pathways and therapeutic activity.  
The use of carboxylate-containing drug molecules as modulators for synthesis of UiO-66 
nanoparticles, in this study the anticancer metabolic target dichloroacetic acid, was studied 
during Chapter 2. DCA modulation in particular generates colloidally-stable nanoparticles with 
high DCA-loading values, for which postsynthetic surface modifications will be illustrated 
during Chapter 5, following the protocols investigated during this chapter, in order to study the 
effect of surface chemistry on therapeutic activity and anticancer selectivity.  
3.7 Experimental 
All reagents unless otherwise stated were obtained from commercial sources and were used 
without further purification. 
1-Azidodecane 
1-Bromodecane (4 g, 0.018 mol, 1 eq) was dissolved in DMF (50 ml). Then, sodium azide 
(2.39 g, 0.036 mol, 2 eq) was added dropwise, and the mixture was allowed to react at 50ºC 
overnight. After the solvent was evaporated, the remaining mixture was poured into water (100 
ml) and extracted with DCM (3x 25 ml). The organic phase was further washed with water (2x 
15 ml). The product was obtained pure as a slightly yellow oil (3.2 g, 97 % yield), whose 
spectroscopic data matched that found in the literature.49 
1H NMR (400 MHz, DMSO) δ 0.86 (t, J = 6.9 Hz, 3H), 1.36 – 1.19 (m, 14H), 1.58 – 1.45 (m, 
2H), 3.31 (t, J = 6.9 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 14.38, 22.55, 26.60, 28.70, 28.99, 
29.13, 29.37, 29.38, 31.64, 51.10. 
PEG550-propargyl 
In a typical PEG550-propargyl synthesis (n = 11), 1 eq (2 g, 3.64 
mmol) of PEG550 methyl ether is dissolved in 50 ml anhydrous 
tetrahydrofuran (THF) under nitrogen. After that, 1.5 eq (236 mg, 5.46 mmol) of 60% NaH in 
mineral oil, and 1.5 eq (0.96 ml, 5.46 mmol) of propargyl bromide, are added. The solution is 
stirred overnight at room temperature. The resulting mixture is then filtrated and evaporated 
under vacuum. A clear, brown oil is obtained (1.225 g, 2.125 mmol, 59%).50 
1H NMR: (500 MHz, DMSO) δ 3.25 (s, 3H), 3.47 – 3.40 (m, 4H), 3.54 – 3.48 (m, 44H), 3.68 (t, 
J = 1.8 Hz 1H), 4.15 (d, J = 2.4 Hz, 2H); 13C NMR: (101 MHz, DMSO) δ 57.95, 58.51, 68.98, 
70.25 (high intensity, polymeric chain), 71.75, 77.51, 80.79. 
Note that triplet at 3.68 appears close the the polymer chain and determination is difficult. 





ESIMS: calculated for C4H5O(C2H4O)nC2H5O, M+Na+ (n = 6) m/z = 401.2151; found m/z = 
401.2160, (found from n=6 to n=17). 
PEG2000-propargyl 
In a typical PEG2000-propargyl synthesis (n = 44), 1 eq (2 g, 1 mmol) of PEG2000 methyl 
ether is dissolved in 100 ml anhydrous tetrahydrofuran (THF) under nitrogen. After that, 1.5 
eq (65 mg, 1.5 mmol) of 60% NaH in mineral oil, and 1.5 eq (0.25 ml, 1.5 mmol) of propargyl 
bromide, are added. The solution is stirred overnight at room temperature. The resulting 
mixture is then filtered and evaporated under vacuum. A white, hard powder is obtained (993 
mg, 0.51 mmol, 51%).50  
1H NMR (500 MHz, DMSO) δ 3.25 (s, 3H), 3.46 – 3.41 (m, 4H), 3.52 (s, 88H), 3.68 (t, J = 1.8 
Hz 1H), 4.15 (d, J = 2.4 Hz, 2H); 13C NMR: (101 MHz, DMSO) δ 57.95, 58.51, 68.98, 69.97, 
70.05, 70.25 (high intensity, polymeric chain), 70.65, 71.75, 77.52, 80.79. 
Note that triplet at 3.68 appears close to the polymer chain and determination is difficult. 
No ionisation was observed in ESIMS, IR showed a stretch at = 2883 cm-1, which is 
representative of the alkyne functionality. 
L1-dodecyne 
1-Dodecyne (1.98 mmol, 327 mg, 1.2 equivalents) was dissolved in DCM (50 ml), DiPEA (4 
mol%, 138 µl), AcOH (4 mol%, 45 µl) and CuI (2 mol%, 7.5 mg) were added, and the mixture 
stirred 15 minutes under nitrogen. Then, p-azidomethylbenzoic acid (L1) (1.65 mmol, 291 mg, 
1 equivalent) was added to the reaction mixture, which was allowed to react overnight at room 
temperature under nitrogen atmosphere. Then, the reaction solvent was washed with water 
(3 x 15 ml) with an aqueous EDTA solution (2 x 15 ml) and with water (2 x 15 ml). Pure product 
was obtained as a white powder after evaporation of the organic solvent. 
1H NMR (400 MHz, DMSO) δ 0.85 (t, J = 6.8 Hz, 3H), 1.34 – 1.12 (m, 14H), 1.65 – 1.46 (m, 
2H), 2.60 (t, J = 7.5 Hz, 2H), 5.64 (s, 2H), 7.35 (d, J = 8.2 Hz, 2H), 8.11 – 7.79 (m, 3H), 13.02 
(s, 1H); 13C NMR (101 MHz, DMSO) δ 14.40, 22.55, 25.43, 28.99, 29.15, 29.20, 29.35, 29.42, 
31.74, 31.78, 52.65, 122.75, 128.26, 130.12, 130.18, 130.85, 141.57, 147.75. 
  






1-Azidodecane (2.5 mmol, 461 mg, 1.2 equivalents) was dissolved in DCM (50 ml), DiPEA (4 
mol%, 146 µl), AcOH (4 mol%, 48 µl) and CuI (2 mol, 8.0 mg) were added, and the mixture 
stirred 15 minutes under nitrogen. Then, p-propargyloxybenzoic acid (L2) (2.1 mmol, 500 mg, 
1 equivalent) was added to the reaction mixture, which was allowed to react overnight at room 
temperature under nitrogen atmosphere. Then, the reaction solvent was washed with water 
(3 x 15 ml) with an aqueous EDTA solution (2 x 15 ml) and with water (2 x 15 ml). Pure product 
was obtained as a white–yellowish powder after evaporation of the organic solvent. 1H NMR 
(400 MHz, DMSO) δ 12.63 (s, 1H), 8.25 (s, 1H), 7.89 (d, J = 8.7 Hz, 2H), 7.12 (d, J = 8.7 Hz, 
2H), 5.22 (s, 2H), 4.36 (t, J = 7.1 Hz, 2H), 1.92 – 1.65 (m, 2H), 1.23 (s, 14H), 0.85 (t, J = 6.9 
Hz, 3H); 13C NMR (101 MHz, DMSO) δ 204.59, 194.88, 162.04, 161.77, 131.71, 114.93, 
49.85, 31.78, 31.73, 29.35, 29.32, 29.30, 29.10, 28.97, 28.82, 28.69, 26.26, 22.57, 14.41. 
Postsynthetic Surface Coordination of UiO-66-L1 
In a typical postsynthetic surface coordination, UiO-66-L1 (250 mg) was dispersed by 
sonication in a solution of MeOH/Water (50 mL) containing 150 mg of the surface reagent in 
question during 20 minutes and stirred overnight. The NMOF was collected by centrifugation 
and washed by centrifugation with water (x2), acetone (x1), and methanol (x3).  
UiO-66-L2 Synthesis 
UiO-66-L1 (300 mg) was dispersed in methanol (50 mL). Separately, a solution of L2 (300 
mg) in methanol (50 mL) containing triethylamine (TEA, 0.3 mL) in order to extract the proton 
of L2 carboxylic acid and therefore favour the surface ligand exchange was prepared. As L2 
is added in great excess compared to the amount of L1 present on UiO-66-L1 surface, it is 
expected to favour L2 incorporation over L1. Both solutions were mixed, sonicated for 15 
minutes and heated to 60°C overnight. After cooling down and centrifugation, UiO-66-L2 was 
washed with MeOH (x5) and dried by centrifugation in order to remove unreacted materials. 
Postsynthetic Covalent Surface Modification of UiO-66-L1 and UiO-66-L2 
In a typical CuAAC reaction performed on the modified MOF, 200 mg of the MOF in question, 
in this example UiO-66-L1, was placed in a 100 mL two neck round bottom flask. The MOF 
nanoparticles were dispersed in DCM (40 mL) by sonication (10 minutes). The solvent was 
bubbled with N2, diisopropylethylamine (DiPEA, 304 μL, 0.053 mmol, 4 mol %) was added, 
then acetic acid (92 μL, 0.053 mmol, 4 mol %) was added, CuI (5 mg, 0.0264 mmol, 2 mol %) 
was added, and the mixture was stirred for 5 min under an N2 atmosphere. Propargyl-
terminated Poly-L-Lactide, or the alternative surface reagent, was added dropwise. The 





mixture was allowed to react for 24 h at room temperature under nitrogen. The precipitate was 
collected by centrifugation and washed with DCM (x2) and methanol (x3). 
High-Resolution Electrospray Ionisation Mass Spectrometry (HRESI-MS) Sample 
Preparation  
NMOF samples were digested in an acidic aqueous solution, which was subsequently 
extracted with DCM. The organic phase was washed several times with an aqueous solution 
of Na2EDTA in order to remove the metals present in solution. The organic phase was then 
evaporated and dissolved in a 1:1 mixture of MeOH and MeCN. 
Folic acid and Calcein Determination 
2 mg of sample was dispersed by sonication, heated in 10 mL of phosphate buffered saline 
(PBS) at pH = 7.4, and the dispersion was stirred for 48 h. The remaining precipitate was 
collected by centrifugation prior to folic acid or calcein absorbance measurement in PBS 
against a previously calculated calibration curve. 
Dynamic Light Scattering (DLS) Measurements 
In a scintillation vial, dispersions with a concentration of 250 g of MOF per mL of dispersant 
were prepared by sonication over 5 min prior to the measurement of each sample. Three 
recordings, consisting of 14 runs each, were performed consecutively at 37ºC on the same 
sample for each measurement, at approximately 15 minute intervals. The waiting time 
between recordings was 5 seconds. No stirring was provided during the course of the 
experiment.  
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4.1 Introduction to Cellular Internalisation 
To be efficient DDSs, MOFs should be easily internalised by the cells that are intended to be 
treated and able to release their cargo in intracellular conditions. Importantly, the DDS should 
avoid immune system recognition, and thus not be internalised by immune system cells such 
as macrophages.1, 2 Nanoparticle uptake by cells depends on many factors, including size, 
morphology and surface chemistry among others,3-8 and attempts have been made to 
enhance uptake and also control the endocytosis mechanisms of MOFs.9, 10 
Generally, molecules enter cells by passive diffusion, whereas nanoparticles are generally 
internalised by cells through active transport (energy-dependent) such as endocytosis. 
However, if small enough (< 20 nm), nanoparticles can also be internalized by passive 
diffusion.7, 11 
Endocytosis can be categorised into phagocytosis (i.e. “cell eating”) and pinocytosis (i.e. “cell 
drinking”).5, 12, 13 Phagocytosis refers to the process of engulfing large particles and is carried 
out by macrophages and neutrophils whereas pinocytosis refers to the internalization of 
molecules and small particles in the fluid phase and is carried out by all eukaryotic cells, and 
includes clathrin-mediated, caveolae-mediated, non-mediated endocytosis, and 
macropinocytosis among other routes (Figure 4.1).5 
 
Figure 4.1. Representation of cell internalisation pathways.5 




Clathrin-mediated endocytosis is the most understood endocytosis pathway and is used by all 
known eukaryotic cells, where receptors on the cell surface recognize the cargo and then 
internalize it into protein- (clathrin) coated vesicles, called early endosomes.14-16 These early 
endosomes then mature into late endosomes and finally fuse with lysosomes, causing the 
degradation of the DDS along with its loaded cargo, thus voiding its therapeutic effect. 
Caveolae-mediated endocytosis is associated with the formation of lipid raft-enriched flask 
shape invaginations coated with caveolin.17, 18 Particles internalized via caveolae-mediated 
endocytosis can be delivered to different locations in the cell. For instance, the formed vesicles 
can fuse with early endosomes and then with lysosomes for further degradation as in the case 
of clathrin-mediated endocytosis, but more interestingly, the internalized particles can also 
escape the early endosome, by the alternative formation of a pH neutral compartment called 
caveosome that will release its content to the cytosol in a more efficient way, avoiding 
lysosomal degradation (Figure 4.2). Thus, DDS internalised by caveole-mediated endocytosis 
are more likely to be therapeutically efficient than those internalised by the clathrin-mediated 
route as consequence of the faster cytosolic release, allowing cargo to reach the cells’ 
organelles in a more effective way.8, 17 
Macropinocytosis is a non-selective process in which cells uptake large quantities of fluids. 
Finally, in clathrin and caveolae-independent endocytosis- which is found in almost all cell 
types- particles are internalized non-specifically via vesicles.19 
  
Figure 4.2. Routes of cellular internalisation and subsequent intracellular localisation.8 




4.1.1. Cellular Internalisation of MOFs 
For MOFs, fluorescent linkers, cargo molecules or fluorescent active metal clusters are usually 
used to monitor endocytosis through confocal microscopy and fluorescence-activated cell 
sorting (FACS). 
Xie and co-workers investigated the internalisation of UiO-66 coated with carboxyl-
functionalised diiodo-substituded BODIPY (UiO-PDT) by B16F10 mouse melanoma cells for 
different incubation times (0.5, 2 and 4 hours) using FACS, and compared it with the mean 
fluorescence intensity when cells were incubated with the same concentration of free linker 
(I2-BDP), which exhibits characteristic fluorescence.20 A dose-response behaviour for the 
uptake of both was found, which was higher at 2 hours incubation time in the case of UiO-
PDT (1.5 fold increase). By confocal fluorescence microscopy it was observed that the red 
fluorescence was mainly located in the cytoplasm of B16F10 cells for both cases. Although 
the authors did not investigate the endocytosis routes of internalisation, these results could 
be a consequence of either MOF internalisation through the caveolae-mediated route, MOF 
degradation allowing linker internalisation through passive uptake during the course of the 
experiment, or a conjunction of both.  
Internalisation of UiO-66 coated with fluorescent molecules of flavin mononucleotide (UiO-66-
FMN) by HepG2 human liver carcinoma cells has been investigated after 4 and 12 hours 
incubation time, finding that after 4 hours more than 80% of the cell population have high 
fluorescent mean intensity, while after 12 hours only a slightly increase is found.21 These 
results indicate that UiO-66-FMN cell uptake occurs rapidly during the first 4 hours, after which 
the cell uptake rate decreases. Through confocal microscopy, high green fluorescence in the 
cells cytoplasm was observed. 
Zhou and co-workers investigated HeLa human cervical cancer cells uptake of a porphyrinic 
MOF (PCN-224) by varying particle size (Figure 4.3), with the aim to enhance internalisation 
and cytotoxicity through passive targeting,22 based on the fact that nanoparticles accumulate 
in cancer tissue due to the EPR effect.23 Confocal microscopy showed that the NMOF was 
co-localised with the lysosomes and mitochondria, while no nucleus co-localisation was found 
(Figure 4.3a). Note that further studies, such as mitochondria isolation and content 
determination by ICP-MS, should be performed to unequivocally confirm mitochondria co-
localisation. The authors analysed the zirconium content by ICP-MS of digested cells, which 
were incubated with samples of the MOF of varying size (30, 60, 90, 140, and 190 nm) over 
different times (0-40 hours). The highest cell uptake was found for nanoparticles of 90 nm 
diameter, and generally reached a plateau after 12 hours of incubation (Figure 4.3b and c).22 





Figure 4.3 a) Subcellular localization of PCN-224 nanoparticles by staining with organelle markers, 
Hoechst 33342, Lyso Tracker, and Mito Tracker green. b) Cellular uptake of PCN-224 samples with 
different sizes at various incubation time. Concentration = 20 μM. (c) Cellular uptake of different sized 
PCN-224 nanoparticles at various concentrations. Incubation time = 24 h. Data are based on ICP 
analysis of the Zr concentration internalized into HeLa cells. Data are means ± s.d. (N = 3).22 
Endosomal escape is a key feature for efficient siRNA delivery. Lin and co-workers performed 
co-localisation studies of siRNA@UiO-66 with human ovarian cancer SKOV-3 cells using 
confocal laser assisted microscopy, demonstrating siRNA and lysosome separation after 2 
hours of incubation time.24 The authors postulate that when siRNA@UiO gets entrapped in 
the endosomes, the presence of high endogenous phosphate concentration, and the acidic 
pH of those will result in structure degradation, and zirconium ions will disrupt the endosome 
structure, thus facilitating siRNA release. The authors did not study the endocytosis routes of 
cell internalisation, for in which the NMOF is internalised through caveolae-mediated route,17 
could also escape endosome by forming a caveosome that will release its cargo to the cytosol. 




SiRNA uptake was remarkably higher (11 fold increase) when it was attached to the NMOF 
structure compared to free siRNA (Figure 4.4 a and b).24 
Surface modification has been used to enhance endocytosis efficiency and tune the cell 
uptake routes of MOFs. Mirkin et al incubated DNA-modified UiO-66 with HeLa cells for 24 
hours, with fluorescent Tamra functionality on the DNA showing that conjugation to the MOF 
resulted in enhanced uptake of the DNA sequence (Figure 4.4 c and d).25 ICP-MS analysis of 
the zirconium content of the cells when incubated with the bare MOFs or DNA-functionalised 
MOFs, showed enhanced uptake for the UiO-66-DNA conjugates compared to the bare MOF, 
which was more remarkable for 19 nm sized nanoparticles than for 14 nm nanoparticles.  
 
Figure 4.4. (a) siRNA/UiO-Cis significantly increase (by >11-fold) the siRNA uptake amount compared 
to naked siRNA (n = 3). (b) siRNA (TAMRA-labeled, red) successfully escaped from endosomes as 
evidenced by the separation of green and red fluorescence (white arrows). Endosome/lysosome and 
nuclei were stained with Lysotracker Green and DAPI, respectively. Bar represents 5 μm.24 c) Cell 
uptake by flow cytometry of DNA-modified UiO-66. (d) Confocal microscopy of cells treated with 14 nm 
MOF nanoparticle–DNA conjugates and with free DNA. Scale bar = 10 μm.25 
In 2016, Fairen-Jimenez et al first reported the study of internalisation of calcein-loaded UiO-
by HeLa cells.10 The authors loaded the MOFs with calcein, a fluorescent molecule not able 
to efficiently cross the cell membrane by itself, in order to track the MOFs internalisation routes 
by FACS, and utilised inhibitors to suppress the various endocytosis routes, including 
nystatin26 as a caveolae-mediated inhibitor, chlorpromazine27 and sucrose28 as clathrin-
mediated inhibitors and rottlerin as macropinocytosis inhibitor.29 It is important to consider that 




sucrose also inhibits non-mediated endocytosis routes. cal@UiO-66 cell uptake was 
drastically decreased when cells were incubated with the MOFs at 4 °C compared to 37 °C, 
confirming that cell internalisation occurs predominantly by active transport. The authors 
observed that UiO-66 generally undergoes cell internalisation through clathrin-mediated 
endocytosis, with minor contributions of the macropinocytosis process. Only a minor 
contribution of the caveolae route was found when the size of the particles was increased from 
150 nm to 260 nm.10 The authors performed fluorescence co-localisation studies in which they 
observed a lower degree of lysosome-MOF co-localisation for the bigger nanoparticles, 
correlating well with the proposed endocytosis routes. 
Fairen-Jimenez and co-workers further studied HeLa cells internalisation routes of the UiO 
isoreticular series of Zr MOFs- including UiO-66 and its bromo, nitro and amino derivatives, 
Zr-naphthalene and UiO-67- indicating the effect of linker substitution, and thus external 
surface chemistry presented by the particles, together with particle size, on endocytosis 
efficiency and routes.9 
At first, a study of cal@UiO-66 internalisation efficacy and routes, based on particle size (50, 
75, 92, 260 and 652 nm), revealed that UiO-66 MOFs with a size of 50 nm are the most 
efficiently internalised, and the only which its uptake is not inhibited by chlorpromazine, 
meaning that its internalisation does not occur by clathrin-mediated endocytosis. As only 
significant inhibition was found by sucrose, the results suggests that 50 nm UiO-66 is mainly 
internalised by non-mediated endocytosis. The bigger MOFs, on the other hand, are 
internalised by clathrin-mediated endocytosis (ca.60 % inhibition) with only minor contribution 
of the caveolae-mediated route (ca. 20 % decrease in uptake).9 
Functionalised MOFs with more polar surfaces, such as UiO-66-NO2, were taken up by HeLa 
cells in greater quantities, as determined by FACS using calcein-loaded nanoparticles. These 
more polar MOFs were predominantly internalised by clathrin-mediated endocytosis, in 
contrast to less polar, unfunctionalised materials (e.g. Zr-naphthalene and UiO-67), which had 
lower overall uptake, but primarily by caveolae-mediated endocytosis.9 
Fairen-Jimenez et al reported the HeLa cell internalisation routes of NU-1000 and compared 
it to amorphised NU-901.30 Whilst pristine, calcein loaded NU-1000 was taken up primarily by 
clathrin-mediated routes, with potentially a small contribution by caveolae-mediated uptake, 
the amorphised sample showed a more significant decrease in cellular fluorescence when 
incubated with nystatin but also with chlorpromazine, suggesting caveolae-mediated uptake 
with some contribution from clathrin-mediated endocytosis. The authors also visualised cell 
internalisation and intracellular location of the MOFs using structured illumination microscopy 




(SIM), finding the NMOFs to be located mainly at vesicles. They observed that NMOFs start 
to be internalised after one hour, increasing the uptake gradually up to 24 hours.  
PCN-223 is the only zirconium MOF to date for which its intracellular bio-stability has been 
measured.31 The authors incubated HeLa and human hepatocarcinoma SMMC-7721 cells 
with bare nanoPCN-223, PCN-223-PBLs and TCPP, the linker of the NMOF structure, which 
is itself fluorescent and thus allows tracking of MOFs inside the cells. Passive uptake of free 
TCPP lead to low, well-distributed red fluorescence confined to the cytoplasm, while when 
cells were incubated with solutions of the bare MOF, only traces of nanoPCN-233 were 
observed as well-defined dots in the lysosomal locations inside the cells. Free TCPP located 
uniformly in the cell could also be observed, indicating possible degradation of the MOF 
sample in growth media. In contrast, they found that PBLs-coated nanoPCN-223 is only 
located in the lysosomes with no evidence of released TCPP in the cytoplasm. FACS showed 
that although TCPP undergoes passive diffusion into the cell and the mean fluoresce intensity 
is similar to bare nanoPCN-223, after coating with PBLs the cell uptake efficiently is enhanced 
ca. 1.7 fold within the first 4 hours of incubation, as no increase in fluorescence was found 
after longer incubation times of 12 and 24 hours.31 
Targeting peptides have also been utilised to enhance MOF uptake by particular cell lines. 
DOX@UiO-66-Py-PGA-PEG-F3 (where the fluorescence of doxorubicin serves to track 
NMOFs location inside the cell) internalisation by human breast adenocarcinoma MCA-MB-
231 cells was found to be remarkably higher than DOX@UiO-66-Py-PGA-PEG, as determined 
by flow cytometry measurements and confocal microscopy (Figure 4.5).32 This is so because 
MCA-MB-231 cells over express the nucleolin receptor (n+), which is targeted by the F3 
peptide attached to the MOF. In contrast, both targeted and non-targeted NMOFs were 
internalised considerably less by L929 mouse fibroblast cells, which do not over express the 
nucleolin receptor (n-).33 DOX fluorescence was mainly located in the cytoplasm, with some 
co-localisation in the lysosome when FITC-modified MOFs were examined. The authors 
observed that DOX@UiO-66-Py-PGA-PEG-F3 internalisation plateau occurs within the first 
0.25 h of incubation, in which a similar amount of internalised MOF and MOF binding to the 
cells surface was found. It was found that once internalised, during the next 24 hours 30% of 
the NMOF can be externalised by cells through exocytosis processes.32 





Figure 4.5. In vitro evaluation of UiO-66/Py–PGA-PEG conjugates. (a) Representative confocal 
fluorescence microscopy images of MDA-MB-231 (nucleolin+) and L929 cells (nucleolin–) incubated 
with DOX@UiO-66/Py–PGA-PEG-F3 and DOX@UiO-66/Py–PGA-PEG (both containing 50 μg/mL of 
DOX). Scale bar: 20 μm. (b) Flow cytometry analysis of DOX@UiO-66/Py–PGA-PEG-F3 (blue) and 
DOX@UiO-66/Py–PGA-PEG (orange) in MDA-MB-231 and L929 cells (incubation time: 0.5 h).32 
HeLa cells internalisation of Zr-fum coated with various fluorescent peptides through imidazole 
his-tag coordination has been reported, and it is illustrated in Figure 4.6.34 The authors also 
investigated the cellular uptake of model peptides and proteins attached to Zr-fumarate and 
compare it to the uptake of the free moiety. For example, they observed a 20 fold increase in 
the mean cell internal fluorescence of HeLa cells when incubated with Zr-fum-H6CF compared 
to when cells were incubated with a solution of the same concentration of free peptide in 
growth media, highlighting the efficiency of Zr-fum to internalise biomolecules not able to do it 
efficiently by themselves. A 30-fold increase in cell internalisation was found for the peptide 
H6-GFP when it was attached to Zr-fumarate. They investigated the use of multifunctional Zr-
fumarate to simultaneously internalise two peptides, H6-GFP and H6-Tf* (a transferrin modified 
peptide). Co-localisation of both peptides was observed by confocal microscopy, whereas in 
contrast to free H6-GFT, H6-Tf* can be internalised by HeLa cells, as those over express the 
transferring receptor. However, when attached to Zr-fum, its uptake increased 5 times. 
The endocytosis pathways of Zr-fum-H6-GFP were studied.34 The cells were pre-incubated 
during 30 minutes with different concentration of the various inhibitors – In this case amiloride 




to suppress macropinocytosis, genistein to inhibit caveolae-mediated endocytosis, and 
chlorpromazine to inhibit clathrin-mediated uptake – and then incubated with the NMOFs 
during 2 hours. They found that the peptide-coated NMOFs are mainly internalised by 
macropinocytosis, although minor contributions of the caveolae-mediated route is also 
observed. In general, higher levels of inhibition were found when cells were pre-treated with 
higher concentration of the inhibitors.  
 
Figure 4.6. Simultaneous cellular uptake of fluorescent proteins H6-GFP and H6-Tf* mediated by Zr-
fum NPs. (a) Cellular uptake of Zr-fum/H6-GFP+H6-Tf* (upper row) or control without MOF NPs (lower 
row). CLSM left to right: green fluorescence of H6-GFP, red fluorescence of H6-Tf*, nuclear staining 
with Hoechst dye, brightfield picture, overlay of all four channels, yellow color indicates colocalization 
of H6-GFP and H6-Tf*. Flow cytometry analysis: HBG (left) or H6-GFP + H6-Tf* (right) with Zr-fum MOF 
NPs (upper row) or Ctrl without MOF NPs (lower row). Scale bar: 25 μm.34 
Uptake by immune cells is also of great importance when considering an in vivo treatment,1, 2 
but examples of MOF internalisation by macrophages in the literature are quite rare, and 
further work is clearly needed to understand this process and enhance NMOFs potential as 
DDS. Considering the amount of work into studying and enhancing cell internalisation of Zr 
MOFs by endocytosis processes, there is also very little research into determining and 
understanding the exocytosis processes, which may also play an important role in their 
therapeutic efficiency. The exocytosis of other nanoparticulate materials has been studied in 
vitro, and shown that it tends to occur over longer incubation times, especially if removing the 
nanoparticles present in the incubation media.35 Being able to extend the time that the 
nanoparticles are present inside cells, or suppressing exocytosis processes while enhancing 
endocytosis processes, could be of vital importance to enhance therapeutic effect.  
 
 





Understanding the effect of surface chemistry of MOFs on their cell internalisation routes and 
efficacy is imperative for their development as efficient DDSs, as it is strictly related with their 
therapeutic efficiency, providing insights that might reduce early-stage animal testing, while 
enhancing their efficacy.  
In order to further study cancer cells internalisation of coated and uncoated UiO-66, both UiO-
66-L1 and UiO-66-L2 will be postsynthetically loaded with calcein, a fluorescent molecule, and 
the former postsynthetic surface modification protocols described during Chapter 3 will be 
applied to the calcein loaded MOFs. Calcein has been selected as molecular probe for MOFs 
internalisation, due to the fact that its hydrophilic nature hinders its cellular internalisation 
unless it is loaded into a DDS. Thus, if calcein is released in growth media during the course 
of the experiment, false positives in cell internalisation will not be observed. 
Calcein release from the bare and PEGylated MOFs will be investigated at pH 7.4 and pH 5.5, 
in order to study calcein release kinetics from the MOF in simulated extracellular conditions 
(pH 7.4) and intracellular conditions (pH 5.5). Particularly, extracellular pH (i.e blood current) 
is 7.4, while healthy and cancerous cells intracellular pH is around 6.8 and 5.5 respectively. 
The cellular internalisation efficacy of bare and coated calcein-loaded UiO-66 MOFs- with 
PEG chains of different sizes, PolyLactide, PNIPAM, Heparin, Biotin and Folic acid- will be 
analysed by FACS and compared to the uptake of a solution of free calcein, with the ultimate 
aim of determining more desirable coatings to enhance cell internalisation, as a way of indirect 
cancer targeting, due to the fact that nanoparticles accumulate in cancerous over healthy 
tissue due to the EPR effect.  
The effect of surface coating on endocytosis routes will be studied by FACS using inhibitors 
for certain routes. DDS internalised through caveolae-mediated endocytosis have been 
proven to be more efficient to deliver their cargo to the cellular organelles, and thus can be 
more therapeutically active.17 Additionally, the contribution of active and inactive transport will 
be studied by incubating HeLa cells with MOFs at 37°C and at 4°C, where the metabolic 
activity is attenuated. The findings described during this chapter will be related to the 
therapeutic efficacy of the MOFs during Chapter 5. 
Cellular internalisation of cal@UiO-66-L1, cal@UiO-66-L1-PEG550 and cal@UiO-66-L1-
PEG2000 will be also studied by confocal microscopy, in order to visually determine the 
cellular integrity of the cells after MOFs internalisation and the MOFs location inside the cells.  




4.3. Postsynthetic Surface Functionalisation of Calcein-Loaded Samples 
Calcein was selected as a fluorescent molecule to track the NMOFs inside cells, in order to 
study endocytosis fates and pathways (Sections 4.5 and 4.6). Calcein’s hydrophilicity does 
not allow it to efficiently cross the cell membrane, and thus intracellular cytoplasmic 
fluorescence is significantly increased when calcein is incorporated into a carrier.9 UiO-66-L1 
and UiO-66-L2 were postsynthetically loaded with calcein by soaking the MOFs in a calcein 
solution in methanol (Section 4.9), and their surfaces subsequently modified either using the 
click modulation method or postsynthetic external surface ligand exchange (PS) (Figure 4.7), 
ensuring all samples were of similar particle size as they originated from one batch of UiO-66-
L1. 
 
Figure 4.7. Synthesis of calcein-loaded, surface modified MOFs obtained through postsynthetic 
exchange (PS) and click modulation. 
The samples retained their crystallinity after calcein loading and subsequent surface 
modification, as confirmed by PXRD.36, 37  
Figure 4.8 shows the thermal decomposition of cal@UiO-66-L1 compared to free calcein, UiO-
66-L1 and UiO-66-AcOH. For cal@UiO-66-L1, the absence of a significant calcein 
decomposition step at 200 ºC, together with its bigger size compared to the pore cavity, 
suggests that calcein is attached to the zirconium clusters present in the surface and defect 
sites through its carboxylic acid groups. The multi-step degradation profile makes quantitative 
calcein content analysis by TGA difficult, however, it is clearly present. 





Figure 4.8. TGA profiles of cal@UiO-66-L1 in air and its comparison with UiO-66-AcOH, UiO-66-L1 
and calcein. 
Adsorption isotherms (N2, 77 K) were used to investigate the mode of calcein incorporation, 
showing only a minor decrease in surface area and pore volume from SBET=1565 m2g-1 and 
pore volume= 0.762 ccg-1 for UiO-66-L1 to SBET = 1002 m2g-1 and pore volume = 0.469 ccg-1 
for cal@UiO-66-L1, indicating that the majority of the calcein is attached to the outer surface 
and defect sites of the MOFs rather than being stored in the pores. The azide band 
characteristic of L1 was still present in the FT-IR spectra, confirming the presence of the 
modulator after the loading process.  
As previously, full characterisation of the samples confirmed the surface moieties’ attachment 
to the calcein-loaded NMOFs’ surface, and calcein loading was measured by UV/Vis 
spectroscopy of all acid-digested samples (Table 4.1). 
Table 4.1. Calcein loadings of the surface modified MOFs, determined by UV-Vis spectroscopy. 
Sample Calcein Loading 






cal@UiO-66-FA (PS) 9.8 
cal@UiO-66-Hep (PS) 13.0 
cal@UiO-66-Biot (PS) 12.8 




An illustrative example of TGA analysis of cal@UiO-66-L1-PEG550 and cal@UiO-66-L1-
PEG2000 is shown in Figure 4.9, where the appearance of a new degradation step at the 
reported degradation temperature of PEG confirms that the PEGylation has been successful. 
As the thermal degradation of calcein and PEG occur across the same temperature ranges, it 
is not possible to determine exact contents of either functionality by TGA. 
 
 
Figure 4.9. a) TGA traces of cal@UiO-66-L1-PEG550 in air and its comparison with cal@UiO-66-L1, 
UiO-66-L1-PEG550, and calcein. b) TGA traces of cal@UiO-66-L1-PEG2000 in air and its comparison 
with cal@UiO-66-L1, UiO-66-L1-PEG2000 and calcein. 
Similarly, the TGA profiles of the postsynthetically coated, calcein loaded samples (PolyLact, 
PNIPAM, Folic acid, Biotin and Heparin) show decomposition steps characteristic of the 
surface reagents, while their characteristic vibration bands could also be observed by FT-IR, 
and the MOFs prepared by postsynthetic exchange on cal@UiO-66-L1 showed 
disappearance of the azide stretch of L1 (Figure 4.10).36, 37 





Figure 4.10. FT-IR spectra of calcein-loaded MOFs prepared by ligand exchange, compared to the 
precursor and the surface functionality, for a) cal@UiO-66-Biot (PS), b) cal@UiO-66-Hep (PS), and c) 
cal@UiO-66-FA (PS). 
Nitrogen adsorption and desorption isotherms confirmed that the porosity of the samples is 
retained after surface functionalisation, and an example of the PEGylated samples is shown 
in Figure 4.11, which shows a similar decrease in porosity, in concert with surface mass 
addition, to the analogous empty samples described during Chapter 3.36, 37 
 
Figure 4.11. a) Adsorption and desorption isotherms (N2, 77 K) of calcein loaded UiO-66 samples. 
Filled symbols represent adsorption, empty symbols represent desorption. b) Pore size distribution (slit 
pore, N2 at 77 K on carbon, QSDFT equilibrium model) of the calcein loaded UiO-66 samples. 




4.4 The Effect of PEG Coating on UiO-66 Calcein Release Kinetics 
Due to the higher degree of initial stabilisation of UiO-66-L1-PEG550 and UiO-66-L1-
PEG2000 towards phosphates compared to their precursor (see Chapter 3), drug release 
kinetics were further studied for this two samples and UiO-66-L1. Monitoring release at 
different pH values is important, given that extracellular pH is ~7.4, intracellular pH is ~6.8, 
and the intracellular pH of cancer cells is close to 5.5,38, 39 providing a potential mechanism for 
targeted drug delivery. 
In a typical calcein release experiment, between 5 and 10 mg of NMOF were dispersed in a 
dialysis bag with 10 ml of PBS (required pH), and dialysed against 100 ml of PBS (same pH) 
under magnetic stirring at room temperature. A full UV-Vis spectrum (210-550 nm) was 
performed for each measurement, which was taken in situ, and the liquid was added back to 
the dialysis media prior to the next measurement. Characteristic peaks for calcein absorbance 
were analysed against previously calculated calibration curves for calcein in PBS at pH 7.4 
and 5.5 (max = 498 and 452 nm respectively). For each experiment, calculations were 
performed with the exact mass of NMOF added. The release of calcein from both PEGylated 
and uncoated samples was affected by the pH, however, the release at pH 7.4 was drastically 
decreased for the PEGylated samples compared to their precursor cal@UiO-66-L1, which 
releases in contrast its full calcein cargo after 2 days, with an initial burst released of ca.40 % 
after 2 hours.. Both cal@UiO-66-L1-PEG550 and cal@UiO-66-L1-PEG2000 initially release 
calcein slowly at pH 7.4 and do not release more than ~30% of their total cargo after 5 days. 
In contrast, they rapidly release ca 80% of cargo within an hour at pH 5.5, and release nearly 
the full amount in pH 5.5 after 2 days (Figure 4.12a).  
 
Figure 4.12. a) Calcein release profiles from cal@UiO-66-L1, cal@UiO-66-L1-PEG550 and cal@UiO-
66-L1-PEG2000 in PBS at pH = 7.4 and pH = 5.5. b) pH-responsive release of calcein from the 
PEGylated MOFs. Inset: chemical structure of calcein. Error bars denote standard deviations from 
triplicate experiments. Release kinettic profile fittings are given in the appendix.  




If this behaviour can be retained in vivo, PEGylated UiO-66 samples could be expected to 
store the majority of cargo in extracellular conditions, avoiding the non-selective distribution 
of therapeutics, while being able to release it once it has reached its target. The stimuli-
responsive release of calcein from the PEGylated MOFs was therefore assessed by a similar 
experiment, where the pH of the PBS solution was adjusted from 7.4 to 5.5 after 5 days (Figure 
4.12b). An immediate, rapid release of calcein was observed, with slightly less calcein 
released from UiO-66-L1-PEG2000 than the analogue with the shorter chain. Nonetheless, 
this result is highly promising for drug delivery applications, should the particles by efficiently 
internalised by cells. 
To gain further insight into the mechanism of release, samples of the MOFs were subjected 
to simulated release conditions at pH 7.4; cal@UiO-66-L1 after 1 day and cal@UiO-66-L1-
PEG2000 after 2 days. The amount of calcein released from both individual experiments 
determined by UV-Vis spectroscopy - 67.5% from cal@UiO-66-L1 and 42.7% from cal@UiO-
66-L1-PEG2000 - is in concordance with the release profiles. 
Both samples showed a decrease in crystallinity by PXRD after calcein release, although the 
characteristic UiO-66 reflection peaks could be determined (Figure 3.13), meaning that the 
core of the materials remains crystalline.  
 
 
Figure 4.13. Stacked PXRD patterns of NMOFs before and after simulated release conditions. 
TGA analysis showed the disappearance of the PEG moiety from cal@UiO-66-L1-PEG2000, 
and an increase on the metal residue for both samples (Figure 4.13), suggesting some 
degradation.  





Figure 4.13. TGA traces in air of a) cal@UiO-66-L1 and b) cal@UiO-66-L1-PEG2000, before and after 
release. 
Both samples remain porous, with an increase in surface area of cal@UiO-66-L1 (from SBET 
= 1002 to 1155 m2g-1) resulting from release of significant amounts of calcein mass, and a 
slight decrease in the surface area of cal@UiO-66-L1-PEG2000 (from SBET = 683 to 554 m2g-
1) possibly due to pore blocking or incorporated additional mass, such as phosphates (Figure 
4.14). 
 
Figure 4.14. a) N2 adsorption isotherm (77 K) for cal@UiO-66-L1 after 1 day in PBS compared to the 
pristine material, alongside b) the calculated pore size distributions (slit pore, N2 at 77 K on carbon, 
QSDFT equilibrium model). c) N2 adsorption isotherm (77 K) for cal@UiO-66-L1-PEG2000 after 2 days 
in PBS compared to the pristine material, alongside d) the calculated pore size distributions (slit pore, 
N2 at 77 K on carbon, QSDFT equilibrium model). 




It is hypothesized that, at pH 7.4, the phosphates present in PBS attack the zirconium 
positions40 displacing the surface ligands and the calcein. When UiO-66 is not PEGylated, the 
MOF is much more accessible (both internally and externally) and therefore so are the 
zirconium clusters, enabling a faster exchange between phosphates and ligands, modulators 
and calcein. On the other hand, for surface modified cal@UiO-66-L1-PEG2000, the 
phosphates must diffuse through the PEG coating before reaching the MOF. A corona of 
coordinating phosphates could be then formed, obstructing the MOF and hindering further 
phosphate attack to release remaining calcein molecules. Indeed, FT-IR spectra of cal@UiO-
66-L1-PEG2000 after 1 day in PBS at pH 7.4 showed more significant signals for phosphates 
(at ~1000 cm-1) than in the case of cal@UiO-66-L1 under the same conditions, suggesting the 
PEG coating induces a corona build-up while unmodified UiO-66 simply undergoes surface 
exchange for the first stages of release (Figure 4.15). When the pH is more acidic, the 
carboxylate units of bdc ligands, surface functionality and calcein are easier to protonate, and 
therefore MOF degradation and calcein release is much more pronounced. 
 
 
Figure 4.15. Stacked FTIR spectra of a) cal@UiO-66-L1 compared to the sample after 1 and 2 days 
simulated release conditions, and b) cal@UiO-66-L1-PEG2000 compared to the sample after 1 and 5 
days simulated release conditions. 
 
  




4.5 Endocytosis Efficacy of MOFs 
As all the cal@NMOF samples were prepared from the same base batch, it is expected that 
variations are caused by changes in external surface chemistry, not particle size, in concert 
with previous work which shows particle size has only minor effect until sizes >500 nm are 
reached.9 
The endocytosis efficiency was calculated by incubating cervix cancer HeLa cells with 0.5 
mgmL-1 of NMOF in growth media (See section 4.9), and adjusting the cells’ cytoplasmic 
fluorescence with the weight percent of calcein determined for each NMOF (Table 4.2). The 
data are expressed as mean and standard error of five replicates (n = 5), and the cytoplasmic 
fluorescence has been normalised taking cal@UiO-66-L1 as 100% (Figure 4.16). In addition, 
the cells were also incubated with a solution of free calcein in media with the same 
concentration reached with cal@UiO-66-L1 incubation, proving that due to its hydrophilic 
nature, calcein is not efficiency internalised by cells without a carrier. 
 
Table 4.2. Calcein loadings of the surface modified MOFs, determined by UV-Vis spectroscopy, and 
their subsequent endocytosis efficiencies for HeLa cells normalised to cal@UiO-66-L1. 
Sample Calcein Loading 
(UV-Vis, % w/w) 
Endocytosis 
Efficiency % 
cal@UiO-66-L1 17.9 100 
cal@UiO-66-L1-PEG550 13.1 149 ± 2 
cal@UiO-66-L1-PEG2000 10.3 116 ± 1 
cal@UiO-66-L1-PolyLact 6.9 141 ± 2 
cal@UiO-66-L2-PNIPAM 8.0 150 ± 1 
cal@UiO-66-FA (PS) 9.8 184 ± 2 
cal@UiO-66-Hep (PS) 13.0 171 ± 3 
cal@UiO-66-Biot (PS) 12.8 37 ± 1 
 
 





Figure 4.16. Endocytosis efficiency of calcein-loaded MOFs for the HeLa cell line, normalised to 
cal@UiO-66-L1. Error bars represent the standard deviation of 5 meassurements.  
In general, cal@UiO-66 uptake is highly efficient compared to free calcein (6-10 fold increase), 
proving the validity of NMOFs as carriers to internalise cargo not able to efficiently cross the 
cell membrane by themselves. cal@UiO-66-Biot (PS) was, however, poorly internalised by 
HeLa cells compared to cal@UiO-66-L1, with very close efficiency (37 ± 1%) to free calcein 
(17 ± 1%) showing that biotin coating might not be desirable to enhance NMOF cell 
internalisation, although biotin could be used as a platform for further postsynthetic 
modifications, such as N-alkylation. 
cal@UiO-66-FA (PS) had the highest internalisation, followed by cal@UiO-66-Hep (PS), 
cal@UiO-66-L2-PNIPAM, cal@UiO-66-L1-PEG2000, cal@UiO-66-L1-Poly-Lact and 
cal@UiO-66-L1-PEG550 (Table 4.2). 
HeLa, and other cancerous cells, are known to over express the folate receptor (FR) on their 
surface,41-43 and therefore the folate present on the surface of cal@UiO-66-FA (PS) could bind 
to the FR, providing a mode of targeting and enhanced internalisation of the NMOF. Similarly, 
some cancer cells overexpress receptors to which heparin can bind.44  
Although NPs passively accumulate in cancer tissue in vivo due to the EPR effect,23 increasing 
the endocytosis efficiency is clearly one way to increase their therapeutic efficiency. However, 




targeting units, such as folate, can be used to enhance the uptake of MOFs in cancer cells 
without compromising healthy cells. Additionally, the mechanism of cell internalisation is 
important if the MOFs are to avoid degradation in the lysosome before releasing their 
therapeutic cargo. 
4.6 Endocytosis Routes of MOFs 
To monitor the endocytosis routes by which the different MOFs are internalised by HeLa cells, 
a series of pharmacological inhibitors was employed.10 Chlorpromazine27 and sucrose28 were 
used to inhibit clathrin-mediated pathways16 although it is important to consider that sucrose 
can additionally inhibit some non-mediated endocytosis processes. Nystatin26 was used as an 
inhibitor of caveolae-mediated endocytosis17 and rottlerin29 was used to inhibit 
macropinocytosis.19 If uptake is found to be lower when a certain inhibitor is used, this 
indicates the particular route being inhibited is significant in internalising the nanoparticles.  
As positive controls for the inhibitors, tracers known to follow each pathway were used: 
transferrin45 and ceramide46 for clathrin- and caveolae-mediated pathways respectively, and 
dextran47 for macropinocytosis. Cells were incubated with each inhibitor for 30 minutes and 
then for 90 minutes together with the NMOF (Section 4.9), confirming the inhibition of the 
specific routes (Figure 4.17). It should be noted that inhibition of one route may allow other 
routes to be utilised, and so significant decreases may not always be observed. 
 
Figure 4.17. FACS of the positive controls of desired endocytosis routes, showing statistical difference 
for the concentration of tracers used. Error bars represent the standard deviation of 3 measurements.  
Cell internalisation studies without the use of inhibitors were performed at 37 °C, to which the 
inhibited uptakes were normalised to, and at 4 °C, in order to attenuate energy-dependent 
internalisation. When cells were incubated at 4 °C cell internalisation of the NMOFs decreased 
by 50-85% compared to the control at 37 °C (Figure 4.18). However, the difference in 
cytoplasmic fluorescence of the HeLa cells after incubation with cal@UiO-66-Biot (PS), which 
was the less efficiently internalised MOF, at 37 ºC and 4 ºC is not as remarkable as for all 




other NMOFs, only decreasing by 28%. Indeed, apart from cal@UiO-66-Biot and cal@UiO-
66-L1-PolyLact, the decrease in cells’ internal fluorescence is more remarkable for the surface 
coated samples than for cal@UiO-66-L1.  
 
Figure 4.18. Endocytosis efficiency of cal@MOFs at 37 ºC and 4 ºC with no inhibitors. 4ºC 
internalisation indicates non-active transport contribution. Error bars represent the standard deviation 
of 5 measurements.  
At 4 ºC most cellular functions are attenuated, and therefore active transport, such as 
endocytosis, is highly decreased. These results indicate that cal@UiO-66-Biot (PS) is not 
significantly internalised by active transport, explaining why the endocytosis efficiency is 
remarkably decreased when compared to unfunctionalised UiO-66. Therefore, biotin coated 
materials might not be especially effective as DDSs, although biotin functionalities could 
provide a platform for further postsynthetic modifications that might increase the NMOFs 
efficiency. As no efficient internalisation is observed, no further experiments were carried out 
with this sample. 
It has been previously reported that naked UiO-66 nanoparticles generally enter HeLa cells 
through clathrin-mediated endocytosis, ultimately resulting in lysosome storage, reducing their 
potential therapeutic efficiency.9, 10 The uptake of cal@UiO-66-L1 after exposure to the 
clathrin-mediated inhibitors, sucrose and chlorpromazine, was reduced to ~27 ± 1% and 37 ± 
5% respectively, whereas exposure to nystatin had no effect (~107 ± 7%), revealing that the 
unfunctionalised MOF is not internalised through the caveolae-mediated route, while pre-
incubation with rottlerin decreased its uptake to ~79 ± 6% (Figure 4.19). 




PEG chains have an amphiphilic character that resembles that of the cell membrane, which 
should be assessed to the PEGylated MOF surface, while cal@UiO-66, in contrast, has a 
hydrophilic surface. Hence, PEGylation might tune their internalisation pathways.  
 
Figure 4.19. Normalised internal fluorescence, obtained through FACS, of HeLa cells after the uptake 
of cal@UiO-66-L1, cal@UiO-66-L1-PEG550, and cal@UiO-66-L1-PEG2000 in the presence and 
absence of the pharmacological endocytosis inhibitors. Error bars represent the standard deviation of 
5 measurements.  
On the one hand, the PEG550 coating did not affect the routes of endocytosis with values 
similar to cal@UiO-66-L1. For example, the uptake after exposure to sucrose and 
chlorpromazine decreased to ~36 ± 2% and 26 ± 2% respectively, whereas there was no 
reduction in uptake upon exposure to nystatin (~106 ± 3%), and rottlerin slightly decreased 
the uptake to ~89 ± 4% (Figure 4.10). On the other hand, significant changes in cell 
internalisation routes were found upon PEG2000 coating. Exposing the cells to sucrose and 
chlorpromazine decreased cal@UiO-66-L1-PEG2000 uptake to ~28 ± 2% and 27 ± 2% 
respectively, but more importantly, with nystatin and rottlerin the uptake was reduced to ~51 
± 2% and 45 ± 4%, respectively, showing cal@UiO-66-L1-PEG2000 is partially internalised 
through macropinocytosis and more importantly, through caveolae-mediated endocytosis 
(Figure 4.10), suggesting that its therapeutic efficiency might be enhanced compared to 
uncoated MOF. 
This indicates that the UiO-66 internalisation pathway is significantly affected by the 
functionality attached to its surface, with the longer PEG chains (Mw ~2000) allowing the 
NMOFs to partially avoid lysosomal degradation, possibly due to its amphiphilic nature, which 




is thought to be more compatible with the caveolae-mediated route. In addition, part of the 
cellular trafficking of all three MOFs occurs through macropinocytosis, as the uptake is 
affected by the presence of rottlerin. However, macropinocytosis is a non-selective process 
allowing the internalisation of large quantities of material, independent of its constitution. 
Although this route contribution could be a consequence of aggregation of nanoparticles, the 
contribution to cal@UiO-66-L1-PEG2000 internalisation is greater than for cal@UiO-66-L1-
PEG550 and cal@UiO-66-L1, while the later exhibit a higher degree of aggregation, as 
determined by DLS measurements (See Chapter 3). 
Folate receptors have been reported to often be located within caveolae invaginations.43, 48 
cal@UiO-66-FA (PS) uptake decreased to 62 ± 2% when HeLa cells were incubated with 
nystatin, indicating caveolae-mediated internalisation, while no significant inhibition was found 
when incubated with chlorpromazine (96 ± 3%), meaning that the MOF is not internalised by 
clathrin-mediated endocytosis, and only a minor effect (81 ± 5%) was observed when rottlerin 
was inhibiting macropinocytosis pathways. Sucrose significantly decreased cal@UiO-66-FA 
(PS) uptake to 36 ± 4%, meaning that folate coating not only provides a way of cancer 
targeting, but also alters cancer cell endocytosis selection pathways from clathrin-mediated to 
both caveolae-mediated and non-mediated endocytosis (Figure 4.20). These results suggest 
that drug loaded UiO-66-FA samples have potential to be efficient therapeutic DDSs, as they 
could potentially escape the early endosomes, avoiding lysosome storage and being released 
to the cytosol to reach target organelles.  
 
Figure 4.20. Endocytosis efficiency of cal@UiO-66-FA (PS) in the presence of different inhibitors 
normalised to the efficiency observed at 37 ºC with no inhibitor. Error bars represent the standard 
deviation of 5 measurements.  




The endocytosis pathways of cal@UiO-66-Hep (PS) show differences compared cal@UiO-66 
(Figure 4.21). Exposing HeLa cells to nystatin decreased cal@UiO-66-Hep (PS) cell 
internalisation to values of 60 ± 1%, showing that the heparin coated MOF is also partially 
internalised by caveolae-mediated endocytosis. However, in contrast to cal@UiO-66-FA (PS), 
clathrin-mediated routes also play a role in HeLa cell internalisation of cal@UiO-66-Hep (PS), 
as normalised cell cytoplasmic fluorescence decreases to values of 70 ± 2%, while inhibiting 
macropinocytosis decreases the MOF normalised uptake to 83 ± 3%. Additionally, sucrose 
also decreased its cell internalisation to values of 41 ± 4%.  
 
Figure 4.21. Endocytosis efficiency of cal@UiO-66-Hep (PS) in the presence of different inhibitors, 
normalised to the efficiency observed at 37 ºC with no inhibitor. Error bars represent the standard 
deviation of 5 measurements.  
In the cases of cal@UiO-66-L1-PolyLact and cal@UiO-66-L2-PNIPAM, cell internalisation 
decreased when inhibiting with sucrose (50 ± 5% and 54 ± 1%, respectively), while no 
significant decrease was found when inhibiting clathrin-mediated (84 ± 11% and 105 ± 5% 
respectively) or caveolae-mediated routes (106 ± 13% and 103 ± 4% respectively), and only 
minor macropinocytosis attributions upon PNIPAM coating (80 ± 4%). Surprisingly, even 
though cal@UiO-66-L1-PolyLact uptake is more efficient than for cla@UiO-66-L1, its uptake 
at 4 ºC is not as low as for the other surface functionalised NMOFs, indicating that cell 
internalisation does not occur exclusively by active transport. These results suggest that these 
polymer-coated samples are mainly internalised by non-mediated endocytosis processes, 
with a significant contribution for cal@UiO-66-L1-PolyLact from energy independent 
processes. (Figure 4.22). 





Figure 4.22. Endocytosis efficiency of a) cal@UiO-66-L1-PolyLact, and b) UiO-66-L2-PNIPAM, in the 
presence of different inhibitors, normalised to the efficiency observed at 37 ºC with no inhibitor. Error 
bars represent the standard deviation of 5 measurements.  
Comparing the uptake routes of functionalised samples together (Figure 4.23), some features 
are notable. In general, cell uptake through clathrin-mediated endocytosis (inhibited by 
chlorpromazine), which was the major route for cal@UiO-66-L1, cal@UiO-66-L1-PEG550, 
and contributes partially to cal@UiO-66-L1-PEG2000 internalisation, has remarkably 
decreased to similar levels upon all the other coatings. Nearly all samples show some 
inhibition by rottlerin, most significantly for cal@UiO-66-L1-PEG2000, suggesting some 
contribution from macropinocytosis, apart from cal@UiO-66-L1-PolyLact, which has greater 
levels of non-active transport. Inhibition by nystatin, which indicates caveolae-mediated 
uptake and should be favourable for drug delivery, is observed for cal@UiO-66-FA (PS), 









Figure 4.23. Endocytosis efficiencies of the calcein-loaded MOFs for the HeLa cell line when 
incubated with various inhibitors. The statistical significance was determined by ordinary one-way 
ANOVA and is indicated on the part b): * = P≤ 0.05 ** = P≤ 0.01 *** = P≤ 0.001 **** = P≤ 0.0001. Error 
bars represent the standard deviation of 5 replicates. 
4.7 Confocal Fluorescence Microscopy  
Confocal fluorescence microscopy has been used to confirm successful internalisation of the 
MOF nanoparticles by HeLa cells and their subsequent intracellular calcein release. On the 
one hand, calcein cannot cross the cell membrane alone, on the other hand, it self-quenches, 
and so the green fluorescence is only observed upon release of calcein from the internalised 
NMOF. 






Figure 4.24. Confocal microscopy images of HeLa cells incubated with different materials, from top to 
bottom: control; free calcein; cal@UiO-66-L1; cal@UiO-66-L1-PEG550; cal@UiO-66-L1-PEG2000. 
Cells were subsequently stained with Hoechst 33342 (5 μg/mL) and CellMask™ Orange (1X). Scale 
bar represents 25 µm in all images except for cal@UiO-66-L1, in which it represents 10 μm. Performed 
by S. Haddad.  
Figure 4.24 shows the confocal microscopy images of HeLa cells incubated during 2 hours 
with, from top to bottom: nothing (control); free calcein; cal@UiO-66-L1; cal@UiO-66-L1-
PEG550; cal@UiO-66-L1-PEG2000. Hoechst 33342 (H33342) and CellMask were used to 
stain the nucleus and the membrane of the cells, respectively. CellMask acts as a viability 
control, probing the cell membrane integrity, and shows that the MOFs are inside the cells. 
The effectiveness of calcein as a probe is demonstrated by the fact that free calcein is not 
taken up by cells - the control cells and those incubated with free calcein show no green signal 




- in concert with previous reports.9 As calcein self-quenches, any green fluorescence within 
cells comes from released calcein from internalised MOF materials. Therefore, it is visually 
proven that cal@UiO-66-L1, cal@UiO-66-L1-PEG550 and cal@UiO-66-L1-PEG2000 all 
transport and deliver calcein into HeLa cells. 
Laser confocal microscopy was also used to qualitatively determine the degree of co-
localisation between the calcein-loaded NMOF particles (green) and the lysosomes (red), 
using LysoTracker®-Deep red (Figure 4.25).10 After 2 hours of incubation, a high level of co-
localisation was found for all three MOFs, as FACS confirmed that clathrin–mediated uptake 
takes place in all NMOFs. However, in the case of cal@UiO-66-L1-PEG2000, a higher degree 
of localised light green particles outside the lysosomes can also be observed, suggesting 
altered uptake mechanisms. Despite the fact that the release profiles determined that 
PEGylated UiO-66 samples only release ~15% of calcein at pH 7.4 after 2 hours of exposure 
(See section 4.4), the green fluorescence is clearly visible outside the lysosome, suggesting 
a proportion of cal@UiO-66-L1-PEG2000 is internalised by a different uptake mechanism (in 
the more acidic lysosome 85% of calcein would be expected to be released in pH 5.5 at the 
same exposure time).  
 
 
Figure 4.25.Confocal fluorescence microscopy images of NMOF uptake into HeLa cells using a 
lysotracker (red) to stain the lysosome and showing calcein internalisation (green). Non-lysosomal 
calcein is highlighted in white boxes for UiO-66-L1-PEG2000. Scale bars represent 25 m, 10 m and 
7.5 m, from left to right. Performed by S. Haddad.  
In summary, these results shown that UiO-66 and functionalised analogues are efficiently 
internalised, and demonstrate the power of surface functionalisation in MOFs cellular 
internalisation efficacy and pathways, which can be tuned from clathrin-mediated to caveolae-
mediated endocytosis, the second being more desirable for DDSs to be efficient, as facilitates 
early endosome escape and subsequent cytosolic release.  





In order to study MOFs’ cancer cells internalisation, a fluorescent molecule (calcein) has been 
loaded into UiO-66-L1 and UiO-66-L2, which have been further postsynthetically modified 
following the protocols detailed in Chapter 3, confirming the orthogonality of the postsynthetic 
surface modifications with cargo loading.  
Calcein release from bare UiO-66-L1, UiO-66-L1-PEG550 and UiO-66-L1-PEG2000 has been 
studied in PBS at pH 7.4 and 5.5. The release kinetics were drastically reduced at pH 7.4 for 
the PEGylated MOFs (ca. 10% w/w linker release after 1 hour versus 52% w/w for cal@UiO-
66-L1), while they were maintained at pH 5.5 (total release in 10 hours), as the nature of the 
MOFs’ metal-linker coordination bond enhances their degradation at more acidic pH. The 
PEGylated MOFs did not release further cargo (ca. 30% w/w) after approximately 10 hours in 
PBS at pH 7.4, whereas the non-PEGylated MOF released all its cargo after 2 days. More 
importantly, stimuli-responsive release was achieved by changing the pH of the release media 
of the PEGylated MOFs from 7.4 to 5.5 during the course of the experiments. This phenomena 
has been explained by the formation of a phosphate corona at pH 7.4, which hinders further 
calcein release from the PEG-coated MOFs, which partially protonates under acidic pH and 
breaks down 
The ability of surface functionalised and bare UiO-66 to be internalised by cells through active 
transport, such as endocytosis, and to deliver its cargo has been proved both by FACS and 
confocal microscopy. Loading the MOFs with calcein enables the monitoring of their 
internalisation by cells, as compared to free calcein, cells have a 6-fold increase in internal 
fluorescence after treatment with cal@UiO-66-L1, a consequence of free calcein’s poor 
internalisation due to its hydrophilic nature. The cellular uptake of cal@UiO-66-L1 has been 
enhanced by almost all surface functionalisations, apart from the biotin coated sample, which 
was poorly internalised (ca. 37 %) compared to its precursor bare sample, with almost no 
internalisation through active-transport. Due to the over expression of the folate receptor by 
HeLa cervix cancer cells, cal@UiO-66-FA internalisation was twice as effective when 
compared to the bare precursor MOF.  
 
Surface modifications have proven to alter the endocytosis routes of uptake. Although 
cal@UiO-66 and cal@UiO-66-L1 are mainly internalised through clathrin-mediated 
endocytosis, with partial contribution of macropinocytosis, different uptake routes are found 
depending on the surface coating. While cal@UiO-66-L1-PEG550 internalisation does not 
differ significantly from its precursor, caveolae-mediated endocytosis is significant in the 
uptake of cal@UiO-66-L1-PEG2000, whose uptake was inhibited by ca. 40% by nystatin, 




meaning that the amphiphilic character of the PEG chains favour the caveolae-mediated route 
only when the PEG chains are long enough. Clathrin-mediated endocytosis and 
macropinocytosis have been also assessed as important routes of internalisation for both 
PEGylated MOFs, with a higher degree of macropinocytosis contribution upon longer PEG 
chains.  
As the folate receptors are often located within caveolae invaginations, cal@UiO-66-FA was 
also internalised through the caveolae-mediated route, with no contribution of clathrin-
mediated endocytosis. Thus, folic acid coating not only targets cancer cells and enhanced the 
cellular internalisation of MOFs, it also tunes their internalisation to more desired pathways. 
Heparin is on the other hand internalised by both clathrin and caveolae-mediated endocytosis, 
with minor contribution upon macropinocytosis.  
Samples coated with the polymers Poly-L-lactide and PNIPAM were not internalised through 
caveolae or clathrin-mediated endocytosis, with only minor contribution of the 
macropinocytosis route upon PNIPAM coating. The high degree of inhibition by sucrose, 
known to inhibit also non-mediated uptake routes, indicates that non-mediated endocytic 
processes are the major routes of internalisation of these MOFs, with a high degree of non-
active transport in the case of cal@UiO-66-L1-PolyLact.  
With these results in mind, the cytotoxicity of the samples will be studied in Chapter 5. The 
bare and surface functionalised materials, empty and drug-loaded, will be incubated with HeLa 
cells, and the viability of these will be measured, with the aim of understanding the effect of 
the endocytosis routes in their therapeutic activity.  
  





4.9.1 General Experimental remarks 
Flow Cytometry: Measurements were carried out using Cytek DxP8 analyser cytometer; BLU 
mode (laser)-FLU1 (fluorenscence detector). The analysis was done using FlowJo and Prism 
softwares. (University of Cambridge)  
Confocal Microscopy: Measurements were carried out using Leica TCS SP5 confocal 
microscope. The microscope was equipped with 405 diode, argon and HeNe lasers. Leica 
LAS AF software was used to analyse the images. (University of Cambridge) 
4.9.2 Protocols 
Calcein Loading of UiO-66-L1 and UiO-66-L2 
300 mg of UiO-66-L1 or 150 mg UiO-66-L2 were dispersed by sonication (15 minutes) in 150 
mL or 75 mL of a methanolic solution of calcein (10 mgmL-1) respectively, and stirred at room 
temperature for 48 hours. The solid was collected by centrifugation (4500 rpm, 20 min), and 
submitted to dispersion centrifugation cycles with fresh methanol until the supernatant solution 
remained colorless (around 5 times). The calcein loaded materials were obtained as a bright 
orange powder. 
Postsynthetic Modifications of Calcein Loaded MOFs 
Surface modification of cal@UiO-66-L1 and cal@UiO-66-L2 followed the previous protocols 
for surface ligand exchange and covalent modification than during Chapter 3, as per Figure 
4.7.  
Calcein Release Experiments 
The pH of the release media was adjusted from 7.4 to 5.5 during the course of the experiment 
by adding 50 µL of concentrated HCl to the 100 ml of PBS pH 7.4 placed in contact with the 
dialysis bag, in order to obtain pH 5.5. The quantity of concentrated HCl need to change the 
pH of the dialysis media was determined previous to the experiment.  
Simulated Calcein Release  
To simulate release conditions on a larger scale, 50 mg samples of the calcein-loaded NMOFs 
were dispersed in 50 ml of PBS pH 7.4, which was stirred at room temperature for 2 days in 
the case of cal@UiO-66-L1-PEG2000 and for 1 day for cal@UiO-66-L1. Then, the NMOF was 
collected by centrifugation (4500 rpm, 15 minutes), and washed with water 3 times. The 
NMOFs were dried for 24 hours under vacuum before further analysis.  




Flow Cytometry Assays (FACS) 
In all the FACS experiments, HeLa cells were seeded in a Cellstar 24-well plate at a density 
of 5 x 104 cells/well and incubated for 48 h at 37 ºC with 5% CO2 in complete medium. 
Endocytosis Efficiency  
The endocytosis efficiency of the calcein loaded MOFs was measured by fluorescence 
assisted cell sorting (FACS) using the HeLa cell line. After 48 h of cell growth, the cells were 
washed with PBS and incubated with a solution of the NMOF in question in media for 2 h.Then, 
the media of each well was aspirated and the wells were washed extensively (PBS x 3) to 
remove non-internalised MOF or incubation conditions. The cells were then harvested by 
adding 0.1 mL of trypsin and incubated for 5 min at 37 ºC with 5% CO2. The cells were 
recovered by centrifugation (5 min at 1200 rpm) and re-suspended in 100 μL of cDMEM 
without phenol red. Finally the samples were measured in a Cytek DxP8 analyser cytometer 
within 30 min. The analysis of the data was done using FlowJo and Prism software. 
Positive Control of Endocytosis Routes 
After cell growing for 48 h, each well containing cells was washed with PBS and pre-treated 
with sucrose (102.7 mgmL-1, 0.3 M), chlorpromazine (31.9 μgmL-1, 100 μM), nystatin (250 
μgmL-1), and rottlerin (2.6 μgmL-1, 5 μM) for 30 min at 37 ºC. Subsequently, endocytosis 
tracers (transferrin-AlexaFluor-633, 25 μgmL-1; BODIPY TR-ceramide, 3.5 μgmL-1; and Texas 
Red-dextran-10 kDa, 0.5 mgmL-1) known to specifically go through the clathrin, caveolae, and 
macropinocytosis pathways respectively, were added and incubated for another 1.5 h. After 
each treatment, the medium of each well was aspirated and the wells were washed 
extensively to remove all the conditions. The cells were then harvested by adding 0.1 mL of 
trypsin and incubated for 5 min at 37 ºC with 5% CO2. Cells were recovered by centrifugation 
(5 min at 1200 rpm) and re-suspended in 100 µL of complete medium without phenol red. 
Finally the samples were measured in a Cytek DxP8 analyser cytometer within 30 min. The 
analysis of the data was done using FlowJo and Prism software. 
Inhibition Studies of Endocytosis Routes 
After culturing for 48 h, each well containing cells was washed with PBS and pre-treated with 
either sucrose (102.7 mgmL-1, 0.3 M), chlorpromazine (31.9 μgmL-1, 100 μM), nystatin (250 
μgmL-1), or rottlerin (2.6 μgmL-1, 5 μM) for 30 min at 37 ºC. Then, the different NMOFs (0.5 
mgmL-1 in growth media) were added and incubated for another 1.5 h. Subsequently, following 
the general procedure, the samples were measured by flow cytometry. 
 





For all the co-localization experiments, HeLa cells were seeded in a NUNCTM imaging four-
well plate at a density of 1.11 x 105 cell/mL and incubated for 24 h at 37 ºC with 5% CO2 in 
cDMEM. At the end of the incubation period the four-well plate was placed on a Leica TCS 
SP5 confocal microscope to be imaged. The microscope was equipped with 405 diode, argon 
and HeNe lasers. Leica LAS AF software was used to analyse the images.  
The cells were then washed with PBS and incubated with 0.5 mg/mL of UiO-66-L1, UiO-66-
L1-PEG550, or UiO-66-L1-PEG2000, along with LysoTracker®-Deep red for 2 h at 37 ºC with 
5% CO2 in cDMEM. Subsequently, the cells were washed with PBS to remove the conditions, 
with trypan blue (0.4%) to quench any external fluorescence, and again three times with PBS. 
Finally, fresh media without phenol red was added to each sample. 
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5.1 Introduction  
5.1.1 In vitro Studies of MOFs 
The therapeutic efficiency of any DDS is strictly correlated to its ability to cross the cell 
membrane and successfully deliver the drug to the various cell compartments.1, 2 As described 
in Chapter 4, both cell internalisation rates and routes are of crucial importance for efficient 
drug delivery, as well as low toxicity and the ability to deliver active cargo into cells. Typically, 
in vitro cell proliferation experiments, such as MTS and MTT assays after incubation of cells 
with the DDSs, are used as key initial evaluators of the effect of factors such as surface 
modification and drug loading. A summary of the most relevant in vitro studies carried out with 
MOFs is given in table 5.1.  
During Chapter 1, the biocompatibility of bare Zr MOFs, such as UiO-66 (IC50 of 1.50 ± 0.15 
mg/mL after 24 hours of exposure),3, 4 PCN-223, ZJU-8005 or Zr-fumarate,6 was discussed. 
This biocompatibility and their high storages capacities mean many examples of Zr MOFs in 
vitro and in vivo anticancer activity are emerging in the literature. 7-9 
The efficiency of therapeutic cargo delivery into cells can be monitored in vitro, by comparing 
cell proliferation in the presence of drug loaded MOF with that of the free drug and the empty 
MOF. The therapeutic efficiency of UiO-66-AL, coated on its inner and outer surface with the 
drug Alendronate, was tested in human liver carcinoma HepG2 cells (Figure 5.1a) and human 
breast cancer MCF-7 cells (Figure 5.1b) using the MTT protocol.10 The authors found that 
after 24 hours of incubation, the free drug had a higher effect than the loaded NMOFs, while 
after 48 hours, incubation with UiO-66-AL decreased cell viability to a slightly higher extent 
than when cells were treated with a solution of the same free drug concentration. These results 
could indicate slow uptake of the MOF or particles reaching different intracellular locations 
after different time periods, but it is also important to consider that if the NMOF itself degrades 
during the incubation time, the free drug subsequently present in the growth media could then 
be internalised through passive diffusion and thus inhibit cancer cell growth.  
  




Table 5.1: Summary of in vitro studies carried out using Zirconium MOFs as DDs 
MOF Drug Loading Cell line Results 






n/a SMMC-7721 (human 
hepatocellular carcinoma) 
HeLa 
Biocompatibility of empty MOF (0-50 µM based on 
linker TCPP) 11 
UiO-66-AL Alendronate 
(AL) 51.4 % 
w/w 
MCF-7 human breast carcinoma 
HepG2 human liver carcinoma 
Higher efficacy than free drug for 48 h incubation 
time 10 
UiO-PDT PDT based on 
linker I2-
BODYPI 
B16F10 mouse melanoma 
CT26 murine colon carcinoma 
C26 mouse colon carcinoma 
No dark cytotoxicity (0.625 mg/mL of NMOF)  
Similar cytotoxicity to free linker under UV light12 
IC50= 0.70 µg/mL 
IC50 = 1.15 µg/mL 
IC50 = 0.51 µg/mL 
PCN-224 
PCN-224-FA 
PDT based on 
linker 
 
HeLa (over express FR) 
A549 human lung carcinoma (no 
FR over expression) 
No cytotoxicity in dark 
2 fold increase compared to free linker and more 
efficiency  upon FA coating only for HeLa cells 13 
NU-1000 
NU-091 
α-CH (ca. 81 
% w/w ) 
HeLa Higher cytotoxicity than the free drug14 
UiO family α-CH (ca. 30 
w/w %) 
HeLa Cytotoxicity accordingly with endocytosis routes of 




(50 % w/w) 
MDA-MB-231 triple negative 
breast cancer 
L929 fibroblast 
F3 functionalised samples higher cytotoxicity in 
cancer cells than non F3 targeted MOF (nucleolin 
targeting)  





SKOV-3 human ovarian cancer 
(cis-platin resistance) 
MCF-7, H460 human lung 
carcinoma  and A2780 human 
ovarian carcinoma (cis-platin 
sensitive) 
Co-delivery cis-platin and siRNA to overcome cis-
platin resistance.  
Lower IC50 values than free cis-platin when cis-platin 
resistant cells are incubated with siRNA- SiRNA-
UiO-Cis more effective than UiO-Cis 
For cis-platin sensitive cell lines UiO-Cis and siRNA-












MFC-10A breast epithelial cells 
Time-dependant apoptosis studies  
Empty MOFs no cytotoxicity in both cell lines 
Nucleolin targeting MOF slightly higher cytotoxicity 
than non-targeted. 





3T3 Mouse fribroblast  
Empty MOF no cytotoxic up to 0.5 mg/mL 
Ca. 60 % cancer cells death upon treatment with 
0.02 mg/mL of DOX loaded MOF, while 3T3 cells 
proliferation is not affected up to 0.5 mg/mL of 





HeLa Higher cytotoxixicty than free peptides due to higher 
fate of cell internalisation 6 
 




The biocompatibility of UiO-PDT, UiO-66 surface-modified with I2-BODIPY (I2-BDP), was 
investigated for mouse colon carcinoma C26 cells, murine colon carcinoma CT26 cells, and 
B16F10 mouse melanoma cells, with no induced cytotoxicity when cells were incubated for 
24 h with concentrations up to 1 mgmL-1.12 As UiO-PDT can generate singlet oxygen (1O2) 
under UV-light irradiation with similar efficiencies to I2-BDP (the free linker), the in vitro 
phototoxicity of UiO-66-PDT (0-0.625 mgmL-1) was assessed using the MTT assay with CT26, 
C26 and B16F10 cells (Figure 5.1c). The authors observed that free I2-BDP has IC50 levels 
>15 µgmL-1 in the dark, which decreases to IC50< 0.8 µgmL-1 when irradiated at a power 
density of 80 mW cm−2 for 10 min for the studied cell lines. UiO-PDT has similar cytotoxicity 
values to free I2-BDP under UV irradiation, with IC50 values of 0.70, 1.15 and 0.51 μgmL−1 for 
B16F10, CT26 and C26 cells in turn (Figure 5.1d), despite the higher cell internalisation of 
UiO-66-PDT compared to I2-BDP (1.5 fold), as determined by FACS.12 The fact that I2-BDP 
can potentially undergo passive diffusion and thus be located in the cytoplasm rather than in 
vesicles, might be the reason why there is not a more pronounced cytotoxic effect when cells 
are incubated UiO-PDT, together with the fact that free linker has a slightly better ability to 
generate singlet oxygen.  
 
Figure 5.1. Cell viabilities of (a) HepG2 and (b) MCF-7 cells incubated with free AL and AL-UiO-66 at 
different concentrations for 24 and 48 h.10 (c) In vitro cytotoxicities of free I2-BDP and UiO-PDT 
nanocrystals against B16F10 cells before and after being irradiated with visible light at a power density 
of 80 mW cm−2 for 10 minutes. (d) Half maximal inhibitory concentration (IC50) of I2-BDP and UiO-PDT 
with and without light irradiation against B16F10 cells.12 




The potential of five PCN-224 samples of different particle sizes as PDT devices was also 
tested on HeLa cells, and therapeutic efficiency was consistent with the cell uptake results.13 
PCN-244 is a porphyrinic–based Zr MOF, which is also PDT active. Particles of 90 nm size, 
which were the most efficiently internalised size fraction, were also the most cytotoxic under 
light irradiation, with a 2 fold increase in cytotoxicity compared to free linker, while no 
remarkable effect on cell proliferation was found in dark. HeLa cells overexpress the folate 
receptor,20-22 and thus coating the MOF with folic acid (PCN-224-FA) resulted in an 
enhancement of its therapeutic efficiency in comparison to the unmodified MOF. A control 
experiment, in which folate receptor negative negative cells (human lung carcinoma A549 
cells) were treated with PCN-224-FA and bare PCN-224 was performed, showing no 
enhancement in either cell internalisation or PDT efficacy upon folate coating.13 
α-Cyano-4-hydroxycinnamic acid (α-CHC) has been proposed as an anticancer drug, and has 
been loaded postsynthetically into the pores of Zr MOFs.4 An investigation of the delivery of 
α-CHC into HeLa cells by UiO-66 series MOFs showed that cell proliferation was dependent 
on the endocytosis pathways of the MOFs.15 As UiO-66 is internalised through clathrin-
mediated endocytosis, α-CHC@UiO-66 (31% w/w α-CHC loading) did not have a negative 
effect on HeLa cells after incubation for 24 hours, but as UiO-67 partially undergoes caveolae-
mediated endocytosis, incubation with α-CHC@UiO-67 (20% w/w α-CHC loading, 0.25-1 
mgmL-1) decreased cell proliferation to < 70% for the concentrations studied, while the empty 
MOF was non-cytotoxic.4 Due to the larger porosities of NU-1000 and NU-901, α-CHC 
loadings of up to 81% w/w have been reached.14 The therapeutic effect in HeLa cells of α-
CHC loaded NU-1000 and NU-901 before and after amorphisation through temperature 
treatment was studied using the MTS assay and compared to a control in which the cells were 
incubated with a solution of the same concentration of free drug (Figure 5.2).  
 
Figure 5.2. MTS Assays measuring enzymatic metabolic activity for α-CHC-loaded NU-1000 in both 
crystalline and temperature treated complexes for (a) 11 h and (b) 48 h of in vitro incubation. The free 
drug control, α-CHC, is shown incubated for both time points in yellow. Samples were run in minimum 
of four replicates. Standard errors are shown for each given concentration.14 




Although both α-CHC@NU-1000 and α-CHC@tt-NU-1000 induce higher cell cytotoxicity than 
the free drug after 11 hours incubation, there is no significant difference between pristine and 
amorphised MOF (Figure 5.2a). The enhancement in cytotoxicity compared to the free drug 
could be a consequence of its greater internalisation when loaded in the DDS compared to 
passive diffusion, and to the internalisation of the MOF through caveolae-mediated 
endocytosis, enabling endosomal escape. After 48 hours of incubation time a notable 
difference upon temperature treatment was found, especially for lower concentrations of the 
temperature-treated NU-1000 (Figure 5.2b). While the free drug and α-CHC@NU-1000 did 
not induce any cytotoxicity up to 0.6 mgmL-1 drug concentration, cell viability decreased to ca. 
80% for 0.2 mgmL-1 α-CHC loaded in thermally treated NU-1000, while α-CHC@tt-NU-1000 
killed all cells at a drug concentration of 1.60 mgmL-1 of drug. Similar behaviour is observed 
for α-CHC@NU-901 and α-CHC@tt-NU-901, which have the same effect on HeLa cell viability 
after 11 hours of incubation, again showing considerably more cytotoxicity than the free drug, 
while after 48 hours of treatment, the efficacy of the thermally treated sample difference is 
more pronounced at lower concentrations. However, the loaded-MOF concentration 
necessary to reach the drug concentration stated during the experiment are quite high (around 
2 mgmL-1 for the maximum concentrations), while the authors only studied the cytotoxicity of 
empty NU-1000 after 24 hours of incubation at concentrations up to 1.6 mgmL-1, being non-
cytotoxic, and no cytotoxic values of NU-901 are reported.14 
The effect of empty and DOX loaded core-shell Fe3O4@UiO-66-NH2 on HeLa cells growth 
was investigated using the MTT assay. While empty MOF did not induce cytotoxicity even at 
concentrations of 0.5 mgmL-1 of MOF (Figure 5.3a), HeLa cells growth was significantly 
affected upon treatment with DOX@Fe3O4@UiO-66-NH2, which induced 60% cell death when 
treated with a solution of MOF containing 0.02 mg/mL of DOX during 24 hours.19 The NMOF 
possessed similar anti-cancer activity to DOX when incubation time was 24 hours, which was 
enhanced after 48 hours (Figure 5.3b). Noteworthy, the loaded NMOF did not affect 
considerably mouse fibroblast 3T3 cells for concentrations up to 0.5 mg/mL of NMOF, showing 
no negative effects on normal cells (Figure 5.3c).  





Figure 5.3. (a) Cell viability of HeLa cells after incubation with different concentrations of Fe3O4@UiO-
66. (b) Cell viability of HeLa cells after incubation with free DOX and Fe3O4@UiO-66-DOX for 24 h or 
48 h at the same concentration of DOX. (c) Cell viability of 3T3 cells after incubation with Fe3O4@UiO-
66 and Fe3O4@UiO-66-DOX for 24 h at the same concentration of Fe3O4@UiO-66.19 
The potential of Zr-fumarate as a delivery vector for biomolecules was investigated by 
attaching various pro-apoptotic peptides (Bak, Bad, KLK) and a cytochrome c protein (CytC), 
which due to their membrane impermeability are not able to efficiently cross the cells 
membrane by themselves, to the NMOF surface using His-tags.6 A decrease in HeLa cell 
viability when treated with the peptide-modified NMOFs was considered a consequence of 
efficient cytosolic release of the attached peptides. The authors compared the effect on cells 
growth to those obtained when incubating cells with free peptide or naked Zr-fumarate during 




the same period of time. The peptide or protein conjugated MOFs induced remarkably higher 
cytotoxicity (ca. 40% cells viability) compared with the free peptide (ca. 90%), while naked 
MOF did not exhibit any cytotoxicity, confirming the intracellular delivery of the peptides by the 
MOF.6 
Lin and co-workers investigated siRNA transfection efficiency mediated by siRNA-UiO-Cis, 
which possess loaded-cisplatin and attached siRNA through phosphates, in SKOW-3 ovarian 
cancer cells, which have cis-platin resistance.17 By siRNA delivery, the authors aimed to inhibit 
three genes (surviving, Bcl-2 and P-gp) in order to overcome cis-platin resistance. ELISA 
assays showed that while when cisplatin resistant cells were incubated with UiO-66-Cis 
together with a pool of siRNA or with siRNA specific to inhibit certain genes, induced potent 
gene silencing, while free siRNAs on their own did not have the same effect (Figure 5.4a). 
These results correlated with the therapeutic effect, as when SKOW-3 cisplatin resistant cells 
were incubated with either UiO-Cis or free cis-platin plus a pool of siRNA, a similar cytotoxic 
effect to the free drug on its own (IC50= 53.9 ± 4.7, 53.2 ± 4.4 and 45.1 ± 7.0 µM cis-platin for 
free cis-platin, UiO-Cis and free cis-platin/pool siRNA respectively) was observed, whereas 
when were cells incubated with UiO-Cis/pool siRNA or free cis-platin/siRNA-UiO remarkably 
lower IC50 values (4.7 ± 1.8 and 6.6 ± 0.3 µM cis-platin respectively) were found (Figure 5.4b). 
Importantly, no cytotoxicity was found for siRNA-UiO, confirming that it is the co-delivery of 
siRNA and cis-platin what induces KOV-3 cells cytotoxicity.17 
 
 
Figure 5.4. In vitro gene silencing efficiency and anticancer efficacy. (a) siRNA/UiO-Cis-mediated 
efficient gene silencing in SKOV-3 cells at a 30 nM siRNA dose. Silencing efficiency was expressed as 
percentage values of control group treated with PBS. (b) SKOV-3 cells were incubated with free 
cisplatin, UiO-Cis, pooled siRNAs/UiO-Cis, free cisplatin plus free pooled siRNAs, and free cisplatin 
plus pooled siRNAs/UiO at different concentrations for 72 h, and then the cytotoxicity was determined 
by MTS assay.17 




Experiments using cis-platin sensitive cell lines, such as human ovarian carcinoma A2780, 
human breast carcinoma MCF-7 and human lung carcinoma H460 cells, demonstrated that 
both UiO-Cis and siRNA-UiO-Cis had similar levels of cytotoxicity, strongly suggesting that 
siRNA and cis-platin co-delivery using UiO-68 as a DDS could overcome cis-platin resistance 
of certain cancer cells through the combined effect of therapeutics and MDR-gene silencing. 
Through Annexin V conjugate staining and DNA ladder assays, siRNA-UiO-Cis cytotoxicity 
was proved to occur due to induced apoptosis rather than necrosis.17 
In vitro tumour targeting using the F3 nucleolin targeting peptide was investigated with 89Zr-
UiO-66-py-PGA-PEG-F3 against both the MDA-MB-231 triple-negative breast cancer cells, 
which over express the nucleolin receptor (n+) ,and L929 fibroblasts, which do not (n-).16 89Zr-
UiO-66-py-PGA-PEG-F3 is surface-modified with surface PEG and targeting F3 peptide chains 
introduced through π-π stacking. The empty MOF did not affect MDA-MB-231 cell growth in 
concentration range (0-50 µgmL-1), and the doxorubicin loaded targeted MOF decreased 
MDA-MB-231 cell viability to a greater extent than an analogue without the F3 peptide, as a 
consequence of enhanced MOF internalisation through targeting receptor-mediated 
endocytosis.16 
The cytotoxicity of various doxorubicin loaded UiO-68-N3-DNA conjugates has also been 
assessed against MDA-MB-231 cells by measurement of time-dependent apoptosis.18 The 
empty NMOFs induced less than 20% cell death after 42 hours, while the DOX-loaded MOF 
functionalised with a cytosine-rich DNA sequence induced around 50% of cell apoptosis for 
the same incubation time. Addition of the AS1411 aptamer, which binds to the nucleolin 
receptor (overexpressed on the surface of cancer cells) to the doxorubicin-loaded MOF 
induced 100% of cell death for the same incubation time, again as a consequence of targeting.  
Cell apoptosis was found to be a function of time, with different slopes depending of the 
NMOF. Cytotoxicity of the NMOFs was investigated in both MFC-10A breast epithelial cells 
and MDA-MB-231 breast cancer cells after incubation with the NMOF during 6 hours, followed 
by cells washing and further three and five days of incubation, showing no remarkable 
cytotoxicity for the empty MOFs in any cell line. The difference between the two surface-
functionalised NMOFs was not remarkable. While C-rich DNA sequences reduced cell 
proliferation to levels of ca. 65 %, the extra nucleolin receptor on the NMOF surface reduced 
cell proliferation to levels of ca. 55% after 72 hours of incubation time. When the NMOF was 
surface functionalised with Mg2+-dependent DNAzyme subunit separate by ATP-aptamer 
sequences, empty MOF did not induce cell death on any of the two cell lines, while DOX 
loaded MOF decreased cell viability of breast cancer cells to ca. 70% after 3 days and ca. 60 
% after 5 days, while not affecting the growth of healthy breast cells.18 




5.1.2 In vivo Studies of MOFs 
In vivo studies have also been performed using Zr-based MOFs as DDSs. For example, the 
distribution and clearance profile of Zr89UiO-66 up to 120 hours post-injection was investigated 
in vivo using PET. The health of the mice was monitored after treatment of medium doses (10 
mg/kg) and high doses (50 mg/kg) of Zr89UiO-66-Py-PGA-PEG, finding no side effects or 
acute, medium or chronic toxicity. PET scans of MDA-MB-231 tumours were taken at point 
times of 0.5, 2, 20, 24, 48, 72, 96 and 120 hours.16 
The circulation half-life of Zr89-UiO-66-Py-PGA-PEG was determined through serial blood 
sampling method, being 118.8 min, indicating that the PEG surface density achieved by π-π 
interactions might not be high enough to prolong circulation times. Zr89-UiO-66-Py-PGA-PEG-
F3 tumour uptake was found to be higher at all the time points than Zr89-UiO-66-Py-PGA-PEG 
as a consequence of the targeting peptide F3. However, after a maximum uptake around 2 
hours after injection, MOF accumulation in tumour tissue gradually decreases with time. The 
MOFs were found to be highly accumulated in the liver and spleen, with no major decrease 
over time. In order to study F3 targeting properties, the NMOFs were administered together 
with a nucleolin blocking dose (10 mg/kg) five minutes before Zr89-UiO-66-Py-PGA-PEG-F3, 
causing tumour uptake reduction and thus confirming that targeting through F3 peptide is one 
of the reasons why tumour uptake is slightly enhanced, while liver and spleen accumulation 
were not affected. The MOFs have slow clearance from the liver, while no radioactivity 
deposition was found in the bone or kidney. Tumour-muscle contrast was found to be efficient 
and as high as 76.3 ± 3.9 at 2 hours post-injection, while 19.6 ±5.4 after 120 hours.16 The 
DOX@UiO-66-Py-PGA-PEG and DOX@UiO-66-Py-PGA-PEG-F3 in vivo DOX release was 
studied by ex vivo fluorescence imaging, showing a 4-fold increase DOX signal in tumour 
upon F3 peptide targeting.16 
The potential of Fe3O4@UiO-66-NH2 core-shell composites as MRI contrast agents was also 
evaluated in vivo.19 Previously, magnetic resonance (MR) images of HeLa cells treated with 
different concentration of Fe3O4@UiO-66-NH2 were performed in order to gain insights into 
the T2-weighted images obtained during in vivo treatment (Figure 5.5a). Bio distribution and 
toxicology studies were performed in vivo to evaluate potential toxic effects, and thus T2-
weighted images of the Kumming mice were taken 1, 7, 14 and 30 days after injection (Figure 
5.5b). Since no darkening effect was found in the urinary bladder, while high darkening with 
time-recovery signal was observed in the liver, Fe3O4@UiO-66-NH2 seems to be excreted 
from the liver rather than from the kidney. Remarkable signal darkening was found in the liver 
10 min post-injection, and after 1 hour in the tumour, which remarkably increased for 9 hours 
post-injection time (Figure 5.5c), thus confirming NMOFs accumulation in tumour tissue after 
prolonged times. The biodistribution of the core-shell MOFs was determined ex vivo in 




specimens after 1, 7 and 30 days of injection by ICP-MS determination of the iron and 
zirconium levels of the different digested organs. In concordance with T2-weighted images, 
high accumulation of Zr and Fe was found in the liver and spleen. The levels decreased with 
prolonged times, reaching similar levels to untreated control after 30 days. However, the iron 
content in the liver was slightly higher than the untreated mice after 30 days. The body weight 
and growth of mice was found not to be affected when treated with Fe3O4@UiO-66-NH2, and 
blood analysis was consistent with the untreated control. In general, it was proved that 
Fe3O4@UiO-66-NH2 is relatively safe for in vivo treatments. The anti-cancer therapeutic effect 
of the core-shell MOFs was measured in vivo towards HeLa bearing tumour mice. While 
tumours in control mice growth quickly, mice treated with DOX@Fe3O4@UiO-66-NH2 showed 
tumour growth inhibition with a 4 fold decrease in weight. The tumour growth was monitored 
in vivo through MRI. Darkening effect was observed in the tumour area, thus indicating passive 
accumulation in the tumour (Figure 5.5c).19 
 
Figure 5.5. (a) MR images of HeLa cells after incubation with different concentrations (0, 25, 50, 100, 
150 and 200 mg L−1) of Fe3O4@UiO-66-NH2 for 24 h. (b) T2-weighted MR images of the Kunming 
mouse before and after intravenous injection of Fe3O4@UiO-66-NH2 at different time points (liver region 
marked by red cycles). (c) T2-weighted MR images and T2-MR signals of tumor on HeLa-tumor bearing 
mice before injection, 1 h and 9 h post injection of Fe3O4@UiO-66-NH2 intravenously (tumor region 
marked by red cycles).19 
Accumulation in the liver and spleen is often a consequence of high macrophage recognition 
and uptake. Therefore developing surface functionalisations that avoid macrophage 
recognition, while enhancing cancer cells uptake through targeting units might be an 
alternative to overcome accumulation in the body. Additionally, surface modifications that 




ensure adequate colloidal dispersion and ideal drug release kinetics under extracellular 
conditions, while fast surface detachment and consequent degradation under intracellular 
conditions might be an alternative to overcome accumulation issues.  
5.1.3 Dichloroacetate, a Metabolic Target 
Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (PDK) inhibitor which has been 
investigated for over 40 years for the treatment of mitochondrial disorders such as lactic 
acidosis.23-26 PDK is one of the main enzymes responsible for promoting glycolysis over 
glucose oxidation in cancer cells, as it can inhibit pyruvate dehydrogenase (PDH), an enzyme 
that converts pyruvate to acetylCoA.27-29 Once glucose has been transformed to pyruvate, 
instead of being decarboxylated to form acetylCoA and entering the Krebs cycle in the 
mitochondria, pyruvate is alternatively transformed to lactate in the cytosol of cancer cells,30, 
31 allowing them to grow in hypoxic conditions (low presence of oxygen) and resist 
apoptosis.32-34 DCA shifts cancer cells metabolism from glycolysis back to glucose oxidation 
by PDH re-activation, decreasing the mitochondrial membrane hyperpolarisation and 
activating Kv channels, thus unlocking cancer cells from a state of apoptosis resistance 
without affecting growth of healthy cells.35-39 
Although DCA is not currently under clinical use as an anticancer drug, due to its ability to 
target glycolysis it has been studied as a potential metabolic cancer therapy since 2007,38, 40 
with several clinical trials showing significant tumour remission without healthy cells damage, 
low side effects and toxicity, and safe chronic use.35, 37, 39, 41, 42 However, due to its ability to 
cross the brain membrane barrier, chronic exposure to very high DCA doses can result in 
reversible peripheral neuropathy.43 
The hydrophilic nature of DCA means it does not efficiently cross the cell membrane,44 with 
limited ability to reach its target mitochondria, and thus free DCA displays low cytotoxicity, with 
IC50 values in the milimolar range, three orders of magnitude higher than anticancer drugs 
such as cisplatin.45 DCA is rapidly cleared out from the blood stream, with initial half-life times 
of about an hour,25 leading to poor efficacy and targeting when the drug is injected alone.39, 45 
Nevertheless, cancer cells have shown remarkably lower resistance factors to DCA compared 
to cisplatin and other anticancer therapeutics (Figure 5.6),45 which is a notable drawback for 
anticancer therapy. 
For example, oxaliplatin, a prodrug of cisplatin with FDA approval,46 modified with DCA axial 
ligands (Figure 5.6) displayed enhanced anticancer activity in cisplatin sensitive and resistant 
cancer cells lines compared to cisplatin and oxaliplatin.45 After 72 hours of incubation with 
MCF-7 cisplatin resistant breast cancer cells, oxaliplatin had IC50 doses of 19 ± 1 µM, while 
the oxaliplatin DCA conjugates had IC50 doses of 1.6 ± 0.2 µM. Importantly, the resistant factor 




was also lowered from 6.7 to 1. The authors found that when oxaliplatin was incubated with 
free DCA there was no significant decrease in the IC50 dose, possibly as a consequence of 
poor internalisation of DCA on its own. 45 
Polymeric nanoparticulate encapsulation of a cisplatin prodrug containing DCA axial ligands 
(mitaplatin) in poly(D,L-Lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG) has 
been performed and evaluated in vivo, showing that encapsulation increases circulation times 
while reduces accumulation in the kidneys, with controlled release of mitaplatin overtime 
compared to free mitaplatin, thus enhancing its long-term anticancer efficacy.47 
 
Figure 5.6. Cisplatin and its prodrugs: Mitaplatin, a derivate of cisplatin containing DCA axial ligands47 
oxaliplatin, a produg of cisplatin, and a derivate of oxaliplatin with DCA axial ligands.45 
DCA is known to enhance the potency of the thymidylate synthase inhibitor 5-FU effects,48, 49 
and thus its IC50 dose towards HCT116 colon cancer cells was also reduced from 18 ± 2 µM 
to 14 ± 2 µM when 2 mM of DCA was incubated together with 5-FU.49 A dose-dependent 
synergic effect of 5-FU and DCA has been reported for colorectal cancer cells, for which DCA 
enhanced IC50 doses and 5-FU antiproliferational effects due to apoptosis induction through 
inactivation of cancer cells glycolysis, shifting the metabolism of pyruvate back to glucose 
oxidation in the mitochondria.48 However, the doses of DCA needed to achieve this effect are 
again quite high due to its poor cellular internalisation. 
 
Figure 5.7. DCA prodrugs designed to target mitochondria: compounds backboned with phosphonium 
or ammonium salts and tertiary amine scaffolds. 44 
Due to the high membrane potential across the mitochondrial inner membrane (negative 
inside), positively charged molecules, such as phosphonium or ammonium salts, are often 
used to target mitochondrial internalisation.50-52 Hence, DCA prodrugs, containing compounds 




backboned with phosphonium or ammonium salts and tertiary amine scaffolds (Figure 5.7), 
have been evaluated with the aim of developing DCA analogues with enhanced mitochondria 
targeting effects.44 The authors analysed the anticancer activity of the new DCA-loaded 
compounds, as well as the cytotoxicity of their non-loaded backbones, towards a panel of 
leukaemia cell lines, finding a 30 fold increase on its activity when attached to the amino 
scaffold, while the scaffold on its own was non-cytotoxic.44 
DCA was chosen as the object of the study due to the fact that its cytotoxic effect will only be 
observed if MOFs are able to deliver cargo into the cytosol and subsequently reach the 
mitochondria. This allows experimental confirmation that therapeutically active DCA-loaded 
MOF nanoparticles have been successfully internalised, and by specific endocytosis 
mechanisms that result in the DDS being localised in the cytosol rather than lysosomes. As 
such, DCA is an excellent mechanistic probe for the therapeutic efficiency and cellular 
internalisation of NMOFs, while its less problematic side-effects, together with the lower 
cancer cells resistance towards it, compared to other anticancer drugs, make it a potential 
therapeutic candidate if it can be efficiently delivered.  
5.2 Aims 
The ultimate aim of this Chapter is to find rationalisation between the surface chemistry, the 
endocytosis efficiency and routes of Zr MOFs and their therapeutic efficacy, with the ultimate 
goal of providing insights that might reduce early-stage animal testing by the design of suitable 
MOF structures for drug delivery applications for which their routes of internalisation and 
therapeutic efficacy could be predicted.  
From a chemical point of view, the lower pKa value (1.36) of dichloroacetic acid means 
considerable amounts can be attached to UiO-66 Zr positions at defect sites during synthesis 
as described during Chapter 2, even in the presence of other functionalised modulators. 
Additionally, this concept of defect loading of drugs that act as modulators in synthesis could 
be applied to any therapeutic molecule containing carboxylate groups, such as doxorubicin.  
The therapeutic efficacy of the UiO family of isoreticular DCA@MOFs, whose syntheses were 
described during Chapter 2, to deliver the anticancer metabolic target DCA will studied in 
MCF-7 breast cancer cells in order to gain insights into the effect of both particle size and 
surface chemistry on therapeutic activity. As such, the bigger DCA@UiO-66 derivate MOFs 
(ca. 100 nm) will be compared with DCA@DUT-52 and DCA@UiO-67 due to their similar size. 
Later, the cytotoxicity of the bigger DCA@UiO-66 derivate MOFs will be compared with their 
smaller analogues (< 20 nm), to investigate if these small nanoparticles can be internalised 




by passive diffusion, thus avoiding lysosome storage and reaching the cytosol in a more 
effective manner.53, 54 
On the one hand the DCA@UiO-66 derivative MOFs possess different pendant functional 
groups in their linkers, and consequently different surface chemistry. On the other hand 
DCA@DUT-52 and DCA@UiO-67 linkers are more hydrophobic, enabling the determination 
of hydrophobicity on anti-cancer therapeutic efficacy. Importantly, the endocytosis routes of 
this family of MOFs have been reported, and while the UiO-66 derivatives are mainly 
internalised through clathrin-mediated endocytosisis, the caveolae-mediated endocytosis 
plays a more important role on the internalisation of DUT-52 and UiO-67.  
Since it has been shown during Chapter 2 that introducing DCA during synthesis as a 
modulator results in highly porous MOFs,55 whose porosity can be used to store a second 
drug (in this case 5-FU),56 the ability of the smaller Zr-terephthalate derivate MOFs and the 
bigger DUT-52 and UiO-67 MOFs to delivery two drugs (DCA and 5-FU) in tandem will also 
be investigated during this chapter and compared to the anticancer effect of both free drugs 
separately and incubated together with MCF-7 cells to determine if there could be a synergic 
effect on the co-delivery of 5-FU and DCA.48, 49 
The postsynthetic surface modification protocols detailed during Chapter 355, 57 will be applied 
to the DCA@UiO-66 MOFs synthesised by coordination modulation during Chapter 2 in order 
to investigate the anti-cancer therapeutic activity depending on the MOF surface coating (Folic 
acid, Biotin, Heparin, PEG, Poly-L-Lactide and PNIPAM). Hence, the cytotoxicity of empty and 
loaded bare and surface functionalised UiO-66 will be investigated at first using the HeLa 
cervical cancer cell line, for which the endocytosis efficacy and routes of these calcein-loaded 
MOFs was investigated during Chapter 4, aiming to find a correlation between their surface 
chemistry, endocytosis fate and routes, and final therapeutic effect. 
The most promising surface functionalised candidates will be then tested against a series of 
both cancerous and healthy cells lines to assess their anti-cancer selectivity and possibly side 
effects towards healthy cells. Evaluation of the in vitro immune response towards these MOFs 
will be also investigated, including uptake, cytotoxicity and reactive oxygen species 
production, using both macrophages and lymphocytes isolated from the blood of human 
donors, which might provide a possible idea of their in vivo performance without animal testing. 
  




5.3 Therapeutic Efficiency of the DCA@UiO family 
The therapeutic efficacy of the DCA@MOFs of the UiO family of different particle sizes, 
described during Chapter 2, is studied towards MCF-7 breast cancer cells in order to find 
insights into the effect of both particle size and surface chemistry. The particle size, 
determined by SEM, and the DCA content, determined by TGA, of the different MOFs are 
given in Table 5.2. Additionally, as the small DCA@UiO-66 derivatives, as well as DCA@DUT-
52 and DCA@UiO-67, were postsynthetically loaded with 5-FU, the 5-FU loadings, 
determined by UV-Vis, together with the DCA content after 5-FU loading, determined by TGA, 
are also given in Table 5.2 
Table 5.2. Particle size and DCA content of the DCA@MOFs of the UiO family.  
Sample Size / nm % DCA w/w a % 5-FU 
DCA@UiO-66  77 ± 24 17.2  
DCA@UiO-66-Br  131 ± 30 16.7  
DCA@UiO-66-NO2  121 ± 27 16.2  
DCA@UiO-66-NH2  81 ± 26 16.9  
DCA@UiO-66 small 12.8 ± 3.6 26.2 (22.3) 1.9 
DCA@UiO-66-Br small 30.2 ± 7.9 19.3 (13.1) 3.8 
DCA@UiO-66-NO2 small 21.7 ± 5.3 21.5 (8.7) 4.3 
DCA@UiO-66-NH2 small 12.5 ± 2.9 26.4 (12.6) 2.4 
DCA@DUT-52 232 ± 30 14.1 (15.5) 1.5 
DCA@UiO-67 196 ± 32 6.6 (7.1) 2.5 
 
A DCA loadings in brackets correspond to the DCA content after 5-FU loading 
 
5.3.1 Therapeutic Efficiency of DCA@MOFs 
The cytotoxicity of the DCA@MOFs of the UiO family, described during Chapter 2, and free 
DCA (in the form of sodium dichloroacetate, NaDCA) was measured against MCF-7 breast 
carcinoma cells using the MTS assay.  
The MTS assay for NaDCA is shown in Figure 5.8, and confirms that DCA has little effect on 
cell proliferation. A dose-responsive cytotoxicity is evident, but only at very high 
concentrations, with 40.6 ± 18.2% viability after incubation with 9 mgmL-1 of NaDCA, in great 
agreement with literature reports. The maximum dose of DCA delivered by the DCA@MOFs 
will be 0.264 mgmL-1 when cells are incubated with a solution of 1mgmL-1 of DCA@UiO-66-




NH2 small, which has a DCA loading of 26.4% w/w. After incubation with 0.5 mgmL-1 NaDCA, 
the viability of MCF-7 cells is 99.9 ± 26.0%, and it has been previously reported that the empty 
MOFs are none toxic,3, 4 thus, any cytotoxicity comes from enhanced delivery of DCA into the 




Figure 5.8. Viability, as measured by MTS proliferation assay, of MCF-7 cells when incubated with 
different concentrations of sodium dichloroacetate for 72 h. Error bars represent the standard deviation 
from triplicate experiments. 
To examine the effect of ligand functionality and hydrophobicity the cytotoxicities of the larger 
DCA-containing terephthalate derivatives (ca. 70-130 nm) were compared with DCA@DUT-
52 and DCA@UiO-67 (ca. 200 nm), and plotted against MOF concentration (Figure 5.9) and 
DCA concentration (Figure 5.10). DCA@DUT-52 and DCA@UiO-67 are the most 
therapeutically active, decreasing MCF-7 viabilities to around 35% when delivering <0.1 
mgmL-1 of DCA. These results correlate well with the enhanced cytotoxicity towards HeLa 
cancer cells of UiO-67 when delivering the anti-cancer drug α-cyano-4-hydroxycinnamic 
acid,4, 15 likely as a consequence of the preference of DUT-52 and UiO-67 for caveolae-
mediated endocytosis promoting efficient cytosolic cargo release,15 rather than size, as empty 
analogous MOF samples of varying size were found to not be cytotoxic towards HeLa cells.4 
 




DCA@UiO-66, in contrast, shows no cytotoxicity towards MCF-7, likely due to clathrin-
mediated endocytosis leading to lysosome localisation.15, 58, 59 DCA@UiO-66-Br and 
DCA@UiO-66-NO2 only reduce proliferation to 61 ± 16% and 81 ± 15%, respectively, at the 
highest delivered DCA concentrations, while the enhanced therapeutic effect of DCA@ UiO-
66-NH2, with cell viabilities similar to DCA@DUT-52, could be a result of the positive surface 
charge of protonated amino units in the 2-amino terephthalate enhancing internalisation 
efficiency.60, 61 
 
Figure 5.9. Viability, as measured by MTS proliferation assay, of MCF-7 cells when incubated with 
different concentrations of the larger DCA@MOF nanoparticles for 72 h. Error bars represent the 
standard deviation from triplicate experiments. 





Figure 5.10. Viability, as measured by MTS proliferation assay, of MCF-7 cells when incubated with 
different concentrations of the larger DCA@MOF nanoparticles for 72 h, based on the DCA 
concentrations reached by their respective loadings. Error bars represent the standard deviation from 
triplicate experiments. 
The effect of particle size was assessed by comparing the cytotoxicities of the DCA@UiO-66 
small derivatives (~20 nm) towards MCF-7 cells with their larger analogues (~100 nm). Figure 
5.11 shows a comparison of MCF-7 cell proliferation on incubation with the small and large 
terephthalate MOFs, plotted against MOF concentration, and the analogous chart plotted 
against DCA concentration is given in Figure 5.12.  
Generally the smaller nanoparticles showed enhanced cytotoxicity when plotted against DCA 
concentration, suggesting enhanced internalisation and cell uptake by passive diffusion 
resulting in cytosolic release.54 Figure 5.12 shows the more pronounced cytotoxicity of 
DCA@UiO-66-NO2 small compared to its larger analogue, which shows no appreciable 
deleterious effects, with similar trends observed for DCA@UiO-66small and DCA@UiO-66-
Brsmall. Only DCA@UiO-66-NH2 small (ca 13 nm) was less efficient than its larger analogue 
DCA@UiO-66-NH2 (ca 86 nm), but both samples still reduced cell proliferation, again likely 
due to their surfaces having significant positive charge.60, 61 





Figure 5.11. Comparison of the viability, as measured by MTS proliferation assay, of MCF-7 cells when 
incubated with different concentrations of the DCA-loaded terephthalate MOF nanoparticles of different 
sizes for 72 h. Error bars represent the standard deviation from triplicate experiments. 
 
Figure 5.12. Comparison of the viability, as measured by MTS proliferation assay, of MCF-7 cells when 
incubated with different concentrations of the DCA-loaded terephthalate MOF nanoparticles of different 
sizes for 72 h, plotted against DCA concentration of the DDSs rather than MOF concentration. Error 
bars represent the standard deviation from triplicate experiments. 




It has been reported that the functionalised UiO-66 derivative MOFs are mainly internalised 
through clathrin-mediated endocytosis by HeLa cervix cancer cells, and hence stored in the 
lysosomes, which hinders their ability to release their cargo into the cytosol.15 These results 
indicate that although surface chemistry plays a more important role than particle size, the 
therapeutic activity of the MOFs can be enhanced by particle size reduction, possibly as a 
consequence of partial internalisation through passive diffusion, enabling the smaller MOFs 
to directly reach the cancer cells cytosol, and releasing their cargo in a more effective manner.  
 
5.3.2. Therapeutic Efficiency of 5-FU@DCA@MOFs 
5-FU acts as a thymidylate synthase (TS) inhibitor, and thus needs to reach the nucleus of 
cancer cells to be effective,62 while DCA inhibits pyruvate kinase and hence acts in the 
mitochondria.38 As such, the efficacy of both drugs depends on localisation in the cytosol after 
uptake, and so successful delivery of both drugs into the cytosol of cancer cells by one DDS 
may result in enhancement of therapeutic activity.  
Importantly, although 5-FU is a well-known and used anticancer therapeutic, its cytotoxic 
effects are an issue to many patients, gastrointestinal toxicity being one of the most commonly 
observed side effects. Hence, dosing is often limited by safety, while its activity is moderate 
at low doses.62 Additionally, many cancer cells are developing resistance towards 5-FU, which 
is itself problematic.63, 64 Although it has been reported that DCA enhances 5-FU activity 
through a dose-dependent synergistic effect, the DCA doses needed to induce this effect are 
still considerably high.48, 49 
The MTS cell viability assays for MCF-7 cells incubated with 5-FU@DCA@MOFs, whose 
syntheses are described during Chapter 2, were performed following the same protocol as for 
the DCA@MOFs, in parallel to enable better comparison of the cytotoxic results. Additionally, 
the MTS assay was carried out against free 5-FU to determine its therapeutic efficiency, also 
in parallel. The results are plotted in Figure 5.13a against MOF concentration and compared 
to their precursor DCA@MOF, and in Figure 5.13b against 5-FU concentration and compared 
to the free drug.  
Free 5-FU has significant cytotoxicity under these conditions, presumably after uptake into the 
MCF-7 cells by passive diffusion. The 5-FU loadings in the 5-FU@DCA@MOFs mean that 
individual MTS assay experiments under the same conditions and MOF concentrations as in 
the Section 5.3.1 will result in delivery of very low quantities of 5-FU (see Figure 5.13b). The 
5-FU concentrations achieved by the 5-FU@DCA@MOFs dispersed in growth media are in 




the range of non-cytotoxic and cytotoxic free 5-FU concentrations, which allows determination 
of any enhancement in cytotoxicity compared to free 5-FU.  
 
 
Figure 5.13. a) Comparison of MCF-7 cell proliferation on incubation with DCA@MOFs versus 5-
FU@DCA@MOFs. b) Comparison of activities of 5-FU@DCA@MOFs plotted against 5-FU 
concentration. Error bars represent the standard deviation from triplicate experiments. 
 




The enhanced cytotoxicity of all the 5-FU@DCA@MOFs towards MCF-7 cells compared to 
their DCA@MOF precursors, despite the decrease in DCA content determined after 5-FU 
loading, is clearly observed when cell proliferation is plotted against MOF concentration 
(Figure 5.13a) suggesting successful intracellular deliver of 5-FU. Of the smaller MOF species, 
5-FU@DCA@UiO-66small exhibits a more significant dose-response effect than its precursor, 
decreasing cell viability with concentration down to 21 ± 7% at 1 mgmL-1. The cytotoxicity of 
5-FU@DCA@UiO-66-Brsmall increases only slightly compared to its precursor, whereas 5-
FU@DCA@UiO-66-NO2small and 5-FU@DCA@UiO-66-NH2small have more notable 
enhancements, with cell viabilities of 19 ± 7% and 33 ± 8%, respectively, when MCF-7 cells 
were incubated with 0.5 mgmL-1 of the MOFs. The most effective of the DCA@MOFs, 
DCA@DUT-52 and DCA@UiO-67, also showed further enhancements in cytotoxicity towards 
MCF-7 cells when loaded with 5-FU; cell viability drastically decreases to values of 7 ± 6% 
and 4 ± 6% when cells were incubated with just 0.5 mgmL-1 of 5-FU@DCA@DUT-52 and 5-
FU@DCA@UiO-67, respectively.  
Free 5-FU itself also has significant dose-responsive cytotoxic behaviour (Figure 5.13b), with 
an IC50 of 0.015 ± 0.001 mgmL-1, but plotting cytotoxicity of the 5-FU@DCA@MOF samples 
against 5-FU concentration shows they have a greater effect than the free drug at lower 
concentrations, which might be a consequence of more efficient or faster internalisation, or a 
synergistic effect of DCA and 5-FU delivered in tandem, in great agreement with literature 
reports.48, 49 
At higher concentrations 5-FU@DCA@UiO-66small and 5-FU@DCA@UiO-66-NH2small 
continue to exhibit greater cytotoxic effects than the free drug, while 5-FU@DCA@UiO-66-
NO2small has no notable enhancement and 5-FU@DCA@UiO-66-Brsmall has a poorer 
performance than free 5-FU. Again, the larger samples, 5-FU@DCA@DUT-52 and 5-
FU@DCA@UiO-67 have the most pronounced cytotoxic effects, significantly enhancing the 
efficacy of free 5-FU and killing nearly all cells at all measured concentrations, suggesting that 
it is the surface chemistry of the MOFs that influences cellular uptake, and thus cytotoxicity, 
to a greater extent than particle size. 
Control experiments were carried out to assess the enhancement in cytotoxicity when 5-FU 
and DCA are delivered in a bimodal fashion by the Zr MOFs. MTS assays on a new batch of 
MCF-7 cells were carried out in the presence of (i) free 5-FU, (ii) free 5-FU spiked with 0.1 
mgmL-1 NaDCA, and (iii) free 5-FU spiked with 0.2 mgmL-1 NaDCA. The addition of NaDCA 
was designed to mimic the concentrations of DCA delivered by the 5-FU@DCA@MOFs; the 
results are shown in Figure 5.14, and are the same within experimental error, showing that no 
enhancement of 5-FU cytotoxicity occurs when administered with free DCA at the given doses, 




which is presumably a consequence of the fact that DCA cannot efficiently cross the cell 
membrane without a suitable DDS. 
 
Figure 5.14. Comparison of the viability, as measured by MTS proliferation assay, of MCF-7 cells when 
incubated with different concentrations of 5-fluoruracil, spiked with different concentrations of NaDCA, 
for 72 h. Error bars represent the standard deviation from triplicate experiments. 
Slightly different cytotoxicities of free 5-FU towards MCF-7 cells were observed at low 5-FU 
concentrations when compared to the data previously collected, presumably as a 
consequence of these additional MTS assays being carried out on a completely new batch of 
MCF-7 cells. When the average cell proliferation values from these two independent MTS 
assays are plotted against the cell proliferation values previously determined for the 5-
FU@DCA@MOFs (Figure 5.15), the trends showed in Figure 5.13b are still evident, and the 
conclusions and hypotheses made do not change. These experiments show that, when 
comparing absolute values from MTS cell proliferation assays, it is important to collect data 
from assays run concurrently on the same batch of cells to ensure experimental error is 
reduced. The data presented in Figure 5.13 come from assays carried out on the same batch 
of cells in parallel, which should give a better comparison. 





Figure 5.15. Comparison of MTS cell proliferation assays of 5-FU@DCA@MOFs plotted against 5-FU 
concentration compared to a value for free 5-FU that is the average of two separate sets of assays 
carried out at different times on different batches of MCF-7. Error bars represent the standard deviation 
from triplicate experiments. 
The results show that although therapeutic efficiency can be enhanced by particle size 
reduction, possibly as a consequence of passive diffusion or higher internalisation fates, 
surface chemistry plays a more important role than particle size in therapeutic efficacy. This 
observation is in great agreement with reported endocytosis routes of internalisation,15, 58 
showing that DUT-52 and UiO-67, for which the caveolae-mediated route plays a more 
important role in their internalisation, are more therapeutically active than the terephthalate 
derivative MOFs, which are mainly internalised through clathrin-mediated endocytosis, and 
hence stored in the lysosomes before reaching their target.  
5.4. Postsynthetic Surface Functionalisation of DCA-Loaded Samples 
Since it has been proven during Section 5.3 that surface chemistry plays a more important 
role than particle size in MOFs therapeutic activity, DCA@UiO-66 was chosen as the object 
of further study of postsynthetic modifications in order to avoid surface chemistry variability 
due to functional groups present on its surface. The fact that DCA@UiO-66 has poor 
anticancer performance when its size is ca. 77 nm, not being therapeutically active, enables 
determination of therapeutic enhancement after postsynthetic surface modifications. 




Moreover, UiO-66 is amenable to functionalisation and it is the most porous MOF of the Zr-
terephthalate derivatives.  
During Chapter 2 the validity of the coordination modulation protocol to introduce a small 
molecule with high metabolic anticancer activity, dichloroacetate (DCA), as a modulator that 
is attached to UiO-66 metal nodes during synthesis was proven.55, 56 Importantly, the 
attachment of DCA throughout the MOF ensures it is not lost on postsynthetic modification.57 
Post-synthetic surface modifications (Figure 5.16) were performed under the same conditions 
as in Chapter 3 and in Chapter 4, and full characterisation proved the surface moieties 
attachment without major DCA leakage from the NMOF structure. 55, 57 
 
Figure 5.16. Synthesis of DCA-loaded, surface modified MOFs obtained through coordination 
modulation (CM), click modulation, and postsynthetic exchange (PS). 
Surface modification of DCA@UiO-66 by postsynthetic exchange was carried out with 
heparin, folic acid and biotin, while the click modulation protocol was used to attach the 
polymers to the surfaces of the modulated samples DCA@UiO-66-L1 and DCA@UiO-66-L2 
(Figure 5.16). The samples retained their crystallinity upon the postsynthetic surface 
modifications, as confirmed by PXRD. 
The 1H NMR spectra of digested samples of the postsynthetically modified DCA@UiO-66-FA 
(PS) and DCA@UiO-66-Biot (PS) showed high incorporation of both surface reagents. 
Through analysis of the 1H NMR spectrum of acid-digested DCA@UiO-66-FA (PS) (Figure 
5.17), the DCA content in the sample was estimated to be 25.9 mol % compared to bdc, 
slightly lower than the precursor sample DCA@UiO-66, for which a 35.2 mol % of DCA was 
estimated. Interestingly, even though the amount of washes after the postsynthetic 
modification was considerable, a 24.5% molar ratio of folic acid to bdc was found, while the 
mass quantity of folic acid determined by UV-Vis spectroscopy was 17.9% w/w. 





Figure 5.17.1H NMR spectrum of DCA@UiO-66-FA (PS) digested in D2SO4 / DMSO-d6 (top) compared 
to the spectrum of folic acid. 
A similar phenomenon occurs in the case of DCA@UiO-66-Biot (PS), where DCA content 
decreased upon biotin coating, from 35.2% to 19.0% molar ratio, suggesting DCA on the 
surfaces of the MOFs can be exchanged (Figure 5.18), and that due to the high defectivity of 
the DCA@MOFs, more metal nodes could be exposed and hence the coordination of the 
surface reagents is higher than in Chapter 3.  
 
Figure 5.18.1H NMR spectrum of DCA@UiO-66-Biot (PS) digested in D2SO4 / DMSO-d6 (top) 
compared to the spectrum of biotin. 




1H NMR spectra of digests of the samples containing polymers (DCA@UiO-66-Hep (PS), 
DCA@UiO-66-L1-PEG2000, DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM) 
were complex and did not give useful information about the surface moieties, but showed the 
presence of resonances for the polymers. 
Thermogravimetric analysis of the postsynthetically coated, DCA-loaded samples confirmed 
the presence of DCA and of the surface reagents. The TGA profile of DCA@UiO-66-FA (PS) 
profile shows a more gradual degradation profile than its precursor and a lower metal content, 
consistent with the high incorporation of folic acid observed by 1H NMR spectroscopy. In the 
case of DCA@UiO-66-Biot (PS), again a higher amount of organic matter is present in the 
structure compared to its precursor, and the decomposition step attributed to DCA starts at a 
slightly higher temperature and in a more gradual manner, presumably as a consequence of 
the decomposition of biotin molecules coating the surface. As the major heparin 
decomposition step occurs at a similar temperature to DCA, for DCA@UiO-66-Hep (PS) the 
DCA content cannot be accurately determined by TGA (Figure 5.19). 
 
Figure 5.19. TGA profiles of DCA-loaded, surface modified MOFs compared to the empty modified 
MOF and DCA@UiO-66 for a) DCA@UiO-66-FA (PS), b) DCA@UiO-66-Biot (PS), and c) DCA@UiO-
66-Hep (PS). 




While TGA analysis confirmed the presence of the PEG functionality in DCA-UiO-66-L1-
PEG2000, the mass loss events for DCA and the PEG chains occurred simultaneously (Figure 
5.20a), precluding calculation of DCA loading, and so the ICP-MS methodology was used. 
In agreement with previous covalent surface modifications performed during Chapter 3, 
DCA@UiO-66-L1-PolyLact exhibits a lower thermal stability than its precursor DCA@UiO-66-
L1, as confirmed by its TGA profile (Figure 5.20b). A similar DCA decomposition step, 
although at a slightly higher temperature, is observed after the surface modification, while the 
metal residue is slightly higher than the precursor, possibly due to partial DCA detachment 
during the postsynthetic modification or solvent trapped in the precursor. In the same way, the 
structure of DCA@UiO-66-L2-PNIPAM is less thermally stable, with a slightly higher metal 
residue, than its precursor (Figure 5.20c). 
 
Figure 5.20. TGA profiles of DCA-loaded, click modulated MOFs compared to the empty modified MOF 
and the DCA-loaded precursor for a) DCA@UiO-66-L1-PEG2000 b) DCA@UiO-66-L1-PolyLact, and 
c) DCA@UiO-66-L2-PNIPAM.  




TGA clearly shows the presence of DCA in all the materials, and analysis of the traces allowed 
estimation of DCA content for all samples except DCA@UiO-66-Hep (PS), DCA@UiO-66-L1-
PEG2000 and DCA@UiO-66-L2-PNIPAM, as DCA decomposition coincided with other mass 
loss events. The values correlate well with those measured by inductively coupled plasma 
mass spectrometry (ICP-MS) determination of chloride content (Table 5.2). A gradual 
decrease in DCA loading occurring as the mass of the surface functionality increased was 
observed, as would be expected. The TGA values are likely slightly higher due to other mass 
loss events occurring alongside the DCA thermal decomposition. 
SEM images of the samples showed an increase in size of all nanoparticles after surface 
functionalisation, but all were in the appropriate size range for drug delivery.55, 57 The particle 
size distributions are presented in Table 5.2. 
Additionally, the DCA loading and particle size of the co-modulated samples with DCA and 
either folic acid or biotin, which syntheses and characterisation was described during Chapter 
2, are also given in Table 5.2, as their therapeutic efficacy will also be studied and compared 
with the postsynthetically modified samples during this chapter. 
Table 5.2. Particle sizes, determined by SEM, and DCA loadings, determined independently by TGA 
and ICP-MS, of the surface modified MOFs and their precursors.  








DCA@UiO-66 77 ± 24 17.0 16.9 
DCA@UiO-66-L1 100 ± 15 15.9 15.5 
DCA@UiO-66-L2 77 ± 11 18.7 18.9 
DCA@UiO-66-L1-PEG2000 130 ± 29 n/aa 12.1 
DCA@UiO-66-L1-PolyLact 138 ± 27 9.0 7.6 
DCA@UiO-66-L2-PNIPAM 159 ± 21 n/aa 3.2 
DCA@UiO-66-FA (PS) 146 ± 38 15.8 13.3 
DCA@UiO-66-Biot (PS) 130 ± 33 15.6 9.4 
DCA@UiO-66-Hep (PS) 133 ± 33 n/aa 5.1 
DCA10@UiO-66-FA0.25 (CM) 158 ± 23 19.6 18.9 
DCA5@UiO-66-FA1 (CM) 91 ± 29 12.1 11.8 
DCA@UiO-66-Biot (CM) 166 ± 22 19.0 20.7 
 
aCould not be calculated due to overlapping thermal decomposition events. 




5.5. Therapeutic efficacy of DCA-Loaded, Surface Modified UiO-66 
To investigate the consequences of surface coating on the therapeutic efficacy of the surface 
functionalised NMOFs (synthetized either through coordination modulation, detailed in 
Chapter 2, or through postsynthetic modification, described during this Chapter) the 
cytotoxicity of the materials against three different cell lines – HeLa (cervical cancer), MCF-7 
(breast carcinoma) and HEK293 (healthy kidney) – was analysed by the MTS assay.  
5.5.1 MOFs Cytotoxicity Towards HeLa Cervix Cancer Cells 
At first, the cytotoxicity of the modulators L1 and L2 was investigated using the MTS assay. 
UiO-66 itself, and its components, have previously been found to be non-toxic using this 
methodology.3, 4 No decrease in cell viability was observed up to 1 mgmL-1 concentration of 
either of the modulators (Figure 5.21), confirming that they are non-toxic towards HeLa cells.  
 
Figure 5.21. Metabolic activity of HeLa cells after 72 h of exposure to L1 and L2, measured by MTS 
assay. Error bars represent the standard deviation from five experiments. 
Then, HeLa cells proliferation when incubated with the empty surface functionalised NMOFs, 
synthesised and characterised either during Chapter 2 (CM) or during Chapter 3 (PS), for 72 
h was investigated, finding that only UiO-66-L2-PNIPAM was cytotoxic for concentrations 
above 0.25 mgmL-1, while incubation with other coated UiO-66 samples enhanced HeLa cells 
proliferation with a dose-response pattern, presumably as a consequence of the incorporation 
of the NMOFs’ organic components into their metabolic cycle (Figure 5.22).  
 





Figure 5.22. Viability, as measured by MTS assay, of HeLa cells incubated with different concentrations 
of empty, surface modified MOFs for 72 h. Error bars represent the standard deviation from five 
experiments. 
Once the cytotoxicity of the empty samples was assessed, proving their validity as carriers, 
their therapeutic effect when loaded with DCA was analysed. DCA containing folic acid 
surface-functionalised materials, either introduced during synthesis using the coordination 
modulation protocol, or postsynthetically using coordination chemistry, were incubated with 
HeLa cells for 24 and 72 h. 
Folic acid has high binding affinity for folate receptor (FR) proteins – 
glycosylphosphatidylinositol anchored cell surface receptors – which are known to be over 
expressed on the cell membrane of most cancerous cells.20-22, 65 Folic acid is involved in 
nucleotide synthesis and in the metabolic maintenance of 1C-pathways in all living cells,66 
while its high binding affinity for FR has been widely used for targeting drug delivery, to 
enhance FR-mediated endocytosis.22, 65, 67-71 However, the level of expression of FR in healthy 
cells is minimal when compared to malignant cells, such as ovarian endometrial, lung, cervical, 
breast, colorectal, kidney, and brain carcinomas among others, although FR is also 
overexpressed in activated macrophages.72, 73 
Although unfunctionalised DCA@UiO-66 does not decrease HeLa cell proliferation (128 ± 5% 
cell viability at a concentration of 1 mgmL-1 after 72 hours of incubation), likely as a 




consequence of inefficient cytosolic release after clathrin-mediated internalisation,15 after 24 
h of incubation (Figure 5.23a), only the NMOFs synthesised using the coordination modulation 
protocol start to induce cytotoxicity. On the other hand, for 72 h of incubation (Figure 5.23b), 
all the DCA folic acid coated NMOFs exhibit some degree of cytotoxicity, and once again the 
postsynthetically modified sample is less therapeutically efficient, with 74 ± 4% cell viability at 
a NMOF concentration of 1 mgmL-1. Between the two samples synthesised by the one-pot 
coordination modulation protocol, the one with higher folic acid content, DCA5@UiO-66-FA1 
(CM), rather than the highest DCA content DCA10@UiO-66-FA0.25 (CM), is more efficient, 
killing 85 ± 3% of the cells at concentrations of 0.25 mgmL-1 and killing all cells when incubated 
with 1 mgmL-1 of NMOF in growth media. DCA10@UiO-66-FA0.25 (CM) starts to reduce cell 
proliferation at 0.75 mgmL-1 (85 ± 3% cell viability) and only kills 52 ± 5% of cells at 1 mgmL-
1, despite containing more DCA (~19% w/w) than DCA5@UiO-66-FA1 (CM) (~12% w/w). 
Clearly the mode of external surface attachment of folate is key to therapeutic activity: the 
most cytotoxic folate-coated MOF has the lowest drug content. The enhanced cytotoxicity may 
be due to folate coating enhancing endocytosis efficiency possibly due to the extra amount 
being internalised by FR-mediated endocytosis, and promoting caveolae-mediated 
endocytosis,22, 69 as described during Chapter 4 for the calcein-loaded folic acid-coated MOF. 
These findings highlight the importance and correlation of endocytosis efficiency and 
pathways with therapeutic efficiency.  
The postsynthetically coated MOF will have the bulk of the folic acid on the nanoparticle 
external surface, while the NMOFs prepared by coordination modulation may have folate 
throughout the nanoparticles in defect sites, enhancing the targeting properties even after the 
onset of degradation. Cytotoxicity of free NaDCA towards HeLa was later found to be 
negligible until cells were incubated with concentrations >4 mgmL-1 (Section 5.5.3) confirming 
that effective delivery of DCA into cells by the DDSs is occurring, with a greater than 300 fold 
enhancement in cytotoxicity compared to the free drug when DCA is transported into HeLa 
cells by DCA5@UiO-66-FA1 (CM). 
 
 





Figure 5.23. Cytotoxicities of empty and DCA-loaded folic acid coated MOFs against HeLa cells as 
measured by MTS assay after a) 24 h of incubation and b) 72 h of incubation. Error bars represent the 
standard deviation from five experiments. 
It has been reported that the uptake of unfunctionalised UiO-66 by HeLa cells does not 
remarkably vary when size is the only variable.15 While the smaller size of DCA5@UiO-66-FA1 
(CM) might enhance its efficiency, it is postulated that the effect is minor, especially when we 
observe that DCA10@UiO-66-FA0.25 (CM) and DCA@UiO-66-FA (PS) have similar sizes 
(Section 5.4) and very different therapeutic effects. Additionally, it was proven than surface 
chemistry plays a more important role than particle size on anticancer therapeutic activity in 
related Zr MOFs during Section 5.3.56 It is likely that the postsynthetic (PS) coating is less 
stable than when folate is introduced during the synthetic process (CM), thus partially being 
released during the incubation time – as observed by SEM during Chapter 3 – therefore 
decreasing its efficiency. Free folic acid can bind to FR, and therefore decreases the 
availability of those receptors to bind to the folic acid coated NMOFs, decreasing their uptake 
efficiency.20, 22 
DCA@UiO-66-L1-PEG2000, which is also internalised through the caveolae-mediated route, 
is more toxic than the unfunctionalised DCA@UiO-66 derivatives after 72 hours of incubation 
(Figure 5.24), presumably because of enhanced lysosome-escaping capabilities59 and 
stability, although to a lesser extent than the targeted folic acid MOF. 





Figure 5.24. Cytotoxicities of DCA-loaded bare and PEGylated MOFs against HeLa cells as measured 
by MTS assay after 72 h of incubation. Error bars represent the standard deviation from five 
experiments. 
Interestingly, DCA@UiO-66-L1-PolyLact produced a similar effect on HeLa cell growth 
regardless of the incubation time (24 or 72 hours), which could be indicative of its significant 
internalisation by energy-independent endocytosis,1 determined during Chapter 4, while 
empty UiO-66-L1-PolyLact did not show any toxicity. Inhibition of cell growth starts to be 
observed when incubated with 0.75 mgmL-1 of DCA-loaded MOF for 24 h or 72 h (85 ± 3% 
cell viability), while it kills almost all HeLa cells at 1 mgmL-1 (Figure 5.25a). 
Although the empty UiO-66-L2-PNIPAM was already found to be cytotoxic at concentrations 
of 0.5 mgmL-1 and above, DCA loading enhanced its cytotoxic effects, with DCA@UiO-66-L2-
PNIPAM killing all HeLa cells at the NMOF concentration of 0.25 mgmL-1 (Figure 5.25b). These 
MOFs undergo HeLa cells internalisation primarily through non-mediated endocytosis, in 
contrast to the unfunctionalised MOFs, which are mainly internalised through clathrin-
mediated endocytosis. 





Figure 5.25. Cytotoxicities against HeLa cells as measured by MTS assay, for a) empty and DCA-
loaded UiO-66-L1-PolyLact, and b) empty and DCA-loaded UiO-66-L2-PNIPAM. Error bars represent 
the standard deviation from five experiments. 
In concert with the fact that the biotin-coated sample is the least efficiently internalised NMOF 
with almost no active transport, DCA@UiO-66-Biot samples (both prepared by coordination 
modulation and postsynthetically) do not exhibit any cytotoxicity for 72 h of incubation in any 
of the cases (Figure 5.26).  
 
Figure 5.26. HeLa cytotoxicity of empty and DCA-loaded heparin and biotin modified samples. Error 
bars represent the standard deviation from five experiments. 
 




In contrast to folate coated and PEGylated NMOFs, although it was observed that the 
caveolae-mediated endocytosis is enhanced after heparin coating when compared to naked 
UiO-66, DCA@UiO-66-Hep (PS) also does not exhibit any cytotoxicity towards HeLa cells 
even after of 72 h of incubation. UiO-66-Hep (PS) showed undesirable degradation kinetics 
and colloidal stability when compared to UiO-66-L1 precursor samples, as described during 
Chapter 3, and so may not be suitably stable. Additionally, heparin is known to bind to several 
growth factors, and can activate their signalling cascades.74-76 For example, the growth of 
three different colon cancer cell lines has been reported to be stimulated upon heparin 
addition,77 which could explain why no cytotoxicity is observed in this case. This underlines 
the importance of also studying other variables, such as the cell processes in which the 
surface coating, or even the NPs components, are involved.  
5.5.2. Cytotoxicity Against MCF-7 and HEK293 
Based on the cell viability results obtained using the HeLa cervical cancer cell line, it was 
decided to further investigate the in vitro anticancer selectivity of the most effective NMOFs 
against other cell lines. The cytotoxicities of DCA5@UiO-66-FA1, DCA@UiO-66-L1-PEG2000, 
DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM were measured against the breast 
carcinoma cell line MCF-7 using the MTS assay, and compared with DCA@UiO-66. Following 
the protocol detailed for HeLa cells, cells were incubated with different concentrations of the 
NMOFs for 72 h, with three replicates for each concentration (n = 3). In order to study the 
effect of the therapeutically active materials in non-cancerous cells, cell proliferation was also 
studied in human embryonic kidney cells (HEK293) in parallel following the former MTS 
protocol. The incubation time was 72 h, with n = 3. Ideally, in order to be an efficient therapeutic 
agent, the DCA@NMOFs should not significantly decrease healthy cell proliferation. Since 
DCA reprograms the mitochondria of cancer cells to normal functions and restores their 
apoptosis, it may be expected that there shouldn’t be an effect in healthy cells.37, 38, 40 
It was noted that the results had large errors, and it was thought that washing away excess 
MOF with PBS after incubation may have been washing away cells that were not well adhered 
to the plate. To investigate this, the experiments were repeated with only one PBS wash to 
remove excess MOF after the 72 h incubation stage of the MTS protocol and the results 
compared in Figures 5.27 and 5.28. 
Comparing the results obtained for each cell line by both MTS methodologies, one can 
observe that in general smaller errors are obtained when the number of PBS washes is 
reduced and the cell proliferation is higher, which indeed suggests that cells are being washed 
away during the PBS washing stage, as controls in which empty wells are seeded with 




dispersions of MOF in growth media did not have a higher absorbance than controls with only 
media, meaning that MOF adherence to the plate was not giving false positive errors.  
In the case of MCF-7 it can be observed that similar cell proliferations levels were obtained 
for DCA@UiO-66 and DCA@UiO-66-L1-PolyLact. However, MCF-7 cell proliferation changed 
for the samples that were assessed as cytotoxic, DCA5@UiO-66-FA1 and DCA@UiO-66-L2-
PNIPAM, which were “less” cytotoxic when the number of washes was reduced. On the other 
hand, DCA@UiO-66-L1-PEG2000 cytotoxicity is slightly enhanced when MCF-7 cells are only 
washed once (Figure 5.27).  
 
Figure 5.27. Effect of PBS washing on cytotoxicity as measured by MTS assay for the DCA-loaded 
MOFs against MCF-7 cells. Error bars represent the standard deviation from triplicate experiments. 
A similar trend occurs for HEK293 cell proliferation, as generally smaller errors were obtained 
when reducing the number of PBS washes. Again, a larger difference between the values 
obtained from both approaches was found for DCA@UiO-66-L2-PNIPAM, especially at lower 
concentrations. For a concentration of 1 mgmL-1 of DCA@NMOFs the values obtained were 
very close for both methods, with slightly higher proliferations when the cells were washed 
only once, apart from DCA@UiO-66-L1-PEG2000, which was again more cytotoxic when cells 
were only being washed once (Figure 5.28). DCA@UiO-66 exhibits enhanced cell proliferation 
in general, particularly at higher concentrations.  





Figure 5.28. Effect of PBS washing on cytotoxicity as measured by MTS assay for the DCA-loaded 
MOFs against HEK293 cells. Error bars represent the standard deviation from triplicate experiments. 
In general it can be observed that the cell proliferation with both HEK293 and MCF7 cells 
when incubated with DCA@UiO-66 – which already enhanced cell proliferation when washing 
3 times – is slightly enhanced, and although it has the highest DCA content, no negative effect 
against MCF-and HEK293 cells was found, with 136 ± 4% and 212 ± 20% cell proliferation 
after 72 h of incubation with a solution of 1 mgmL-1 of MOF compared to untreated controls. 
As a general trend observed for all the experiments, no matter the number of washes, 
DCA@UiO-66-FA is not cytotoxic for healthy HEK293 cells while it is for cancerous MCF7 
cells, and DCA@UiO-66-L1-PolyLact has similar levels of cytotoxicity for both cell lines, which 
was slightly reduced with the second approach. It is clear that the values obtained with only 
one PBS wash are more representative of actual cytotoxicity for MCF-7 and HEK293, and so 
these are used for comparison with the HeLa cell data (Figure 5.29), in order to assess the 
selectivity of cytotoxicity. 





Figure 5.29. Cytotoxicities against HEK293, MCF-7, and HeLa cells assessed by MTS assay for a) 
DCA5@UiO-66-FA1 (CM), b) DCA@UiO-66-L1-PEG2000, c) DCA@UiO-66-L1-PolyLact, and d) 
DCA@UiO-66-L2-PNIPAM. Error bars represent the standard deviation from triplicate experiments. 
These results strongly indicate that DCA5@UiO-66-FA1 (CM) is the most efficient and safe 
drug delivery vehicle, especially when comparing the cell proliferation trends of the three 
different cell lines, FR(+) HeLa and MCF7,65 and FR(-) HEK293,20 highlighting the effective 
folic acid targeting strategy (Figure 5.29a). The dose-responsive curve towards MCF-7 cells 
showed a similar trend to the HeLa experiment, although with slightly lower efficacy; 71 ± 8% 
cell viability at a concentration of 0.5 mgmL-1 and 35 ± 8% for a concentration of 1 mgmL-1. 
More importantly, after 72 h of incubation with HEK293 cells, proliferation was not reduced in 
the presence of DCA5@UiO-66-FA1 (CM) at any concentration, with 107 ± 5% cell viability at 
the NMOF concentration of 1 mgmL-1 These results suggest that folate induces cancer cell-
targeting, as HeLa cells have a higher FR overexpression than MCF-7,65 and thus therapeutic 
efficacy in HeLa is more pronounced. On the other hand, HEK293 has been reported to have 
normal levels of expression of the FR,20 and thus no effect is observed on their cell proliferation 
possibly as a consequence of poor internalisation and/or a lack of metabolic effect of DCA on 




healthy cells. It is also important to consider that free dichloroacetate was not cytotoxic to 
either MCF-7 or HEK293 cells at the concentrations delivered by the NMOFs (Figure 5.30), 
confirming the efficient delivery of DCA into the cells by the MOF DDSs.  
In general, DCA@UiO-66-L1-PEG2000 does not exhibit any selectivity of cytotoxicity for 
higher concentrations, with similar cytotoxic values for the three cell lines (Figure 5.29b). 
DCA@UiO-66-L1-PEG2000 induced some cytotoxicity to MCF-7 cells, with a 32 ± 3% cell 
when cells were incubated with 1mgmL-1 of MOF, similar to the cell viability reported for HeLa 
cells (50 ± 3%) at the same concentration. However, some unwanted cytotoxicity of 
DCA@UiO-66-L1-PEG2000 was observed against HEK293 (42 ± 6% viability) at the highest 
concentration of 1 mgmL-1.  
Interestingly, DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM were less cytotoxic 
towards MCF-7 and HEK293 than HeLa cells (Figures 5.29c and 5.29d). DCA@UiO-66-L1-
PolyLact is only cytotoxic in cancer cells at higher concentrations, more significant for HeLa 
cells (6 ± 1% cell viability at 1 mgmL-1) than for MCF-7 cells (82 ± 8% cell viability at 1 mgmL-
1). However, cell proliferation in HEK293 cells is also reduced, although not significantly (85 ± 
16% cell viability at 1 mgmL-1). Therefore, if accumulated in the body during an in vivo 
treatment, it might induce healthy tissue damage. DCA@UiO-66-L2-PNIPAM, which already 
exhibits high cytotoxicity even empty in HeLa cells for concentrations of 0.50 mgmL-1 and 
higher, was remarkably less cytotoxic for MCF7 and HEK293 (cell viability 32 ± 8 % and 78 ± 
14 % when treated with 1 mgmL-1 of MOF respectively). Its use might be safe if in low 
concentrations, but cytotoxicity towards healthy HEK293 kidney cells for higher concentrations 
might be a concern. 
5.5.3. Cytotoxicity of Free Dichloroacetate 
The therapeutic effect of dichloroacetate alone against HeLa, MCF-7 and, HEK293 was also 
investigated by MTS assay, using the same protocol as for the DCA-loaded MOFs but 
incubating the cells with different concentrations of sodium dichloroacetate (NaDCA) for 72 h. 
The results (Figure 5.30) show that dichloroacetate does not induce significant toxicity when 
it is not loaded into a drug delivery vehicle. The results are similar for all cell lines, with IC50 
values around 9 mgmL-1. Even at the highest concentration of 1 mgmL-1 of DCA5@UiO-66-
FA1, only ~0.12 mgmL-1 of DCA is delivered and the result is the death of over 50% MCF-7 
cancer cells, while more than 85 % of HeLa cells die when incubated with only 0.25 mgmL-1 
of MOF (ca. 0.03 mgmL-1 of DCA). Thus, it is clear that encapsulation within the MOFs 
enhances cytotoxicity of DCA by a factor of >75 for MCF-7 cells and >350 for HeLa cells, 
considerably higher than for other DCA prodrugs, while no cytotoxicity is found towards 
HEK293 non-cancerous kidney cells. 







Figure 5.30. Cytotoxicity against HeLa, HEK293, and MCF-7 cell lines of sodium dichloroacetateate at 
a) low, and b) high concentrations of NaDCA. Error bars represent the standard deviation from triplicate 
experiments. 
It can also be observed, that the higher DCA loading is around 20 w/w %, and as such, when 
cells are incubated with 1 mgmL-1 of MOF (maximum dose), only a DCA concentration of ca. 
0.20 mgmL-1 is reached, which is non-cytotoxic towards any of the tested cell lines without the 
presence of a carrier. Hence, it is clear than incorporating DCA into MOFs as DDSs enhance 
its effect on cancer cells (with over a 50 fold increase for HeLa cells in all cases) when the 
appropriate coating is provided to the MOF surface, related with cellular internalisation efficacy 
and routes, as bare DCA@UiO-66 was non-cytotoxic towards any of the three cell lines.  
5.6. Immune System Response Towards Surface Modified UiO-66 
The immune response toward exogenous materials plays a crucial role in any treatment 
efficacy; DDSs will not be efficient if they are cleared out of the blood stream by macrophages, 
or if they stimulate/suppress immune response or induce tissue damage.78, 79 Macrophages 
uptake efficiency, cytotoxicity, and Reactive Oxygen Species (ROS) production by 
macrophages and peripheral blood lymphocytes (PBLs) are of importance when considering 
the efficiency of a drug vehicle, but only few studies have assessed these issues so far with 
MOFs.80-82 Importantly, they can provide further insights into possible treatment efficiency 
without resorting to early stage animal testing. As such, cytotoxicity of the NMOFs was 
assessed against the J774 mouse monocyte macrophage cell line and also human peripheral 
blood lymphocytes (PBLs) isolated from the blood of three donors. The generation of ROS by 




these cells in the presence of the MOFs was also assessed by the 2',7'-
dichlorodihydrofluorescein diacetate (H2DC-FDA) fluorescent probe. 
5.6.1. Endocytosis Efficiency Towards J774 Macrophage Cells 
Initially, the uptake of the calcein-loaded MOFs by the J774 macrophage cells was monitored 
by flow cytometry, to confirm that internalisation occurs and help rationalise any cytotoxicity. 
The ratio of the mean fluorescence intensity (MFI) between cells cultured with 0.25 mgmL-1 of 
MOFs and cultured with medium alone was analysed to determine the cells integrity and 
uptake ratio for each MOF in triplicate, normalised to cal@UiO-66-L1 to determine the effect 
of surface chemistry (Figure 5.31). 
Normalised cell fluorescence showed that only PEGylation decreases macrophage uptake, to 
levels of 80 ± 4% compared to cal@UiO-66-L1, which tallies well with observations that 
PEGylation of nanoparticles decreases macrophage recognition.83, 84 cal@UiO-66-FA (PS) 
was the most efficiently internalised NMOF, with values of 189 ± 15% – expected, as activated 
macrophages are known to overexpress the folate receptor72, 73 – followed by cal@UiO-66-
L2-PNIPAM with 176 ± 9% cell internalisation and cal@UiO-66-L1-PolyLact with 155 ± 7% 
macrophage uptake efficiency, correlating well with the endocytosis efficiency experiments on 
the MOFs entering HeLa cells, described during Chapter 4.  
 
 
Figure 5.31. Endocytosis efficiency (J774 cell line) of the surface-modified, calcein loaded MOFs 
normalised to cal@UiO-66-L1. Error bars represent the standard deviation from triplicate experiments. 




5.6.2. Cytotoxicity Against J774 and PBL Cells 
To measure cell proliferation in the macrophage cell line J744 or in PBLs isolated from the 
blood of donors, the cell proliferation kit I MTT (Roche), based on the cleavage of the 
tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, was used. 
J774 cells were incubated with nanoparticles (0.1, 0.25 and 0.5 mgmL-1) for 24 h. PBLs MTT 
assay was performed similarly but the incubation time with nanoparticles was 48 h, meaning 
that the final incubation time of MOFs with macrophages was 48 hours and with PBLs 72 
hours (See Section 5.8). Results were expressed as mean ± standard error of the mean of 
triplicates. The average of the absorbance obtained for each concentration of each 
nanoparticle was compared with untreated cells. 
In parallel, the cytotoxicity of empty surface-functionalised MOFs and DCA5@UiO-66-FA1, 
DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM was studied for both J774 
macrophages and PBLs. No cytotoxicity was observed when incubating J774 cells with either 
UiO-66-FA (CM) or DCA5@UiO-66-FA1 (CM), despite the fact that, in contrast to the folate 
receptor negative HEK293 healthy cell line, activated macrophages overexpress the folate 
receptor.72, 73 In fact, cell proliferation was slightly enhanced (128 ± 10% and 142 ± 11%, 
respectively) at a NMOF concentration of 0.5 mgmL-1 (Figure 5.32a). 
 
Figure 5.32. Cytotoxicity of empty and DCA-loaded UiO-66 samples against a) J774 macrophage cells 
and b) a pool of peripheral blood lymphocytes from three human donors. The key for part a) also applies 
in part b). Error bars represent the standard deviation from triplicate experiments. 
UiO-66-L1-PEG2000 and DCA@UiO-66-L1-PEG2000 materials decreased macrophages cell 
proliferation to levels of 54 ± 1% and 70 ± 2%, respectively, at 0.5 mgmL-1, showing that the 




DCA-containing anticancer MOF was more well tolerated at higher concentrations that the 
empty carrier. 
Cytotoxicity assays showed that UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM were well 
tolerated by J774 macrophages (both having 89 ± 1% cell viability at 0.5 mgmL-1), despite 
empty UiO-66-L2-PNIPAM having proven to be highly cytotoxic for HeLa cells. DCA@UiO-
66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM killed almost all cells, despite the reports that 
DCA does not affect healthy cells. Cell viability values of 27 ± 2% and 4 ± 4%, respectively, 
were induced by incubation with 0.5 mgmL-1 NMOF (Figure 5.32a). The results suggest that 
the surface functionalities, together with DCA, might have some synergistic effect on metabolic 
activity.  
As detailed in Section 5.1.2, DCA inhibits the pyruvate dehydrogenase kinase (PDK), which 
is overexpressed in cancer cells, shifting their metabolism from glycolysis back to glucose 
oxidation.25, 36, 38 High lactate levels are characteristic of metabolism through glycolysis, as 
PDK in cancer cells inhibits pyruvate dehydrogenase (PDH), the enzyme responsible for 
converting pyruvate to acetylCoA , which further enters the Krebs cycle in the mitochondria 
during glucose oxidation, and alternatively, pyruvate is transformed to lactate in the cytosol of 
cancer cells.32, 33 Hence, as lactate is covering the surface of DCA@UiO-66-L1-PolyLact, upon 
internalisation, higher lactate levels could be found in the cytosol of macrophages, and 
together with DCA induce unwanted cytotoxicity, as the empty UiO-66-L1-PolyLact was non-
cytotoxic. This hypothesis would however require further investigation.  
The peripheral blood lymphocyte cytotoxicity (PBLs) assays were performed with a pool of 
PBLs from three different human donors (Figure 5.32b). It is important to remark that PBLs, 
isolated from human donors, provide a way of in vitro analysis close to in vivo conditions 
without animal testing. Each NMOF concentration was incubated in triplicate (n = 3), and the 
experiment was performed twice to ensure reproducibility of the results (Figure 5.33). The 
results obtained in both independent studies showed similar cell proliferation trends when 
PBLs were incubated with the NMOFs in question, with DCA5@UiO-66-FA1 and DCA@UiO-
66-L1-PEG2000 being the only DCA-loaded MOFs not to negatively affect cell proliferation. 
 





Figure 5.33. Cell viabilities of PBLs in the presence of different concentrations of the surface modified 
MOFs with and without DCA. a) and b) are two replicates with two different pools of PBLs extracted 
from human blood at different times. Error bars represent the standard deviation from triplicate 
experiments. 
Incubation of PBLs with UiO-66-FA (CM) or DCA5@UiO-66-FA1 for 72 hours yielded similar 
results to when the same MOFs were incubated with J744 macrophages, obtaining enhanced, 
dose-responsive cell proliferation by MTT assay for two independent experiments (Figure 
5.33) which showed similar trends. Viabilities of 295 ± 24% and 199 ± 34% for empty UiO-66-
FA (CM) and 252 ± 28% and 146 ± 18% for DCA5@UiO-66-FA1 (CM) were found at 0.5 mgmL-
1 incubation. UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM, did not induce PBLs cell death at 
0.5 mgmL-1 (164 ± 59% and 134 ± 14% viability for the former; 138 ± 12% and 101 ± 41% 
viability for the latter), while incubation with DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-
PNIPAM under the same conditions reduced cell viability to values of 45 ± 11% and 17 ± 5% 
for the former, and 7 ± 2% and 3 ± 4% for the latter. These are major issues that may preclude 
the use of the DCA-containing polymer-coated samples in vivo. 
In contrast, UiO-66-L1-PEG2000 and DCA@UiO-66-L1-PEG2000 induced PBL cell 
proliferation from a single pool to levels of 116 ± 12% and 128 ± 21% compared to untreated 
cells at a concentration of 0.5 mgmL-1. Whilst the response of the J774 cells and the HEK293 
cells to DCA@UiO-66-L1-PEG2000 could be problematic, the selectivity of the cytotoxicity of 
folate targeted, DCA loaded, DCA5@UiO-66-FA1 (CM) nanoparticles is very promising, killing 
almost all cancer cells whilst not negatively affecting the proliferation of any healthy cells. 
5.6.3. Reactive Oxygen Species Generation in J774 and PBL Cells 
Reactive oxygen species (ROS) production was investigated to gain insights into the cytotoxic 
effects of the NMOFs and to assess induction of oxidative stress (Figure 5.34 and 5.35).85, 86 
J774 macrophage cells and PBLs were incubated with different doses of the NMOFs over 2 




h, followed by incubation with the intracellular fluorescent probe H2DC-FDA in order to track 
ROS production by flow cytometry. 
In agreement with the cell proliferation results obtained by MTT assay, DCA@UiO-66-L2-
PNIPAM induced the highest ROS production in J744 cells, with a 5.5 fold increase at a NMOF 
concentration of 0.5 mg mL-1 a possible reason for the significant cytotoxicity, while the non-
cytotoxic empty UiO-66-L2-PNIPAM only induced a 1.4 fold increase in ROS production at the 
same concentration. Whilst empty UiO-66-L1-PolyLact did not induce significant cytotoxicity 
in the J774 cell lines, higher ROS production was found when incubating macrophages with 
the empty sample (3.2 fold increase) compared to DCA@UiO-66-L1-PolyLact (1.9 fold 
increase), which is more cytotoxic. Similarly, incubating J774 macrophages with UiO-66-L1-
PEG2000 induced a slightly higher ROS production (2 fold increase) than incubation with 
DCA@UiO-66-L1-PEG2000 (1.5 fold increase) for the same concentration. UiO-66-FA (CM) 
did not induce significant ROS production, with a 1.2 fold increase when incubating 
macrophages with a 0.5 mgmL-1 concentration of NMOF, while DCA5@UiO-66-FA1 (CM) did 
induce ROS production with a 2.8 fold increase, although MTT assays showed cell 
proliferation was enhanced in all cases, suggesting that ROS production is not a major source 
of cytotoxicity for these particular MOFs (Figure 5.34). 
 
Figure 5.34. Reactive oxygen species generation by J774 macrophage cells in the presence of empty 
and DCA-loaded UiO-66 samples. 






Figure 5.35. Reactive oxygen species (ROS) generation in PBLs when incubated with surface modified 
MOFs. 
ROS production in PBLs was also monitored (Figure 5.35) with no discernible trends, although 
DCA5@UiO-66-FA1 was again well tolerated. These results suggest that while higher 
concentrations MOFs can induce some ROS production, it does not seem to result in 
cytotoxicity towards these healthy cells. It is also important to note that concentrations of DCA-
loaded NMOFs lower than 0.5 mgmL-1 did not induce considerable ROS production, despite 
being therapeutically active towards cancer cell lines. 
5.7 Conclusions 
During Chapter 2 it was shown that incorporation of DCA at defects sites during the modulated 
synthesis of Zr MOFs of UiO family offers (i) particle size control in the assembly of highly 
defective ~20 nm nanoparticles of hierarchically porous materials, (ii) high loading (15–25% 
w/w) of the anticancer probe molecule DCA, and (iii) porous MOFs into which further medicinal 
cargo (5-FU in this case) can be loaded. 
During this Chapter, the therapeutic activity of the UiO family of Zr-MOFs - including UiO-66 
(Zr-terephthalate) and its bromo, nitro and amino derivatives, DUT-52 (Zr-Naphthalene 
dicarboxylate) and UiO-67 (Zr-biphenyldicarboxylate) – which have been proven to be non-
cytotoxic when empty up to 1 mgmL-1,4 has been studied towards MFC-7 breast cancer cells, 
in order to rationalise their activity with their reported endocytosis routes of internalisation.15 
In this way, both particle size and surface chemistry were studied. 




On the whole, the smaller (~20 nm) DCA-terephthalate particles exhibit greater cytotoxicity 
towards MCF-7 cancer cells than their larger (~100 nm) analogues; possibly due to partial 
internalisation of the smaller MOFs through passive diffusion, which allows DCA release 
directly into the cytosol to enhance its therapeutic effects. However, the surface chemistry of 
the MOFs has a greater effect, with DCA@DUT-52 and DCA@UiO-67 being the most 
therapeutically efficient MOFs, despite their bigger size. These results are in agreement with 
a recent study on endocytosis mechanisms, which shows that the Zr-terephthalate MOFs are 
mainly internalised by clathrin-mediated endocytosis, hence being stored in the lysosomes 
before releasing their cargo, while the DUT-52 and UiO-67 are partially internalised through 
the caveolae-mediated route, hence being potentially able to escape the early endosome, 
releasing their cargo into the cytosol in a more effective manner. Here it is shown that although 
surface chemistry plays a more important role than particle size, possibly as a consequence 
of the cellular internalisation routes, an enhancement in therapeutic activity can be achieved 
by particle size reduction, potentially allowing the MOFs to partially undergo cellular 
internalisation by passive diffusion. When MTS data for MOFs of comparable size is plotted 
against the maximum DCA concentration delivered for each MOF concentration, it can be 
observed that the best DDS is UiO-67, followed by DUT-52, which has similar activity to UiO-
66-NH2, presumably due to its positively charged surface, which enhances cellular 
internalisation, followed by the bromo and nitro derivative, while unfunctionalised UiO-66 of 
ca.77 nm does not induce any cytotoxicity. 
Concurrent delivery of two drugs from the 5-FU@DCA@MOFs further enhances cytotoxicity 
compared to precursor DCA@MOFs and both free drugs. Delivery of multiple drugs from one 
DDS has the potential to overcome issues with resistance and poor efficacy, and is enabled 
by utilisation of different loading protocols; defect-loading of cargo into Zr MOFs during 
synthesis is possible for any carboxylic acid containing drug. 
Postsynthetic surface functionalisations, using folic acid, biotin, heparin, PEG, Poly-L-Lactide 
and PNIPAM, have been performed on DCA@UiO-66, and it has been proven to be also 
compatible with all the surface modification protocols during this chapter without mayor DCA 
leakage. Extensive in vitro studies of empty, and especially DCA-loaded materials, have 
shown that folic acid coated MOFs exhibit selective cytotoxicity towards HeLa (cervical) and 
MCF-7 (breast cancer) cells, without adversely affecting proliferation of healthy kidney 
(HEK293), macrophage (J774) and PBL cells, possibly due to the over expression of the folate 
receptor on the surfaces of cancer cells and a preference for desirable caveolae-mediated 
endocytosis. The method of folic acid coating is vital – incorporation of folic acid and DCA in 
a one-pot, modulated synthesis produced significantly more active MOFs than 
postsynthetically coating MOFs with folic acid. Hence, the therapeutic efficiency of free DCA 




was drastically improved, with a >350 fold increase in selective cytotoxicity observed when 
loaded into DCA5@UiO-66-FA1 (CM), while uncoated DCA@UiO-66 did not produce any 
negative effect on the various cell lines.  
The polymer-coated, DCA loaded MOFs prepared by click modulation also showed 
therapeutic potential, decreasing proliferation of the cancerous cell lines, but each had 
drawbacks. Both DCA@UiO-66-L1-PolyLact and DCA@UiO-66-L2-PNIPAM induced death in 
J774 macrophage cells and human lymphocytes – key components of the immune system – 
with the latter stimulating significant ROS production in J774 cells. While DCA@UiO-66-L1-
PEG2000 was tolerated well by the immune system cells, as would be expected, it induced 
some cytotoxicity in healthy kidney cells at high concentrations, suggesting in vivo 
accumulation in healthy tissue might induce damage. 
These results demonstrate the power of surface functionalisation and importance of cell 
internalisation pathways in the application of MOFs for drug delivery. The potential of 
DCA5@UiO-66-FA1 for use as a selective anticancer DDS for in vivo localised treatment is 
apparent, particularly given the use of the metabolic probe DCA as a modulator during 
synthesis resulting in a drug-loaded nanoparticle that is still porous and can be loaded with a 
second drug for synergistic multimodal therapy. The work also highlights the broad in vitro 
experimental toolkit available to provide information on cellular uptake, endocytosis 
mechanisms, immune response and cytotoxicity prior to any in vivo treatment, thus reducing 
the need for early stage animal testing and acting according to the three Rs: reduction, 
refinement and replacement.  
  






5.8.1. General Experimental Remarks 
Flow Cytometry (Immune System Response): Measurements were performed using BD 
FACS Canto II. The analysis was done using Infinicyt and Prism softwares (Instituto de 
Investigación Sanitaria Fundación Jiménez Díaz, Spain). 
 
5.8.2 DCA@UiO-66 Surface Modifications 
Postsynthetic Modifications of DCA Loaded MOFs 
Surface modification of DCA@UiO-66, DCA@UiO-66-L1 and DCA@UiO-66-L2 followed the 
previous protocols for surface ligand exchange and covalent modification reported in Chapter 
3, as per Figure 5.16. Surface modifications based on coordination chemistry were performed 
on DCA@UiO-66 (Folic acid, biotin and heparin), while surface modifications based on 
covalent chemistry were performed on DCA@UiO-66-L1 (Poly-L-Lactide and PEG) and on 
DCA@UiO-66-L2 (PNIPAM). 
5.8.3 In vitro Protocols  
5.8.3.1 Cell Culture  
HeLa cervical cancer cell line was maintained at 37 ºC with 5% CO2 in high rich glucose 
(4500 mg/L) Dulbecco's modified Eagle's Medium (DMEM) with phenol red supplemented with 
10% (v/v) Fetal Bovine Serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 
μg/mL streptomycin. This was named complete DMEM (cDMEM). The cells were passaged 
three times a week (at 75-80% of confluence) at a density of 2.8 x 104 cell/cm2. (University of 
Cambridge) 
MCF-7 breast cancer cells and HEK293 human embryonic kidney cells were maintained 
at 37 ºC with 5% CO2 in high rich glucose (4500 mgL-1) Dulbecco's modified Eagle's Medium 
(DMEM) with phenol red supplemented with 10% (v/v) Fetal Bovine Serum (FBS), 2 mM L-
glutamine, 100 unitsmL-1 penicillin and 100 μgmL-1 streptomycin. This was named complete 
DMEM (cDMEM). The cells were passaged once or twice a week (at 75-80% of confluence) 
at a density of 2.8 x 104 cell/cm2. (University of Glasgow) 
J774 mouse monocyte-macrophage cell line was cultured in RMPI-1640 medium 
supplemented with 0.1 mM nonessential amino acids, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 10 mM HEPES, 2 mM L-glutamine, and 10% (v/v) fetal bovine serum and 




passaged twice a week (at 75-80% of confluence) at a density of 2.8 x 104 cellcm-2. (Fundación 
Jiménez Díaz, Spain) 
Human peripheral blood lymphocytes (PBLs) were isolated by gradient centrifugation on 
Lympoprep from the blood of three donors. After washes in RPMI 1640, the PBMCs were 
resuspended in completed RPMI supplemented as described above and were employed to 
analyze reactive oxygen species and for MTT assays. The culture cells were maintained at 
37 ºC in a 5% CO2 atmosphere. (Fundación Jiménez Díaz, Spain) 
5.8.3.2. Cytotoxicity essays 
MTS 
The day before the experiment, cells were seeded into a 96 well plate at a density of 10 x 103 
cells per well (100 µL). Prior to the treatments, cells were washed twice with PBS twice. The 
MOFs were suspended in cDMEM by sonication at different concentrations, added to the cells 
and incubated – with 5 or 3 replicates for each MOF concentration and 8 replicates for media 
without cells and for untreated cells – for 24 h or 72 h at 37 ºC with 5% CO2. To measure the 
toxicity, the cells were washed three times or one time with phosphate buffered saline (PBS), 
the media was replaced with 100 μL of fresh culture media containing 20 μL of 
MTS/phenazinemethosulfate (in a proportion 20:1) solution, and the plate was incubated for 
1 h at 37 ºC with 5% CO2. The plates were read at 490 nm by UV/vis spectrophotometry. 
MTT  
J774 cells at 4 x 104 (100 µl) and 1 x 105 PBLs (100 µl) were cultured with different doses of 
NMOFs previously suspended in RPMI 1640 complete medium. J774 cells were incubated 
with nanoparticles for 24 h and PBLs for 48 hours. After that, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) reagent (10 µl) per well was added. After 4 h of incubation 
in 5% CO2 at 37 ºC with MTT reagent, 100 µl of MTT solubilisation buffer were added, followed 
by overnight incubation. Finally absorbance (λ = 570 nm) was measured in a TECAN Infinite 
F200.  
5.8.3.3 Macrophage Uptake 
5 x 105 J774 cells per well were cultured with the different cal@NMOFs at 0.25 mgmL-1 
concentration for 2 h in 5% CO2 and 37 ºC. Cells were recollected, washed with PBS and 
resuspended in FACS Flow and analysed by flow cytometry. 
5.8.3.4 Reactive Oxygen Species (ROS) Production 
Five hundred thousand (5 x 105) J774 cells (or PBLs) were cultured with the NMOFs at 
different doses in RPMI complete medium without phenol red for 2 h in 5% CO2 at 37 ºC. 
Then, 500 µl of PBS and 0.25 µl of the intracellular fluorescent probe H2DC-FDA (20 mM 




probe, 5 mM final concentration) were added. After incubation, cells were recollected and 
washed with PBS. Cells were resuspended in FACS Flow and analysed by flow cytometry in 
a BD FACS Canto II flow cytometer, analysing the intracellular probe fluorescence. The ratio 
of the mean fluorescence intensity (MFI) between cells cultured with nanoparticles and cells 
cultured with medium alone was analysed. 
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The main aims of each chapter of this thesis are outlined below 
Chapter 2: 
 Develop versatile and reproducible protocols for the one-pot synthesis of surface-
functionalised UiO-66, drug-containing UiO-66 and surface-functionalised drug-
containing UiO-66, with the appropriate size for drug delivery, through coordination 
modulation. 
 Apply the UiO-66 drug modulated synthetises to the UiO family of isoreticular MOFs 
(Zr- BDC and bromo, nitro and amino derivatives, Zr-NDC and Zr-BPDC), obtaining 
two sets of drug@nanoMOFs, one with a size of ca 100 nm and other smaller than 20 
nm), and use the MOFs porosity to load a second drug.  
Chapter 3: 
 Use the functionalities of the p-benzoic acid functionalised modulators, introduced to 
UiO-66 surface as modulators during Chapter 2, to postsynthetically attach various 
polymers (e.g PEG, Poly-L-Lactide and PNIPAM) to UiO-66 surface through copper-
catalysed azide-alkyne cycloaddition (click modulation protocol). 
 Use coordination chemistry to postsynthetically coat UiO-66 surface with the 
modulators introduced to UiO-66 surface during synthesis in Chapter 2.  
 Ultimately study the colloidal dispersion and stability towards phosphates of the bare 
and surface functionalised MOFs in order to gain insights into the effect of surface 
chemistry and coating mode (either by coordination modulation, covalent or 
coordination chemistry) on MOFs physical properties.  
Chapter 4: 
 Apply the postsynthetic surface modification protocols detailed in Chapter 3 to calcein-
loaded analogue UiO-66 samples.  
 Study the effect of PEGylation towards drug release kinetics. 
 Study the effect of surface chemistry on the MOFs internalisation efficacy and routes 
by HeLa cervical cancer cells.  
Chapter 5:  
 Study the anticancer performance (towards MCF-7 breast cancer cells) of the 
DCA@MOFs of the UiO isoreticular series, detailed in Chapter 2, as a function of 
particle size and surface chemistry. 




 Investigate the anticancer performance of 5-FU@DCA@UiO MOFs and compare it 
with their precursor DCA@MOFs and both free drugs, incubated with MCF-7 cells on 
their own or together, in order to understand the effect of the dual-drug MOFs.  
 Apply the former postsynthetic surface functionalisation protocols, detailed in Chapter 
3, to the DCA@UiO-66 modulated samples, synthesised during Chapter 2.  
 Assess the biocompatibility of the bare and surface functionalised MOFs on HeLa 
cervix cancer cells. 
 Investigate the therapeutic effect of all DCA-loaded, bare and surface functionalised, 
UiO-66 MOFs, aiming to find a correlation with the endocytosis routes of internalisation 
determined during Chapter 4 and the physical properties studied for the empty 
analogues from Chapter 3.  
 Asses the anticancer selectivity of the most promising MOF candidates towards a 
series of healthy and cancerous cells lines and study the effect of those empty and 
drug-loaded MOFs in macrophages and lymphocytes proliferation and ROS 
production. 
On the whole, all the aims have been successfully achieved, ultimately providing insights into 
the effect of MOFs surface chemistry on their physical properties, cellular routes of 
internalisation and therapeutic efficacy.  
During Chapter 2 it was shown that carboxylate modulators can be attached to UiO-66 surface 
and defect sites during synthesis, hence resulting in surface-functionalised drug-containing 
MOFs by a simple, versatile and reproducible one-pot protocol. The scope of modulators used 
during this study (p-functionalised benzoic acid derivatives, folic acid, biotin and DCA) has 
proven the versatility of the protocol to introduce simple or more complex functionalised 
modulators to UiO-66 structure, resulting in highly crystalline, porous MOFs with the 
appropriate size for in vitro experiments.  
Importantly, it has been shown that the degree of modulator incorporation is pKa dependent,1 
as, for example, the anticancer metabolic target DCA (pKa 1.4) is significantly incorporated 
into the structure (ca. 20% w/w) while AcOH (pKa 4.8) does not significantly incorporate. Folic 
acid and biotin incorporation is also in great agreement with their respective pKa (3.5 and 4.5 
for folic acid and biotin respectively). In concordance, the porosity of the modulated samples 
is remarkably boosted, with surface areas of ca. 1550 m2g-1 for DCA@UiO-66 vs 1200 m2g-1 
for ideal UiO-66.2 The degree of defects that DCA modulation induces has been estimated by 
TGA, showing that approximately 2 linkers are missing on the structure, being replaced by 
DCA, which results in a high surface charge, and consequently well-dispersed MOFs in 
aqueous solvents, overcoming one of the most relevant drawbacks for MOFs applications in 




drug delivery.3, 4 The low pKa of DCA ensures high incorporation even in the presence of other 
functionalised modulators, and the incorporation of both DCA and functionalised modulator 
has been controlled by tuning the ratio of both. DCA modulation also serves as a size control 
protocol, resulting in homogeneous distributions between 70 and 150 nm regardless of the 
functionalised co-modulator. The one-pot synthesis of multi-drug and multi-functionalised 
MOFs is currently under investigation, in which multiple functionalised carboxylate modulators 
(e.g protecting and targeting units) and multiple carboxylate and phosphate containing drugs 
are introduced as UiO-66 modulators during synthesis. Future work will involve the refinement 
of the protocols and the study of their therapeutic performance. 
The DCA modulation protocol has been successfully applied to the UiO family of isoreticular 
MOFs, for which two different conditions have resulted in two sets of MOFs of different sizes, 
enabling the size and surface dependent study of their cytotoxicity during Chapter 5. The Zr-
terephthalate derivative MOFs synthesised under DCA modulated conditions using ZrCl4 as 
the metal precursor ultimately result in homogenous MOFs of ca. 100 nm, while when ZrOCl2 
is used as the metal precursor, together with an excess of linker, ultrasmall MOFs (10-30 nm) 
are obtained, which are scarce in the literature. 
A general trend, in which terephthalate linkers with electron withdrawing groups (NO2 and Br) 
result in slightly bigger MOFs than terephthalate linkers with electron donating groups (NH2) 
and regular terephthalate, has been found for both synthetic conditions, possibly as a 
consequence of the reduced electron density of the carboxylate groups when electron 
withdrawing groups are present in the structure, which, in comparison, slows down the 
nucleation process. More hydrophobic linkers, such as NDC and BPDC, result is microcrystals 
when ZrCl4 is the metal precursor and nanoparticles of ca. 200 nm when ZrOCl2 is the metal 
precursor. For the second synthetic conditions, a new phase of Zr-NDC has been found, for 
which the particles have an ovoid structure, together with new reflection peaks in the PXRD 
pattern. This new phase is under current examination in a coordination modulation 
investigation of Zr-NDC using various DCA concentrations, temperatures and other co-
modulators with the ultimate aim of obtaining single crystals for structure characterisation. 
In general, and in contrast to analogous MOFs synthesised by AcOH modulation, the DCA 
modulated MOFs of the UiO family are well dispersed in water and in PBS spiked with BSA. 
Although small MOFs usually aggregate more in aqueous solvents than bigger analogues,5 
the ultrasmall DCA@MOFs are well-dispersed in water, and the effect of the presence of 
proteins in the dispersant, such as bovine serum albumin, has been proven to further enhance 
MOFs colloidal stability through the formation of a protein corona.6-8  




The induction of defects under the ZrOCl2 DCA modulated conditions is remarkable, yielding 
in mesoporous Zr-terephthalate derivative MOFs, and since DCA is attached to the Zr6 nodes, 
the remaining porosity has been used to successfully load a second drug - the well-known 
anticancer drug 5-fluorouracil - into the small Zr-terephthalate MOFs and into Zr-NDC and Zr-
BPDC. 
During Chapter 3, a series of surface functionalities – Folic acid, biotin, heparin, PEG, Poly-L-
Lactide and PNIPAM - have been attached postsynthetically to UiO-66 surface for drug 
delivery purposes. The first three reagents have been coordinated to the Zr6 nodes, while the 
last three have been covalently attached to the p-functionalised benzoic acid modulators 
introduced to UiO-66 during Chapter 2, together with other proof-of-concept modifications. 
The postsynthetic covalent modifications have been confirmed by ESI-MS, among other 
characterisation techniques, while the surface reagents introduced by coordination have been 
proven to be attached to the Zr6 clusters, in both cases without major pore blockage.  
The colloidal stability of the MOFs in aqueous solvents has been improved in nearly all cases 
upon surface modification, apart from heparin, more significantly in the case of the polymeric 
coatings through click chemistry, for which size profiles are in great agreement with SEM 
particle size. Similarly, the stability of the MOFs towards phosphate attack has also been 
improved, with induction periods of a few hours in which almost no degradation occurs, but 
reaching similar levels of degradation after 24 h, indicating that although the burst release of 
the drug could be potentially avoided for the first stages of circulation, similar degradation to 
uncoated MOFs should occur for longer stages of treatment. Hence, their accumulation, which 
is one of the major drawbacks of silica coating and of other DDSs,9, 10 should not be enhanced. 
Once again, the polymeric coatings effect was more significant, with a higher degree of initial 
stability. Different degradation profiles for the folic acid and biotin coated samples were found 
depending on the coating mode (coordination modulation and postsynthetic). Although a 
higher degree of stabilisation was found for the postsynthetic samples at first stages - with 
almost no degradation during the first hour possibly due to partial window blockage when the 
coating is performed postsynthetically, as determined by N2 uptake experiments - after a few 
hours the samples synthesised by coordination modulation were more stable than the ones 
synthesised postsynthetically. The folate-coated samples degradation profile is embodied in 
both cases by folic acid release from the structure, indicating that in the case of the modulated 
sample, a considerable amount of coordinated folic acid is present throughout the internal 
structure.  
The postsynthetic modification protocols have been proven to be compatible with cargo 
loading, as during Chapter 4 a fluorescent molecule, calcein, was loaded into the MOFs prior 




to the surface modifications, which were successfully performed without major calcein 
leakage. Calcein, which possesses carboxylates in its structure, was proven to be attached to 
the Zr clusters at defect sites, partially blocking the pore windows, which ensures compatibility 
with surface modifications. Hence, the set of calcein-loaded surface modified UiO-66 enabled 
the study of the endocytosis routes of internalisation by HeLa cells, but also the simulated 
drug release profiles.  
As the PEGylated MOFs were found to have the highest degree of the stabilisation towards 
phosphates, their release kinetics were studied in PBS at pH 7.4 and pH 5.5 and compared 
to the precursor sample. A pH dependent release profile was found in all cases, a 
consequence of the lability of the metal-linker bond under acidic conditions, due to partial 
linker protonation. The release kinetics at pH 7.4 were drastically slowed down upon 
PEGylation, only releasing ca. 30 % after 1 day, and releasing no more cargo for up to 5 days, 
while the uncoated sample released its full cargo after 2 days. By changing the pH of the 
release media during the course of the experiment the full cargo of the PEGylated samples 
was further released, which is highly desirable for an anticancer DDSs. Through 
characterisation of the samples under simulated release conditions it was found that the 
enhancement upon PEGylation at pH 7.4 was a consequence of the in-situ formation of a 
phosphate corona hindering further cargo release, which was protonated under acidic 
conditions, thus enabling stimuli-responsive cargo release.  
MOFs internalisation by HeLa cells was found to be surface chemistry dependent. Surface 
coating improved MOFs internalisation in all cases with exception of the biotin-coated sample, 
which was poorly internalised when compared to the uncoated sample, with similar levels of 
internalisation to free calcein. Due to the over expression of the folate receptor on HeLa cells11 
surface, the folate-coated sample was the most efficiently internalised with a ca. 180 % 
internalisation compared to the uncoated sample. In great agreement with reports of the UiO 
family of isoreticular MOFs HeLa cells internalisation, cal@UiO-66 was mainly internalised by 
clathrin-mediated endocytosis, which ultimately results in lysosome storage, with no 
contribution of the caveolae-mediated route. Certain surface coatings, such as PEGylation 
(only for the longer chains), folate and heparin, tune cal@UiO-66 internalisation from clathrin 
to caveolae-mediated endocytosis, potentially enabling cargo release into the cytosol in a 
more effective manner, while the poly-L-Lactide and PNIPAM coated MOFs are mainly 
internalised through non-mediated endocytosis. Partial uptake by the clathrin-mediated route 
was still significant for the PEGylated and heparin-coated samples, whereas no inhibition was 
found upon folate, Poly-L-Lactide and PNIPAM coatings. Macropinocytosis plays a role in all 
the MOFs internalisation, with exception of Poly-L-Lactide coating, which was partially 
internalised by inactive transport.  




During Chapter 5, an extensive investigation of the therapeutic activity of DCA@MOFs on 
MCF-7 breast cancer cells was performed, with the ultimate aim of obtaining insights of the 
effect of particle size and surface chemistry, finding a correlation with the reported routes of 
cellular internalisation.5 Cytotoxic studies of the DCA@UiO-66 (Zr-BDC) derivative MOFs of 
size ca. 100 nm were compared to DCA@DUT-52 (Zr-NDC) and DCA@UiO-67 (Zr-BPDC), 
of size ca. 200 nm. In great agreement with cellular internalisation reports, which showed no 
caveolae-mediated contribution to UiO-66 cellular internalisation, DCA@UiO-66 had no 
cytotoxic effect. Only a minor contribution of the caveolae-mediated route (ca. 20% inhibition) 
was reported for UiO-66 bromo, nitro and amino derivative MOFs, and although they were 
found to be more efficiently internalised than DUT-52 and UiO-67, the caveolae-mediated 
route played a more important role for the last two. Only minor cytotoxic effects were found 
for DCA@UiO-66-Br and DCA@UiO-66-NO2, whereas DCA@DUT-52 and DCA@UiO-67 
were the most therapeutically efficient MOFs despite their lower DCA content. DCA@UiO-66-
NH2 therapeutic efficacy was considerable, possibly as a consequence of the positive charge 
of the pendant amino groups under physiological conditions.  
It is important to remark, that although the reported routes of cellular internalisation were 
performed on calcein-loaded analogue MOFs synthesised using other modulated conditions 
(generally AcOH and benzoic acid), and such, may have less favourable performance in 
colloidal stability in PBS, and for HeLa cervix cancer instead of MCF-7 cancer cells, the trends 
in therapeutic efficacy of the DCA@MOFs correlate well with the reported caveolae-mediated 
contribution upon internalisation.5 Additionally, the size-dependence internalisation routes of 
cal@UiO-66 (AcOH modulated) have also been reported, finding the smaller MOF (ca. 50 nm) 
to be the most efficiently internalised and the only one not to undergo clathrin-mediated 
endocytosis, indicating significant contribution of non-mediated routes.5 For bigger sizes, 
internalisation was found not to be size-dependent, with major contributions of clathrin-
mediated endocytosis and macropinocytosis in all cases.  
Examples of ultrasmall UiO-66 nanoparticles are scarce in the literature. This thesis has 
shown that DCA@UiO-66 therapeutic effect is enhanced by particle size reduction, as the 
analogous MOF of size ca. 13 nm was therapeutically efficient despite the sample ca.100 nm 
being non-cytotoxic up to 1 mgmL-1. Apart from DCA@UiO-66-NH2, which already decreased 
MCF-7 cells proliferation when particle size was ca. 100 nm, all the small DCA@UiO-66 
derivative MOFs were more efficient than their bigger analogues, presumably as a 
consequence of possible passive diffusion through the cell membrane. However, when 
analysing the cell proliferation data for the small DCA@UiO-66 derivatives as a function of the 
maximum DCA concentration reached upon MOF incubation, and comparing it to DCA@DUT-
52 and DCA@UiO-67, the fact that surface chemistry plays a more important role than particle 




size is evident. DCA@UiO-67 is the most efficient MOF, followed by DCA@DUT-52 and 
DCA@UiO-66-NH2.  
Similar trends in MCF-7 cells proliferation were found upon incubation with 5-
FU@DCA@MOFs, which were significantly more active than their DCA precursor MOFs. 
Comparison of their effect on cells proliferation (against maximum 5-FU concentration 
reached) to free 5-FU, showed surface chemistry dependence, following similar trends to the 
DCA precursors: 5-FU@DCA@UiO-67 and 5-FU@DCA@DUT-52 were the most cytotoxic, 
followed by 5-FU@DCA@UiO-66small and 5-FU@DCA@UiO-66-NH2 small, all of them 
significantly more active than 5-FU, whereas 5-FU@DCA@UiO-66-NO2 small effect in cell 
proliferation was similar to 5-FU, and 5-FU@DCA@UiO-66-Br performance was worse than 
the free drug. The UiO-66 derivative MOFs with electron withdrawing groups (Br, NO2) were 
significantly bigger (ca. 30 nm) than UiO-66 and UiO-66-NH2 (ca. 13 nm), which are more 
likely to undergo passive internalisation. The effect of 5-FU incubation together with free DCA 
was studied for concentrations in the range of those reached by the MOFs, finding no 
enhancement in the IC50 dose in comparison to free 5-FU. Importantly, although it has been 
reported that DCA enhances the effect of 5-FU on cancer cells,12, 13 the DCA doses required 
to reach the synergic effect are at least one order of magnitude higher than the maximum 
dose reached if the MOFs release their full cargo.  
A new project to study the MCF-7 cellular internalisation rates and dose-uptake by FACS is 
currently underway, using calcein-loaded analogues of ca. 100 nm and 200 nm in size, and 
future work will be performed to study the cellular internalisation of smaller analogues both by 
FACS (quantitatively) and by confocal microscopy, in order to assess the intracellular location 
of the MOFs at different incubation times to gain insights into the design of MOFs for high 
therapeutic efficacy. In addition, selectivity towards non-cancerous cells lines will be studied.  
The surface modification protocols detailed during Chapter 3, were successfully applied to the 
DCA@UiO-66 modulated samples synthesised during Chapter 2, proving that DCA 
modulation is compatible with postsynthetic surface modifications without major DCA leakage. 
All the surface functionalised MOFs - apart from UiO-66-L2-PNIPAM, which was cytotoxic for 
concentration of 0.5 mgmL-1 and above - were proven to be biocompatible upon incubation 
with HeLa cells for concentrations up to 1 mgmL-1.14 Their therapeutic effect, when loaded with 
DCA, was again in great agreement with their routes of internalisation. As cal@UiO-66 was 
mainly internalised through the clathrin-mediated route, DCA@UiO-66 was non-cytotoxic for 
concentrations up to 1 mgmL-1, and since the calcein-loaded biotin-coated sample was not 
efficiently internalised, none of the DCA-containing biotin-coated samples were cytotoxic. 
PEGylation, on the other hand, enhanced DCA cytotoxicity (which only had effects on HeLa 




cells proliferation for concentrations higher than 3 mgmL-1) with a >70 fold increase, in 
agreement with the partial internalisation of this sample through caveolae-mediated 
endocytosis. Between the folate-coated samples, different trends in cytotoxicity were found 
depending on the folate content and mode of coating; in all cases the samples synthesised by 
coordination modulation were more efficient than the sample coated postsynthetically. This is 
likely to be a consequence of the presence of folates in the inner surface of the modulated 
samples, for which if degradation occurs during the incubation time, targeting is still taking 
place through folate attached to SBUs in the MOF core. In between the two samples 
synthesised by coordination modulation, the one with the highest folate content was the most 
therapeutically active despite having a slightly lower DCA content, enhancing the IC50 of DCA 
with a >350 fold increase.  
Despite cal@UiO-66-Heparin being found to undergo HeLa cells internalisation partially by 
the caveolae-mediated route, the DCA-loaded analogue did not induce HeLa cells cytotoxicity. 
Heparin is known to bind to several cell growth receptors and activate their signalling 
cascades,15-17 which together with the poorer performance of the empty analogue, UiO-66-
Hep (PS), in colloidal dispersion and stability towards phosphates, may explain why there was 
not an enhancement in therapeutic performance compared to its precursor DCA@UiO-66.  
Although no contribution of the caveole-mediated route was found for cal@UiO-66-L1-
PolyLact and cal@UiO-66-L2-PNIPAM, internalisation of these samples mainly occurred by 
non-mediated routes, with no clathrin-mediated contribution. Thus, DCA@UiO-66-L1-
PolyLact decreased HeLa cells proliferation for high concentrations, while DCA@UiO-66-L2-
PNIPAM killed almost all cells at 0.25 mgmL-1.  
The anticancer selectivity was investigated for the most promising candidates, DCA@UiO-66-
L1-PEG2000, DCA@UiO-66-L1-PolyLact, DCA@UiO-66-L2-PNIPAM and DCA5@UiO-66-
FA1. The DCA-loaded materials were tested against MCF-7 breast cancer cells, HEK293 
embryonic cells, J744 macrophages and lymphocytes, while the empty analogues were also 
tested against macrophages and lymphocytes. DCA@UiO-66 did not affect MCF-7 and 
HEK293 cells proliferation negatively. Although some concerns over cytotoxicity were found 
towards HEK293 human embryonic kidney cells for DCA@UiO-66-L1-PEG2000, with a similar 
decrease in cells proliferation compared to HeLa and MCF-7 breast cancer cells (ca. 50 % for 
1 mgmL-1), macrophages cells proliferation only decreased to ca. 70 %, while no negative 
effect was found to lymphocytes.  
DCA@UiO-66-L2-PNIPAM was selective towards HeLa and MCF-7 breast cancer cells for 
lower concentrations, while DCA@UiO-66-L1-PolyLact was more cytotoxic to HeLa cells than 
for HEK293 and MCF-7, the last two having a similar degree of proliferation (ca. 80 %) upon 




incubation with 1 mgmL-1 of MOF. Although the empty analogues were not remarkably 
cytotoxic towards macrophages and lymphocytes, so were the DCA-loaded analogues.  
DCA5@UiO-66-FA1 was selective towards HeLa and MCF-7 cancer cells, with an effect on 
cells proliferation in great agreement with reports on the overexpression of the folate receptors 
in the cell membrane of both cells,18 while no negative effect on HEK293, macrophages or 
lymphocyte cells proliferation was found. 
These results provide mechanistic insight into the design and functionalisation of MOFs for 
drug delivery, and demonstrate the power of surface functionalisation and importance of cell 
internalisation pathways in the application of MOFs for drug delivery. The potential of 
DCA5@UiO-66-FA1 for use as a selective anticancer DDS for in vivo localised treatment is 
apparent, particularly given the use of the metabolic probe DCA as a modulator during 
synthesis resulting in a drug-loaded nanoparticle that is still porous and could be loaded with 
a second drug for synergistic multimodal therapy. The work also highlights the broad in vitro 
experimental toolkit available to provide information on cellular uptake, endocytosis 
mechanisms, immune response and cytotoxicity prior to any in vivo treatment, thus reducing 
the need for early stage animal testing and acting according to the three Rs: reduction, 
refinement and replacement.  
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7.1 Modulators’ 1HNMR 
1H NMR spectra of authentic samples of the commercially available surface reagents were 
collected in order to identify their characteristic signals and to compare them with the 1H NMR 
spectra of the surface-modified NMOFs digested in D2SO4 / DMSO-d6. 1H NMR spectra in 
acidified DMSO-d6 were also obtained in order to identify changes upon acidification with 
D2SO4 and upon acidification and heating, procedure used to digest the MOFs for their 1HNMR 
analysis. The 1H NMR spectra of folic acid in DMSO-d6 and acidified DMSO-d6 are shown in 
Figure 7.1. The amino and amido resonances disappear upon acidification, presumably due 
to exchange with the deuterated acid, but the other resonances show no significant shifts.  
 
Figure 7.1. Stacked partial 1H NMR spectra of folic acid in DMSO-d6 (bottom) and acidified DMSO-d6 
(top), with signal assignment.  
On the other hand, upon acidification and heating, shifting in the signals are observed, 
together with changes in the integration ratio of the signals (Figure 7.2).  





Figure 7.2: Stacked partial 1H NMR spectra of folic acid in acidified DMSO-d6 (top), and in acidified 
DMSO-d6 after heating, showing signals shifting and changes in the signals’ integration.  
In Figure 7.3, a representation of pH effect on folic acid is shown, which explains why 
resonance signal shifting is more remarkable in signals F and A, which correspond to the 
closer protons to the protonated nitrogen. Additionally, proton exchange with deuterium can 
occur, thus changing the integration ratio.  
 
Figure 7.3: The effect of pH on folic acid structure, showing protonation of N5. 
 




Hence, it is explained why in the MOFs’ acidified 1HNMR not all folic acid signals are observed, 
and why in some cases multiple signals, coming from the multiple species in solution are 
observed, as both acidification and heating are provided. Additionally, due to the presence of 
different species in solution, due to acidification, heating, and Zr presence – metals such as 
zirconium can coordinate to folic acid and form complexes in solution - different sets of signals 
are expected to be observed.   
By comparing the intensity of the resonances of the surface moieties with the aromatic 
resonance of the bdc linker in UiO-66, the molar ratio of the different moieties compared to 
the linker can be estimated. Intengration based on the alkyl signals (H, I, J) is consistent, and 
so their integration ratio was used for folic acid estimation in the MOFs digests.  
The 1H NMR spectra of commercially available biotin in DMSO-d6 (Figure 7.4, bottom) showed 
shifting of the signals and disappearance of resonances for exchangeable N-H protons upon 
acidification (Figure 7.4, top). Apart from the N-H protons, all the characteristic signals were 




Figure 7.4. Stacked partial 1H NMR spectra of biotin in DMSO-d6 (bottom) and acidified DMSO-d6 (top), 
with signal assignment.  
 
 




7.2 Kinetic Fitting of Degradation Profiles 
The kinetic profiles for the degradation of the samples were determined by curve fitting utilising 
Microcal Origin software, and are shown in Table 7.1. 
Table 7.1. Kinetic profiles of the samples’ degradation. 
NMOF Degradation equation  R2 
UiO-66-AcOH % bdc released = 84.24 -84.75 et/2.01 R2= 0.9942 
UiO-66-L1 % bdc released = 86.863 -83.831 et/1.90 R2= 0.9935 
UiO-66-L1-PEG550 % bdc released = 0.72 + 86.50 (t0.08/(1.16+t0.08)) R2= 0.9977 
UiO-66-L1-PEG2000 % bdc released = -1.64+ 89.07 (t1.84/(9.2853+t1.84) R2= 0.9908 
UiO-66-L1-PolyLact % bdc released = 3.31 + (75.82)(t1.64/(2.36 + t1.64)) R2 = 0.9959 
UiO-66-L2-PNIPAM % bdc released = 96.66 (t1.11/2.08 + t1.11) R2 = 0.9798 
UiO-66-Biot (PS) % bdc released = 102.15 – 79.45t R2 = 0.9953 
UiO-66-FA (PS) % bdc released = –2.41 + 94.05 (t1.36 / (5.03+ t1.36)) R2 = 0.9983 
UiO-66-Hep (PS) % bdc released = 103.73 – 66.31t R2 = 0.9984 
UiO-66-FA (CM) % bdc released = 12.69 + (82.12) (t1.63/(8.38 + t1.63)) R2 = 0.9937 
UiO-66-Biot-AcOH (CM) % bdc released = 16.73 + (53.34) (t1.45 / (3.99 + t1.45)) R2 = 0.9913 
UiO-66-FA (PS) % FA released = 84.01 – 64.28t R2 = 0.9937 
UiO-66-FA (CM) % FA released = (–71.64) / (1+e (t-2.08) / 1.82t) + 87.12)) R2 = 0.9913 
 
The uncoated samples, UiO-66-AcOH and UiO-66-L1, exhibit exponential degradation 
profiles: y= y0 +A1ex/t1. In contrast, the PEGylated samples exhibit sigmoidal degradation 
profiles: y= start + (end-start)(xn/(kn+xn)), clearly indicating a different initial degradation 
mechanism. UiO-66-L1-PolyLact and UiO-66-L2-PNIPAM also present sigmoidal degradation 
profiles, with y = start + (end – start)(xn/(kn+xn)) and y = Vmax (Xn/Kn + Xn) equations 
respectively. In contrast, UiO-66-Hep (PS) and UiO-66-Biot (PS) exhibit exponential 
degradation profiles, although following a different equation (y = a – bcx) than their precursor 
UiO-66-L1, while UiO-66-FA (PS) degradation profiles are sigmoidal (y = start + (end – 
start)(xn/(kn+xn)). 
Similar profiles occur for the biotin and folic acid modulated samples, which follow y = start + 
(end-start)(xn/(kn+xn)) sigmoidal degradation kinetics The release of bdc from the folic acid 
coated samples (both postsynthetically coated and modulated) follow similar degradation 




profiles, but for UiO-66-Biot-AcOH (CM), the profile is markedly different from the exponential 
degradation profile of UiO-66-Biot (PS). 
Folic acid release occurs in both cases at a higher rate than bdc release. The differences in 
folic acid release form the modulated and postsynthetically modified UiO-66 are noticeable in 
their kinetics, being exponential (y = a – bcx) for the UiO-66-FA (PS) sample and sigmoidal (y 
= (A1 – A2)/ (1+e(x-x0) / dx) + A2) for the UiO-66-FA (CM), suggesting the coating is easier to 
remove from postsynthetically coordinated samples.  
These results highlight the importance of surface coating to enhance UiO-66 degradation 
kinetics towards phosphates for initial contact times, while ensuring similar final degradation 
rates. The mode of coating has been proved to also play an important role, especially for the 
first stages of degradation. Surface modifications performed by coordination chemistry 
postsynthetically have a more pronounced initial effect than those where the functionality is 
introduced during synthesis, possibly due to the higher hindering of Zr units from phosphate 
attack. Surface modification based on the ‘click modulation’ protocol also highly enhance 

















7.3 Kinetic Fitting of Calcein Release Profiles 
The kinetic profiles of calcein release (Table 7.2) and simultaneous linker release (Table 7.3) 
from the calcein-loaded bare and PEGylated samples were determined by curve fitting utilising 
Microcal Origin software. 
Table 7.2. pH Dependence of calcein release from cal@UiO-66-L1, cal@UiO-66-L1-PEG550 and 
cal@UiO-66-L1-PEG2000.  
 
NMOF Release equation  R2 
cal@UiO-66-L1  
pH 7.4 
% calcein released = 158.66(t0.05/1.13+ t0.05) R2 = 0.99442 
cal@UiO-66-L1-PEG550 
pH 7.4 
% Calcein Released= 33.14(t1.06/0.11+ t1.06) R2= 0.97539 
cal@UiO-66-L1-
PEG2000 pH 7.4 
% Calcein Released= 31.21(t0.90/0.11+ t0.90) R2= 0.99387 
cal@UiO-66-L1  
pH 5.5 
% calcein released = 96.33 - 59.47 e t/2.26 R2 = 0.99061 
cal@UiO-66-L1-PEG550 
pH 5.5 




PEG2000 pH 5.5 




There is a clear difference in the release profiles at pH 7.4. Although calcein release follows a 
sigmoidal profile y=Vmax (Xn/Kn+Xn) in all cases, the rate of release from cal@UiO-66-L1 is 
clearly higher than for the PEGylated samples, while the later also reach a plateau around 30 
% release after 1 day versus total calcein release from caL@UiO-66-L1 for the same release 
time.  
 
At pH 5.5, although all following exponential kinetics, the release profiles differ between bare 
and PEGylated samples - y= y0 +A1ex/t1 for cal@UiO-66-L1 and y=y0 + A1 (1-e –t/t1) + A2 (1-e –
t/t2) for the PEgylated samples - but all release their cargo after 1 day.  
 
